Methods and compositions against anti-CD73 antibodies and variants
By developing antibodies and antigen binding fragments against CD73, the immunosuppression problem of CD73 protein in cancer in the prior art has been solved, and effective treatment of CD73 overexpression diseases has been achieved, especially in cancer, which significantly inhibits tumor growth and immunosuppression. , enhances the anti-tumor immune response.
Patent Information
- Application Number
- CN202410853932.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-07-26
- Filing Date
- 2020-07-17
- Publication Date
- 2024-11-22
AI Technical Summary
Existing antibody agents against CD73 protein have not yet achieved effective, safe and powerful therapeutic effects, especially in cancer, where CD73 overexpression is related to immunosuppression, and the prior art is difficult to effectively block its function.
An anti-CD73 antibody and its variants and antigen-binding fragment was developed to inhibit its enzymatic activity by binding specifically to CD73 and used alone in cancer treatment or in combination with other agents to enhance the anti-tumor immune response.
At least 18 anti-CD73 antibodies, variants and antigen binding fragments are provided, which significantly enhances the therapeutic effect on CD73 overexpression-related diseases, especially in cancer, which can inhibit tumor growth and immunosuppression and improve patient survival.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
[0001] This application is a divisional application of a Chinese patent application with an application date of July 17, 2020, application number CN202080053981.X, and invention name “Methods and compositions for anti-CD73 antibodies and variants”. Technical Field
[0002] The present invention generally relates to anti-CD73 antibodies, their variants or mutants, or antigen-binding fragments thereof, and methods of using the same to treat human cancer. Background Art
[0003] CD73 (known as ecto-5'-nucleotidase (NT5E, EC 3.1.3.5)) is a glycosyl-phosphatidylinositol (GPI)-linked 70-kDa cell surface enzyme found in most tissues (Zhang B., Cancer Res. [Cancer Research], 70(16):6407-6411 (2010)). CD73 (originally defined as a lymphocyte differentiation antigen) is thought to function as a common signaling molecule on T lymphocytes and as an adhesion molecule, which is important for lymphocyte binding to the endothelium. Recent studies have shown that CD73 can control a variety of physiological responses, including epithelial ion and fluid transport, ischemic preconditioning, tissue injury, platelet function, hypoxia, and vascular leakage (Zhang B., Cancer Res. [Cancer Research], 70(16):6407-6411 (2010)).
[0004] The immunosuppressive effects of extracellular adenosine have been demonstrated (Stagg J. et al., Oncogene, 29(39):5346–5358 (2010)). Adenosine interacts with its receptors to inhibit most immune cell functions, including natural killer (NK) cell cytotoxicity, macrophage phagocytosis, T cell cytotoxicity, and cytokine release (Goto T. et al., J. Immunol., 130(3):1350-1355 (1983); Ohta A. et al., J. Immunol., 183(9):5487-5493 (2009)). Blocking adenosine signaling can improve immunotherapy. CD73 is a key molecule involved in adenosine signaling. CD73 hydrolyzes adenosine monophosphate (AMP), a product of the adenosine triphosphate (ATP) hydrolysis pathway by CD39, to adenosine to influence the tumor microenvironment (Allard B. et al., Immunol. Rev., 276(1): 121-144 (2017); Resta R. et al., Immunol. Rev., 161: 95-109 (1998)). The CD73 adenosine axis constitutes one of the most promising pathways in immuno-oncology.
[0005] Studies have reported that CD73 is involved in cell-cell and cell-matrix interactions, and indicated that CD73 is involved in drug resistance and tumor promotion (Spychala J., Pharmacol. Ther., 87(2-3): 161–173 (2000)). CD73 has been shown to be overexpressed in several cancer cells (Gao ZW. et al., Biomed. Res. Int., 2014:460654 (2014)), and this expression is associated with poor prognosis or patient survival in some cancers (Loi S. et al., Proc. Natl. Acad. Sci. USA, 110(27):11091-11096 (2013); Turcotte M. et al., Cancer Res., 75(21):4494-4503 (2015); Xiong L. et al., Cell Tissue Res., 355(2):365-374 (2014)). In some cases, anti-CD73 monoclonal antibody (mAb) treatment can inhibit metastasis and tumor angiogenesis (Allard B. et al., Int. J. Cancer, 134(6):1466-1473 (2014); Terp MG. et al., J. Immunol., 191(8):4165-4173 (2013)). In addition, researchers have demonstrated the immunosuppressive role of CD73-adenosine in cancer, and believe that targeted blockade of CD73 or adenosine receptors can effectively promote anti-tumor immunity and enhance the activity of first-generation immune checkpoint blockers (Allard D. et al., Immunotherapy, 8(2):145-163 (2016)).
[0006] In recent years, targeting CD73 has produced favorable anti-tumor effects in preclinical models, and CD73 blockade together with other immunomodulatory agents is a particularly attractive treatment option (Antonioli L. et al., Trends Cancer, 2(2):95-109 (2016)). Combination with anti-CD73 mAb can significantly enhance the anti-tumor activity of anti-CTLA-4 (cytotoxic T lymphocyte antigen 4) mAb and anti-PD-1 (programmed cell death protein 1) mAb (Allard B. et al., Clin. Cancer Res., 19(20):5626-5635 (2013)).
[0007] However, despite the progress made in research targeting CD73 and the clinical benefits obtained from using this protein, there remains a need to develop effective, safe and potent antibody agents against CD73. The present invention satisfies these needs and others. Summary of the invention
[0008] In accordance with one or more objects of the present invention, as embodied and broadly described herein, the present invention relates in one aspect to anti-CD73 antibodies, variants, mutants, and / or antigen-binding fragments thereof, methods of preparing the same, pharmaceutical compositions comprising the same, and methods of using the same to treat human subjects. For example, the disclosed anti-CD73 antibodies and affinity variants and / or mutants or antigen-binding fragments thereof can be used alone or in combination with other agents in the treatment of diseases associated with CD73 expression, CD73 overexpression, and / or aberrant CD73 function, such as cancer or fibrosis. The antibodies provided herein can also be used to detect CD73 protein in a patient or patient sample by administering an anti-CD73 antibody, and / or affinity variants / mutants, or antigen-binding fragments thereof, to a patient and detecting the anti-CD73 antibody, and / or variant / mutant, or antigen-binding fragment thereof, bound to the CD73 protein in a sample from the patient (e.g., in vivo or ex vivo), or by contacting the anti-CD73 antibody, and / or variant / mutant, or antigen-binding fragment thereof with a sample from a patient and qualitatively or quantitatively detecting the anti-CD73 antibody, and / or affinity variant / mutant, or antigen-binding fragment thereof, bound to the CD73 protein.
[0009] The present invention provides anti-CD73 antibodies and variants, and / or antigen-binding fragments thereof. In certain embodiments, the present invention provides at least eighteen (18) anti-CD73 antibodies, variants and / or antigen-binding fragments thereof, i.e., anti-CD73 antibodies, and / or variants N1 and variants N1 variants (N1#2, N1#2-P, N1#9 and N1#9-PH), N2, N4 and N4 variants (N4#1, N4#4, N4#4-3, N4#5, N4#6, N4#6-2, N4#6-3, N4#6-3-P, N4#6-4, N4#6-4-P and N4#6-5). The nucleic acids and / or their encoded amino acid sequences of the light and heavy chains of each of these (18) anti-CD73 antibodies and / or their variants are provided in the sequence table below. Each light chain (CDR-L1, CDR-L2,
[0010] and CDR-L3) and the CDR sequences of each heavy chain (CDR-H1, CDR-H2, and CDR-H3).
[0011] Table 1. Anti-CD73 Antibody, Variant, and / or Mutant Light Chain CDR Sequences
[0012]
[0013] Table 2. Anti-CD73 antibody, variant, and / or mutant heavy chain CDR sequences
[0014]
[0015]
[0016] In some embodiments, according to (or as applied to) any of the above embodiments, the anti-CD73 antibodies of the invention comprise one or more mutations at the N-glycosylation site of one or more CDRs of its variable domains. The resulting deglycosylated antibody retains the same function as the parent non-deglycosylated antibody.
[0017] In some embodiments, according to (or as applied to) any of the above embodiments, the anti-CD73 antibody of the present invention is a full-length IgG antibody, wherein the light chain consists of the above-mentioned light chain variable region and the human antibody light chain constant region, and wherein the heavy chain consists of the above-mentioned heavy chain variable region and the human antibody heavy chain constant region.
[0018] In some embodiments, according to (or as applied to) any of the above embodiments, the anti-CD73 antibody of the present invention is a full-length IgG antibody, wherein the light chain is composed of the above-mentioned light chain variable region and a human antibody light chain constant region, and the light chain constant region is as shown in SEQ ID NO.115, and the heavy chain is composed of the above-mentioned heavy chain variable region and a human antibody heavy chain constant region, and the heavy chain constant region is as shown in 112, 113 or 114.
[0019] In some embodiments, according to (or as applied to) any of the above embodiments, the anti-CD73 antibody of the invention is a full-length IgG antibody, wherein:
[0020] (Antibody variant N1#2-P) the light chain is shown in SEQ ID NO.93 and the heavy chain is shown in SEQ ID NO.116, or
[0021] (Antibody variant N1#9-PH) the light chain is shown in SEQ ID NO.94 and the heavy chain is shown in SEQ ID NO.117, or
[0022] (Antibody variant N4#6-3-P) the light chain is shown in SEQ ID NO.95 and the heavy chain is shown in SEQ ID NO.118, or
[0023] (Antibody variant N4#6-4-P) The light chain is shown in SEQ ID NO.96 and the heavy chain is shown in SEQ ID NO.119.
[0024] Table 3. Correspondence table of antibody CDR, VH, VL, LV and HC sequence numbers
[0025]
[0026] In some embodiments, according to (or as applied to) any of the above embodiments, the anti-CD73 antibody comprises an Fc sequence of human IgG. In some embodiments, according to (or as applied to) any of the above embodiments, the antigen binding fragment is selected from the group consisting of Fab, Fab', F(ab')2, single-chain Fv (scFv), Fv fragment, diabody, and linear antibody. In some embodiments, according to (or as applied to) any of the above embodiments, the antibody is a multispecific antibody.
[0027] In some embodiments, according to (or as applied to) any of the above embodiments, the anti-CD73 antibody, variant, or antigen-binding fragment thereof is conjugated to a therapeutic agent. In some embodiments, according to (or as applied to) any of the above embodiments, the anti-CD73 antibody, variant, or antigen-binding fragment thereof is conjugated to a label. In some embodiments, according to (or as applied to) any of the above embodiments, the label is selected from the group consisting of a radioisotope, a fluorescent dye, and an enzyme.
[0028] The present invention provides an isolated nucleic acid molecule encoding an anti-CD73 antibody, variant, mutant, or antigen-binding fragment thereof according to (or as applied to) any of the above embodiments. An expression vector encoding a nucleic acid molecule according to (or as applied to) any of the above embodiments is also provided. A cell comprising an expression vector according to (or as applied to) any of the above embodiments is also provided. The present invention also provides a method for producing an anti-CD73 antibody, variant, or antigen-binding fragment thereof, the method comprising culturing a cell according to (or as applied to) any of the above embodiments and recovering the antibody or antigen-binding fragment thereof from the cell culture. In some embodiments, according to (or as applied to) any of the above embodiments, the cell is a mammalian cell. In some embodiments, according to (or as applied to) any of the above embodiments, the mammalian cell is a CHO cell. In some embodiments, according to (or as applied to) any of the above embodiments, the cell is a stable mammalian cell line. In some embodiments, according to (or as applied to) any of the above embodiments, the stable mammalian cell line is a CHO cell line.
[0029] In certain embodiments, isolated antibodies are provided that specifically bind to human CD73 on the cell surface and are capable of neutralizing the 5'-ectonucleotidase activity of soluble or membrane-bound human CD73 protein. The antibody can induce intracellular internalization of CD73.
[0030] In certain embodiments, an antibody is provided that binds to a soluble or membrane-bound human CD73 protein and is capable of inhibiting its enzymatic activity, wherein the antibody is not internalized into cells expressing CD73.
[0031] The present invention provides a composition comprising an anti-CD73 antibody, variant, mutant or antigen-binding fragment thereof according to (or as applied to) any of the above embodiments and a pharmaceutically acceptable carrier.
[0032] The present invention provides a method for detecting CD73 protein in a sample from a patient by contacting an anti-CD73 antibody, variant, mutant, or antigen-binding fragment thereof according to (or as applied to) any of the above embodiments with the sample and detecting anti-CD73 antibodies bound to the CD73 protein. In some embodiments, according to (or as applied to) any of the above embodiments, the anti-CD73 antibody, variant, or antigen-binding fragment thereof is used in an immunohistochemistry assay (IHC) or in an ELISA assay.
[0033] Also provided is a method for treating cancer in a subject, the method comprising administering to the subject an effective amount of a composition according to (or as applied to) any of the above embodiments. Also provided is a composition comprising an anti-CD73 antibody, variant, mutant, or antigen-binding fragment thereof according to (or as applied to) any of the above embodiments for cancer treatment. Provided is the use of an anti-CD73 antibody, variant, mutant, or antigen-binding fragment thereof according to (or as applied to) any of the above embodiments in the manufacture of a medicament for treating cancer (such as a cancer associated with the expression of CD73).
[0034] In some embodiments, according to (or as applied to) any of the above embodiments, the cancer is selected from melanoma, head and neck cancer, urothelial carcinoma, breast cancer (e.g., triple negative breast cancer, TNBC), gastric cancer, classical Hodgkin lymphoma (cHL), non-Hodgkin lymphoma primary mediastinal B-cell lymphoma (NHL PMBCL), mesothelioma, ovarian cancer, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer (NSCLC)), esophageal cancer, nasopharyngeal carcinoma (NPC), biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer and salivary gland cancer. In some embodiments, according to (or as applied to) any of the above embodiments, the subject is further administered a therapeutic agent selected from the group consisting of an anti-tumor agent, a chemotherapeutic agent, a growth inhibitory agent and a cytotoxic agent. In some embodiments, according to (or as applied to) any of the above embodiments, the subject is further administered radiation therapy and / or surgery.
[0035] Other systems, methods, features, and advantages of the present invention will be or will become apparent to those skilled in the art upon study of the following drawings and detailed description. It is intended that all such additional systems, methods, features, and advantages be included within this specification, within the scope of the present invention, and protected by the appended claims. In addition, all optional and preferred features and modifications of the described embodiments may be used in all aspects of the present invention as taught herein. In addition, the individual features of the appended claims, together with all optional and preferred features and modifications of the described embodiments, are combinable and interchangeable with each other. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Many aspects of the invention can be better understood with reference to the following drawings.
[0037] Figure 1A-1B .Light chains of anti-CD73 lead clones N1, N2, and N4 selected from initial phage panning ( Figure 1A )( Figure 1A SEQ ID NOs 79-81) and the heavy chain variable region ( Figure 1B )( Figure 1B The amino acid sequence alignment of SEQ ID NOs 97-99 is disclosed in the order of appearance, respectively. By screening the human Fab initial phage display library with human CD73-ECD / His, three selected antibody lead clones with CD73 enzyme binding and blocking activity were identified. These selected variable sequences were then cloned into the L234F, L235E, and P331S mutants of the human IgG1 Fc backbone to become full-length antibodies. The sequence alignment of the antibody lead clones is listed herein, and the CDRs (complementarity determining regions) defined by Kabat are underlined and marked in bold.
[0038] Figures 2A-2C .CD73 binding of selected antibodies. Test the selected antibodies for binding to recombinant human CD73 protein (by ELISA ( Figure 2A )), CD73-expressing human tumor cells MDA-MB-231 (human breast cancer) cells ( Figure 2B ) and NCI-H292 (human mucoepidermoid lung cancer) cells ( Figure 2C ) (Binding by flow cytometry). Anti-CD73 ref-1 antibody and HLX01 (anti-CD20) were used as positive and negative controls, respectively.
[0039] Figure 3A-3B Effect of anti-CD73 lead clones on soluble CD73 enzymatic activity and cellular CD73 enzymatic activity. Anti-CD73 antibodies were tested for their ability to inhibit the enzymatic activity of human recombinant CD73 protein and cell surface CD73. Recombinant CD73 protein ( Figure 3A) and NCI-H292 cells ( Figure 3B ) were incubated with anti-CD73 antibody, ATP and AMP. The CellTiter-Glo assay was used to determine the AMP concentration in the sample. The luminescence readout value indicated CD73 enzyme activity. Anti-CD73 ref-1 antibody and APCP were used as positive controls, while HLX01 (anti-CD20) was used as a negative control.
[0040] Figure 4 Antibody-mediated CD73 internalization of anti-CD73 lead clone. Cell surface expression of CD73 was measured by flow cytometry after anti-CD73 antibody treatment. Anti-CD73 ref-1 antibody and HLX01 (anti-CD20) were used as positive and negative controls, respectively.
[0041] Figures 5A-5C .CD73 binding of selected antibodies with different IgG Fc regions. The variable sequences of N1, N2 and N4 were also cloned into human wild-type or C219S mutant IgG2 Fc backbones. N1 ( Figure 5A )、N2( Figure 5B )、N4( Figure 5C Binding of different IgG isotypes of ) to human MDA-MB-231 cells expressing CD73. Anti-CD73 ref-1 antibody and HLX01 (anti-CD20) were used as positive and negative controls, respectively.
[0042] Figures 6A-6C Effects of anti-CD73 lead clones with different IgG Fc regions on cellular CD73 enzymatic activity. Anti-CD73 lead clone N1 ( Fig. 6A )、N2( Figure 6B )、N4( Figure 6C ) ability to inhibit cellular CD73 enzyme activity. MDA-MB-231 cells were incubated with anti-CD73 antibodies. ATP, AMP and CellTiter-Glo reagent were added and cold light was recorded. APCP was used as a positive control in the enzyme activity assay.
[0043] Figures 7A-7C Antibody-mediated CD73 internalization with anti-CD73 antibodies having different IgG Fc regions. Fig. 7A )、N2( Figure 7B ) and N4( Figure 7C After incubation of cells with different IgG isotypes of ), the cell surface expression of CD73 was measured by flow cytometry. Anti-CD73 ref-1 antibody and HLX01 (anti-CD20) were used as positive and negative controls, respectively.
[0044] Figures 8A-8B .Tumor growth inhibitory activity of anti-CD73 lead clone in MDA-MB-231 (human triple-negative breast cancer) xenograft mouse model. Mice (n=5 mice / group) were subcutaneously transplanted with MDA-MB-231 cells. 14 days after tumor inoculation, when the transplanted tumor size reached 150-300mm 3 The first dose of the test article was given at 4 pm. Mice were treated intraperitoneally with 5 mg / kg of the antibody at the indicated times. Tumor growth curves are shown in Fig. 8A The individual tumor volumes on day 45 are shown in Figure 8B All data points are mean ± SEM.
[0045] Fig. 9 .Amino acid sequence alignment of light chain variable regions derived from affinity matured N1 and N4 variants. N1 and N4 variants with better CD73 binding affinity and soluble CD73 enzyme blocking activity were identified from in vitro phage display-based affinity maturation experiments. The Kabat-defined CDRs (complementarity determining regions) are underlined and marked in bold. Fig. 9 SEQ ID NOs 82-85, 88, 86-87 and 89-92 are disclosed in order of appearance, respectively.
[0046] Fig.10 .Amino acid sequence alignment of the heavy chain variable regions derived from affinity-matured N1 and N4 variants. N1 and N4 variants with better CD73 binding affinity and soluble CD73 enzyme blocking activity were identified from in vitro phage display-based affinity maturation experiments. The Kabat-defined CDRs (complementarity determining regions) are underlined and marked in bold. These selected variable sequences were then cloned into the human IgG2 Fc backbone to become full-length antibodies. Fig.10 SEQ ID NOs 100-103, 106, 104-105 and 107-110 are disclosed in order of appearance, respectively.
[0047] Figures 11A-11B .CD73 binding of N1 and N4 variants. Selected variants were tested by flow cytometry for binding to CD73-expressing MDA-MB-231 ( Fig.11A ) and NCI-H292 cells ( Fig. 11B HLX01 (anti-CD20) was used as a negative control.
[0048] Fig.12Effect of N1 and N4 variants on immobilized CD73 enzymatic activity. The ability of N1 and N4 variants to inhibit immobilized CD73 enzymatic activity was tested. After incubation of anti-CD73 antibody and CD73 protein, ATP, AMP and CellTiter-Glo reagent were added and luminescence was recorded. Anti-CD73 ref-1 antibody, anti-CD73 ref-2 antibody were used as positive controls, while HLX01 (anti-CD20) was used as a negative control.
[0049] Fig.13 .Antibody-mediated CD73 internalization of N1 and N4 variants. NCI-H292 cells were incubated with N1 and N4 variants, and cell surface expression of CD73 was measured by flow cytometry. Anti-CD73 ref-1 antibody and anti-CD73 ref-2 antibody were used as positive controls, while HLX01 (anti-CD20) was used as a negative control.
[0050] Fig.14 .Alignment of amino acid sequences of the light chains of N1 and N4 front variants. The CDRs (complementarity determining regions) defined by Kabat are underlined and marked in bold. Fig.14 SEQ ID NOs 93-96 are disclosed in order of appearance, respectively.
[0051] Fig.15 .Alignment of amino acid sequences of the heavy chain variable regions of the N1 and N4 front variants. The CDRs (complementarity determining regions) defined by Kabat are underlined and marked in bold. These sequences were then cloned into the human IgG2 Fc backbone to become full-length antibodies. Fig.15 SEQ ID NOs 111, 101, and 108-109 are disclosed in order of appearance, respectively.
[0052] Figures 16A-16C .CD73 binding ability of N1 and N4 variants. The binding of anti-CD73 antibodies to recombinant human CD73 protein was tested by ELISA ( Fig.16A ), and flow cytometry was used to test the CD73 antibody against CD73-expressing human tumor cells MDA-MB-231 ( Fig. 16B ) and NCI-H292( Fig. 16C ). Anti-CD73 ref-1 antibody and anti-CD73 ref-2 antibody were used as positive controls, while HLX01 (anti-CD20) was used as a negative control.
[0053] Figures 17A-17C .N1 and N4 variants have an effect on soluble CD73 enzymatic activity ( Fig.17A ) and cell surface CD73 enzyme activity ( Fig. 17B , Fig. 17C). The ability of anti-CD73 antibodies to inhibit human recombinant CD73 protein and cell surface CD73 enzyme activity was tested. Recombinant CD73 protein ( Fig.17A )、MDA-MB-231( Fig. 17B ) and NCI-H292( Fig. 17C ) cells were incubated with anti-CD73 antibody. ATP, AMP and CellTiter-Glo were added and luminescence was recorded. Anti-CD73 ref-1 antibody, anti-CD73 ref-2 antibody and APCP were used as positive controls. HLX01 (anti-CD20) was used as a negative control.
[0054] Figures 18A-18B . Antibody-mediated CD73 internalization of N1 and N4 variants. MDA-MB-231 ( Fig.18A ) and NCI-H292( Fig.18B ) cells were incubated with anti-CD73 N1 and N4 variants. After incubation, cell surface expression of CD73 was measured by flow cytometry. Anti-CD73 ref-1 and anti-CD73 ref-2 antibodies were used as positive controls, while HLX01 (anti-CD20) was used as a negative control.
[0055] Figures 19A-19B .Reversal of the inhibitory effect of AMP on T cell activity by N1 and N4 anterior variants. Isolated human T cells were cultured with CD3 / CD28 beads, AMP and serially diluted antibodies at 37°C for 4 days. + T cell proliferation was followed by CellTiter-Glo assay ( Fig.19A ), and human IFN-γ ELISA MAX TM Deluxe Kit( Fig.19B ) IFN-γ secretion was measured. Anti-CD73 ref-1 and anti-CD73 ref-2 antibodies were used as positive controls, while HLX04 (anti-VEGF) was used as a negative control.
[0056] Fig. 20 .Tumor growth inhibitory activity of N1 and N4 anterior variants in MDA-MB-231 (human triple-negative breast cancer) xenograft mouse model. Mice (n=5 mice / group) were subcutaneously transplanted with MDA-MB-231 cells. Seven days after tumor inoculation, when the transplanted tumor size reached approximately 100 mm 3 The first dose of the test article was given at 10 mg / kg and 2 mg / kg of the antibody intraperitoneally twice a week for 5-6 weeks. All data points are mean ± SEM.
[0057] Fig.21.Tumor growth inhibitory activity of N1 and N4 anterior variants in the NCI-H292 (human mucoepidermoid lung cancer) xenograft mouse model. Mice (n=5 mice / group) were implanted subcutaneously with NCI-H292 cells. The first dose of the test article was given 3 days after tumor inoculation. Mice were treated intraperitoneally with 50, 10 and 2 mg / kg of the antibody twice a week for 3 weeks. All data points are mean ± SEM.
[0058] Fig. 22 .Effect of N1 and N4 front variants on cellular CD73 enzymatic activity in NCI-H292 xenograft tumors. The ability of N1 and N4 front variants to inhibit CD73 enzymatic activity in the NCI-H292 xenograft model was tested. Mice (n=4 mice / group) were subcutaneously transplanted with NCI-H292 cells 4 days before antibody treatment. Antibodies, APCP, and placebo were injected intraperitoneally on day 0. Tumors were resected on days 1, 3, and 7 after antibody administration. CD73 enzymatic activity in tumors was measured by CellTiter-Glo assay.
[0059] Figures 23A-23B .Effects of N1 and N4 front variants on CD73 expression and cellular CD73 enzyme activity in MDA-MB-231 xenograft tumors. Anti-CD73 antibodies were tested for their ability to downregulate surface CD73 expression and inhibit CD73 enzyme activity in the MDA-MB-231 xenograft model. Mice (n=4 mice / group) were subcutaneously transplanted with MDA-MB-231 cells 7 days before antibody treatment. Antibodies and placebos were injected on day 0. Tumors were collected on days 1, 3, and 7 after antibody administration. CD73 expression ( Fig.23A ), and CD73 enzyme activity in tumors was measured by CellTiter-Glo assay ( Fig. 23B ).
[0060] Figures 24A-24B .N1 and N4 variants cross-bind to mouse and monkey CD73-expressing cells. Anti-CD73 antibodies were tested by flow cytometry for cross-binding to CD73-expressing mouse breast cancer 4T1 cells ( Fig.24A ) and monkey kidney epithelial LLC-MK2 cells ( Fig. 24B HLX01 was used as a negative control.
[0061] Additional advantages of the present invention will be listed in part in the following description, and in part will be apparent from the description, or can be understood through the practice of the present invention. The advantages of the present invention will be realized and obtained by means of the elements and combinations specifically pointed out in the appended claims. It should be understood that the foregoing general description and the following detailed description are only exemplary and descriptive, and are not limitations of the present invention as claimed. DETAILED DESCRIPTION
[0062] In one aspect, the present invention relates to anti-CD73 antibodies, variants, mutants, and / or antigen-binding fragments thereof, methods for preparing them, pharmaceutical compositions comprising them, and methods of using them to treat human subjects. The present invention further provides anti-CD73 antibodies that specifically bind to CD73 and can inhibit tumor growth via inducing macrophage-mediated phagocytosis. The disclosed antibodies exhibit improved efficacy and / or anti-tumor activity compared to conventional anti-CD73 monoclonal antibodies used to treat clinical conditions such as cancer or fibrosis. Immunoconjugates, nucleic acids encoding novel anti-CD73 antibodies, affinity variants thereof, or antigen-binding fragments thereof (as described herein), and compositions (such as pharmaceutical compositions) are also provided.
[0063] In certain embodiments, the present invention provides at least eighteen (18) anti-CD73 antibodies, variants and / or antigen-binding fragments thereof, i.e., the anti-CD73 antibodies, variants, and / or mutants specified in Tables 1 and 2. The nucleic acid and / or encoded amino acid sequences of the light and heavy chains of each of these anti-CD73 antibodies, variants and / or mutants thereof are provided in the sequence-sequence listing section disclosed below. The CDR sequences of each light chain (CDR-L1, CDR-L2, and CDR-L3) and each heavy chain (CDR-H1, CDR-H2, and CDR-H3) of each anti-CD73 antibody, variant and / or mutant thereof are provided in Tables 1 and 2, respectively.
[0064] The present invention also provides methods of using novel anti-CD73 antibodies, affinity variants and / or mutants or antigen-binding fragments thereof to detect CD73 in samples (such as in vivo or ex vivo samples), and / or compositions comprising such antibodies, variants and / or mutants or antigen-binding fragments thereof, which are used to treat clinical conditions or diseases associated with CD73 expression, CD73 overexpression and / or abnormal CD73 function (such as cancer or fibrosis). In other embodiments, the disclosed anti-CD73 antibodies and affinity variants and / or mutants or antigen-binding fragments thereof can be used in combination with other agents in the treatment of diseases associated with CD73 expression, CD73 overexpression, and / or abnormal CD73 function (such as cancer or fibrosis). The present invention further provides the use of such antibodies, variants or antigen-binding fragments thereof in the manufacture of medicaments for cancer treatment.
[0065] The antibodies provided herein can also be used to detect CD73 protein in a patient or a patient sample by administering an anti-CD73 antibody, and / or affinity variants / mutants, or antigen-binding fragments thereof, to a patient and detecting the anti-CD73 antibody, and / or variant / mutant, or antigen-binding fragment thereof, bound to the CD73 protein in a sample from the patient (e.g., in vivo or ex vivo), or by contacting the anti-CD73 antibody, and / or variant / mutant, or antigen-binding fragment thereof with a sample from a patient and qualitatively or quantitatively detecting the anti-CD73 antibody, and / or affinity variant / mutant, or antigen-binding fragment thereof, bound to the CD73 protein.
[0066] With the benefit of the teachings presented in the foregoing description and the associated drawings, those skilled in the art of the disclosed compositions and methods will recognize many modifications and other embodiments disclosed herein. Therefore, it should be understood that the present invention is not limited to the specific embodiments disclosed, and improvements and other embodiments are intended to be included within the scope of the appended claims. The skilled person will recognize many variations and adaptations of the aspects described herein. These variations and adaptations are intended to be included in the teachings of the present invention and are encompassed in the claims herein.
[0067] Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.
[0068] As will be apparent to those skilled in the art upon reading the present specification, each of the individual embodiments described and illustrated herein has discrete components and features that may be readily separated or combined with the features of any other several embodiments without departing from the scope or spirit of the invention.
[0069] Any recited method may be performed in the order of events recited or in any other order that is logically feasible. That is, unless otherwise expressly stated, it is in no way intended that any method or aspect set forth herein be construed as requiring that its steps be performed in a particular order. Thus, in the absence of a method claim specifically stating in the claim or description that the steps are to be limited to a particular order, no order is intended to be inferred in any respect. This applies to any possible non-express basis for interpretation, including matters of logic regarding the arrangement of steps or operational flows, explicit meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification.
[0070] All references cited herein, including patent applications and publications, are incorporated herein by reference in their entirety. Only the disclosure of these publications discussed herein before the filing date of the present application is provided. This article should not be construed as admitting that the present invention is not entitled to predate such publications by virtue of the prior invention. In addition, the publication date provided herein may be different from the actual publication date, which may require independent confirmation.
[0071] Although aspects of the present invention may be described and claimed in specific statutory categories (such as the system statutory category), this is only for convenience and those skilled in the art will understand that each aspect of the present invention may be described and claimed in any statutory category.
[0072] It should also be understood that the terms used herein are only for the purpose of illustrating specific aspects and are not intended to be limiting. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to which the disclosed compositions and methods belong. It will be further understood that terms (such as those defined in commonly used dictionaries) should be interpreted as having a meaning consistent with that in the context of the specification and the relevant art, and unless explicitly defined herein, should not be interpreted as an idealized or overly formal meaning.
[0073] Before describing the various aspects of the present invention, the following definitions are provided and should be used unless otherwise indicated.Additional terms may be defined elsewhere in this disclosure.
[0074] definition
[0075] It should be understood that aspects and embodiments of the present invention described herein include "comprising," "consisting of," and "consisting essentially of," the aspects and embodiments.
[0076] As used herein, "comprising" should be interpreted as specifying the presence of claimed features, integers, steps or components as mentioned, but does not exclude the presence or addition of one or more features, integers, steps or components or groups thereof. In addition, each of the terms "by", "comprising, comprises, comprised of", "including, includes, included", "involving, involves, involved" and "for example" are used in their open, non-restrictive sense and can be used interchangeably. In addition, the term "comprising" is intended to include embodiments and aspects covered by the terms "essentially consisting of" and "consisting of". Similarly, the term "essentially consisting of" is intended to include embodiments covered by the term "consisting of".
[0077] It should be noted that ratios, concentrations, amounts and other numerical data can be expressed in range format herein. It will be further understood that the endpoints of each range are important relative to the other endpoints, and are independent of the other endpoints. It should also be understood that many values are disclosed herein, and in addition to the value itself, each value is also disclosed herein as "about" this particular value. For example, if the value "10" is disclosed, "about 10" is also disclosed. Scope can be expressed as from "about" a specific value, and / or to "about" other specific values in this article. Similarly, when a value is expressed as an approximate value by using the antecedent "about", it will be understood that this specific value forms an additional aspect. For example, if the value "about 10" is disclosed, "10" is also disclosed.
[0078] When expressing a range, additional aspects include from a specific value and / or to other specific values. For example, where the stated range includes one or two limitations, the range excluding one or two of those included limitations is also included in the present invention, such as the phrase 'x to y' includes the range from 'x' to 'y', and the range greater than 'x' and less than 'y'. The range may also be expressed as an upper limit, such as 'about x, y, z or less', and should be interpreted as including the specific range of 'about x', 'about y' and 'about z', and the range of 'less than x', 'less than y' and 'less than z'. Similarly, the phrase 'about x, y, z or greater' should be interpreted as including the specific range of 'about x', 'about y' and 'about z', and the range of 'greater than x', 'greater than y' and 'greater than z'. In addition, the phrase "about 'x' to 'y'", wherein 'x' and 'y' are numerical values, includes "about 'x' to about 'y'".
[0079] It should be understood that this range format is used for the purpose of convenience and brevity, and should therefore be flexibly interpreted to include not only the values explicitly recited as range limits, but also all individual values or subranges encompassed within the range, just as if each value and subrange were explicitly recited. For illustration, a numerical range of "about 0.1% to 5%" should be interpreted to include not only the explicitly recited values: about 0.1% to about 5%, but also individual values (e.g., about 1%, about 2%, about 3%, and about 4%) within the specified range, as well as subranges (e.g., about 0.5% to about 1.1%, about 0.5% to about 2.4%, about 0.5% to about 3.2%, and about 0.5% to about 4.4%, as well as other possible subranges).
[0080] As used herein, the terms "about", "approximately", "at or about" and "substantially" mean that the amount or value in question can be an exact value or a value that provides an equivalent result or effect as described in the claims or teachings herein. References to "about" values or parameters herein refer to the usual error range of the corresponding values that are readily known to those skilled in the art. That is, it should be understood that the amount, size, formula, parameter and other quantities and properties are not and do not have to be exact, but can be (as needed) about and / or larger or smaller, which reflects tolerances, conversion factors, rounding, measurement errors, etc., as well as other factors known to those skilled in the art, so as to obtain equivalent results or effects. In some cases, it is not possible to reasonably determine the value that provides an equivalent result or effect. In such examples, it is generally understood that, as used herein, "about" and "at or about" mean that the nominal value represents a ±10% variation, unless otherwise indicated or inferred. Typically, an amount, size, formula, parameter or other quantity or feature is "about", "approximately" or "at or about", whether or not explicitly stated as such. It should be understood that when "about," "approximately," or "at or about" is used before a quantitative value, unless otherwise specifically stated, the parameter also includes the specific quantitative value itself. That is, references herein to an "about" value or parameter include (and describe) aspects directed to the value or parameter itself. For example, descriptions referring to "about X" include descriptions of "X."
[0081] As used herein, the terms "optional" or "optionally" mean that the subsequently described event or circumstance may or may not occur, and that the description includes embodiments where said event or circumstance occurs and embodiments where it does not.
[0082] As used herein, "CD73" and "CD-73" are used interchangeably and refer to a cell surface enzyme encoded by a human gene comprising eight exons, the cytogenetic location of the human gene being 3q13.12, and the molecular position of base pairs being 85,449,584-85,495,791 on chromosome 6 (Homo sapiens Annotation Release 109, GRCh38.p12). The CD73 protein is a 5'-nucleotidase (Zn +2As a cofactor) enzyme (EC classification: 3.1.3.5). This protein is able to hydrolyze extracellular nucleotides into membrane-permeable nucleosides and is involved in the regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism. It is associated with an intracellular location primarily on the plasma membrane via a GPI anchor. The human CD73 protein has two isoforms produced by alternative splicing. The typical isoform (UniProtKB identifier P21589) contains 574 amino acids and has a molecular weight of approximately 63 kDa. CD73 is also known as ecto-5'-nucleotidase and 5'-nucleotidase. Mutations in the CD73 gene are associated with calcification of the joints and arteries, namely hereditary polycalcification of the arteries and joints syndrome.
[0083] As used herein, "treatment" or "treating" is a method for obtaining beneficial or desired results (including clinical results). For purposes of the present invention, beneficial or desired clinical results include, but are not limited to, one or more of the following: alleviating one or more symptoms caused by the disease, reducing the extent of the disease, stabilizing the disease (e.g., preventing or delaying the deterioration of the disease), preventing or delaying the spread of the disease (e.g., metastasis), preventing or delaying the recurrence of the disease, delaying or slowing down the progress of the disease, improving the disease state, providing relief (partial or complete) of the disease, reducing the dosage of one or more other drugs required for the treatment of the disease, delaying the progress of the disease, increasing or improving the quality of life, increasing weight gain and / or prolonging survival. "Treatment" also encompasses the pathological consequences of reducing cancer (such as, for example, tumor volume). The method provided herein contemplates any one or more of these treatment aspects.
[0084] The terms "recurrence," "relapse," or "recurrent" refer to the return of a cancer or disease after the disease is clinically assessed to be absent. The diagnosis of distant metastasis or local recurrence may be considered a recurrence.
[0085] The terms "refractory" or "resistant" refer to a cancer or disease that does not respond to treatment.
[0086] The term "adjuvant therapy" refers to therapy given after primary therapy, usually surgery. Adjuvant therapy for cancer or disease can include immunotherapy, chemotherapy, radiation therapy, or hormone therapy.
[0087] The term "maintenance therapy" refers to scheduled retreatment that is used to help maintain the effects of a previous treatment. Maintenance therapy is often given to help keep a cancer in remission or prolong the response to a specific therapy, regardless of disease progression.
[0088] The term "invasive cancer" refers to cancer that has spread beyond the tissue layer where the cancer started into normal surrounding tissue. Invasive cancer may or may not be metastatic.
[0089] The term "non-invasive cancer" refers to very early stage cancer or cancer that has not spread beyond the tissue where it originated.
[0090] The term "progression-free survival" in oncology refers to the length of time that cancer does not grow during and after treatment. Progression-free survival includes the amount of time a patient experiences a complete response or partial response, as well as the amount of time a patient experiences stable disease.
[0091] The term "progressive disease" in oncology can refer to tumor growth of more than 20% since the start of treatment due to an increase in mass or tumor spread.
[0092] A "disorder" is any clinical condition associated with CD73 expression, CD73 overexpression, and / or aberrant CD73 function in a subject (e.g., a mammal such as a human) such that the subject would benefit from treatment or prevention using the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions provided herein. For example, a mammal suffering from or in need of prevention of CD73 overexpression. This includes chronic and acute disorders or diseases, including those pathological conditions that predispose the mammal to the disorder in question. Non-limiting examples of disorders to be treated herein include the disclosed cancers (e.g., head and neck cancer, pharyngeal cancer, colorectal cancer, lung cancer, etc.) or fibrosis (including idiopathic pulmonary fibrosis).
[0093] As used herein, "tumor" refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all precancerous and cancerous cells and tissues.
[0094] The term "antibody" is used in the broadest sense and specifically covers, for example, single monoclonal antibodies (including agonists, antagonists and neutralizing antibodies), antibody compositions with multi-epitope specificity, polyclonal antibodies, single-chain antibodies and antibody fragments (see below), as long as they specifically bind to native polypeptides and / or exhibit the biological activity or immunological activity of the present invention. According to one embodiment, the antibody binds to an oligomeric form of the target protein, such as a trimer form. According to another embodiment, the antibody specifically binds to a protein, and the binding can be inhibited by the monoclonal antibody of the present invention (e.g., the deposited antibody of the present invention, etc.). The phrase "functional fragment or analog" of an antibody is a compound having the same qualitative biological activity as the antibody to which it refers. For example, a functional fragment or analog of an antibody of the present invention may be an antibody capable of specifically binding to CD73. In one embodiment, the antibody can induce macrophage-mediated phagocytosis of cancer cells expressing CD73.
[0095] "Isolated antibodies" are antibodies that have been identified and separated and / or recovered from components of their natural environment. The contaminating components of their natural environment are substances that interfere with the diagnostic or therapeutic use of the antibody, and may include enzymes, hormones, and other proteins or non-protein solutes. In a preferred embodiment, the antibody will be purified to (1) greater than 95% by weight of the antibody as determined by the Lowry method, and most preferably greater than 99% by weight, (2) by using a spinning cup sequencer to a degree sufficient to obtain at least 15 residues of the N-terminal or internal amino acid sequence, or (3) by SDS-PAGE under reducing or non-reducing conditions using Coomassie blue or preferably silver staining. The isolated antibody includes the in situ antibody in a recombinant cell, because at least one component of the antibody's natural environment will not be present. However, typically, the isolated antibody is prepared by at least one purification step.
[0096] The basic 4-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains (IgM antibodies are composed of 5 basic heterotetrameric units together with an additional polypeptide called J chain, and therefore contain 10 antigen binding sites, while secreted IgA antibodies can polymerize to form a multivalent combination containing 2-5 basic 4-chain units and J chains). In the case of IgG, the 4-chain unit is usually about 150,000 daltons. Each light (L) chain is linked to the heavy (H) chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds (depending on the H chain isotype). Each H and L chain also has regularly spaced intrachain disulfide bridges. Each H chain has a variable domain (VH) at the N-terminus, followed by three constant domains (CH) of each of the α and γ chains, and four CH domains of the μ and ε isotypes. Each L chain has a variable domain (VL) at the N-terminus and a constant domain (CL) at its other end. VL is aligned with VH, and CL is aligned with the first constant domain (CH1) of the heavy chain. Specific amino acid residues are considered to form an interface between the light chain and the heavy chain variable domains. The pairing of VH and VL together forms a single antigen binding site. For the structure and properties of different classes of antibodies, see, for example, Basic and Clinical Immunology, 8th edition, Daniel P. Stites et al., Appleton & Lange, Norwalk, CT, 1994, page 71 and Chapter 6.
[0097] The L chain from any vertebrate species can be designated as one of two distinct types, called κ and λ, based on the amino acid sequence of its constant domain. Depending on the amino acid sequence of the constant domain of its heavy chain (CH), immunoglobulins can be designated as different classes or isotypes. There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, with heavy chains designated as α, δ, γ, ε, and μ, respectively. Based on the relatively small differences in CH sequence and function, γ and α classes are further divided into subclasses, for example, people express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.
[0098] The term "variable" refers to the fact that certain segments of the variable domain differ greatly in sequence between antibodies. The V domain mediates antigen binding and defines the specificity of a particular antibody for its specific antigen. However, variability is not evenly distributed across the 110 amino acid span of the variable domain. Instead, the V region consists of relatively invariant segments of 15-30 amino acids called framework regions (FRs), which are separated by shorter regions (9-12 amino acids long each) called "hypervariable regions". The variable domains of native heavy and light chains each include four FRs that primarily adopt a β-sheet configuration, which are connected by three hypervariable regions, which are connected to form a loop connecting the β-sheet structure, and in some cases form a part of the β-sheet structure. The hypervariable regions in each chain are held in close proximity by the FRs and, in the case of hypervariable regions from other chains, contribute to the formation of the antigen-binding site of the antibody (see Sequences of Proteins of Immunological Interest, 5th ed., Elvin A. Kabat et al., Public Health Service, National Institutes of Health, Bethesda, MD, 1991). The constant domains are not directly involved in binding the antibody to the antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular cytotoxicity (ADCC).
[0099] As used herein, the term "CDR" or "complementarity determining region" is intended to refer to the non-contiguous antigen binding sites found within the variable regions of heavy and light chain polypeptides. These specific regions have been described in: Kabat EA et al., J. Biol. Chem., 252(19):6609-6616 (1977); Sequences of Proteins of Immunological Interest, 5th Edition, Elvin A. Kabat et al., Public Health Service, National Institutes of Health, Bethesda, MD, 1991; Chothia C. et al., J. Mol. Biol., 196(4):901-917 (1987); and MacCallum RM. et al., J. Mol. Biol., 262(5):732-745 (1996), where the definitions include overlapping or subsets of amino acid residues when compared to each other. However, application of either definition to refer to a CDR of an antibody or grafted antibody or variant thereof is intended to fall within the scope of the term as defined and used herein. The amino acid residues encompassing the CDRs as defined in each of the above references are listed in Table 4 below as a comparison.
[0100] Table 4
[0101]
[0102] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially uniform antibody population, i.e., the antibodies of individuals comprising a population are identical, except for possible naturally occurring mutations that may be present in small amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. In addition, unlike polyclonal antibody preparations (which include different antibodies directed against different determinants (epitopes)), each monoclonal antibody is directed against a single determinant on an antigen. In addition to its specificity, the advantage of monoclonal antibodies is that they can be synthesized without being contaminated by other antibodies. The modifier "monoclonal" should not be interpreted as requiring antibodies to be produced by any ad hoc method. For example, monoclonal antibodies that can be used in the present invention can be prepared by the hybridoma method first described in Kohler G. et al. Nature [Nature], 256 (5517): 495-497 (1975), or can be prepared using a recombinant DNA method in bacteria, eukaryotic animals or plant cells (see, e.g., U.S. Patent No. 4,816,567). "Monoclonal antibodies" can also be isolated from phage antibody libraries using the techniques described in Clackson T. et al., Nature, 352(6336):624-628 (1991), Marks JD. et al., J. Mol. Biol., 222(3):581-597 (1991), and, for example, in the Examples below.
[0103] The monoclonal antibodies herein include "chimeric" antibodies, in which a portion of the heavy chain and / or light chain is identical or homologous to a corresponding sequence in an antibody derived from a particular species or belonging to a particular antibody class or subclass, and the remainder of the chain or chains is identical or homologous to a corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the biological activity of the present invention (see U.S. Pat. No. 4,816,567; and Morrison SL. et al., Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States] 81(21): 6851-6855 (1984)). The chimeric antibodies of interest herein include "primatized" antibodies, which comprise variable domain antigen-binding sequences derived from non-human primates (e.g., Old World monkeys, apes, etc.), and human constant region sequences.
[0104] A "complete" antibody is an antibody that comprises an antigen binding site as well as CL and at least heavy chain constant domains CH1, CH2 and CH3. The constant domain may be a native sequence constant domain (e.g., a human native sequence constant domain) or an amino acid sequence variant thereof. Preferably, the complete antibody has one or more effector functions. The constant domain (constant region) is preferably a human antibody constant region, more preferably a human IgG1, human IgG2, human IgG3 or human IgG4 antibody constant region, the optional heavy chain constant region specific sequence is shown in SEQ ID NO: 112, 113 or 114, and the optional light chain constant region specific sequence is shown in SEQ ID NO: 115.
[0105] "Antibody fragments" comprise a portion of an intact antibody, preferably the antigen binding region or variable region of an intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies (see U.S. Pat. No. 5,641,870, Example 2; Zapata G. et al., Protein Eng. [Protein Engineering], 8(10): 1057-1062 (1995)); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. The expression "linear antibody" generally refers to the antibodies described in Zapata G. et al., Protein Eng. [Protein Engineering] 8(10): 1057-1062 (1995). In short, these antibodies comprise a pair of tandem Fd segments (VH-CH1-VH-CH1) that, together with complementary light chain polypeptides, form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.
[0106] Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, and a residual "Fc" fragment (this name reflects the ability to crystallize easily). The Fab fragment consists of the entire L chain together with the variable region domain (VH) of the H chain and the first constant domain of one heavy chain (CH1). Each Fab fragment is monovalent with respect to antigen binding, i.e., it has a single antigen-binding site. Pepsin treatment of antibodies produces a single large F(ab')2 fragment, which roughly corresponds to two disulfide-linked Fab fragments with divalent antigen-binding activity and is still capable of cross-linking antigen. The Fab' fragment is distinguished from the Fab fragment by having additional residues at the carboxyl terminus of the CH1 domain including one or more cysteines from the hinge region of the antibody. Fab'-SH is the designation herein for Fab' in which the one or more cysteine residues of the constant domains carry a free thiol group. F(ab')2 antibody fragments were originally produced as pairs of Fab' fragments with hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
[0107] The Fc fragment comprises the carboxyl terminal portions of two H chains held together by disulfide bonds. The effector functions of an antibody are determined by sequences in the Fc region, which is also the portion recognized by Fc receptors (FcR) found on certain types of cells.
[0108] A "variant Fc region" comprises an amino acid sequence that differs from a native sequence Fc region due to at least one "amino acid modification" as defined herein. Preferably, the variant Fc region has at least one amino acid substitution compared to the native sequence Fc region or the Fc region of a parent polypeptide, for example from about one to about ten amino acid substitutions in the native sequence Fc region or the Fc region of a parent polypeptide, and preferably from about one to about five amino acid substitutions. In one embodiment, the variant Fc region herein will have at least about 80% homology, at least about 85% homology, at least about 90% homology, at least about 95% homology, or at least about 99% homology with the native sequence Fc region. According to another embodiment, the variant Fc region herein will have at least about 80% homology, at least about 85% homology, at least about 90% homology, at least about 95% homology, or at least about 99% homology with the Fc region of a parent polypeptide.
[0109] The term "polypeptide comprising an Fc region" refers to a polypeptide comprising an Fc region, such as an antibody or immunoadhesion protein (see definition elsewhere herein). The C-terminal lysine (residue 447 according to the EU numbering system) of the Fc region can be removed, for example, during purification of the polypeptide or by recombinant engineering of a nucleic acid encoding the polypeptide. Thus, a composition comprising polypeptides (including antibodies) having an Fc region according to the present disclosure can comprise a population of polypeptides with all K447 residues removed, a population of polypeptides without the K447 residue removed, or a population of polypeptides with and without a mixture of K447 residues.
[0110] Antibody "effector functions" refer to those biological activities attributable to the Fc region (a native sequence Fc region or an amino acid sequence variant Fc region) of an antibody, and vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity; Fc receptor binding; antibody dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors; and B cell activation. A "native sequence Fc region" comprises an amino acid sequence identical to the amino acid sequence of a naturally occurring Fc region. Examples of Fc sequences are described, for example, but not limited to: Sequences of Proteins of Immunological Interest, 5th Edition, Elvin A. Kabat et al., Public Health Service, National Institutes of Health, Bethesda, MD., 1991.
[0111] "Fv" is the smallest antibody fragment, which contains a complete antigen recognition site and an antigen binding site. The fragment consists of a dimer of a heavy chain variable region domain and a light chain variable region domain in tight non-covalent association. Six hypervariable loops (3 loops each from the H chain and the L chain) are emanated from the folding of these two domains, which contribute amino acid residues for antigen binding and confer specificity to the antibody and antigen binding.
[0112] However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although usually at a lower affinity than the entire binding site.
[0113] "Single-chain Fv" (also abbreviated as "sFv" or "scFv") is an antibody fragment comprising VH and VL antibody domains linked into a single polypeptide chain. Preferably, the sFv polypeptide further comprises a polypeptide linker between the VH and VL domains that enables the sFv to form a desired structure for antigen binding. For a review of scFv, see A. Pluckthun, "Antibodies from Escherichia coli" in The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore, eds., Springer-Verlag, New York, 1994, pp. 269-315; or Ahmad ZA. et al., Clin. Dev. Immunol., 2012: 980250 (2012).
[0114] The term "diabodies" refers to small antibody fragments prepared by constructing sFv fragments (see the preceding paragraph) with a short linker (about 5-10 residues) between the VH and VL domains, so that interchain rather than intrachain pairing of the V domains is achieved, resulting in a bivalent fragment, i.e., a fragment with two antigen binding sites. Bispecific diabodies are heterodimers of two "crossover" sFv fragments, in which the VH and VL domains of the two antibodies are present on different polypeptide chains. Diabodies are more fully described in, for example, EP 404,097; WO 404,097.
[0115] 93 / 11161; and Hollinger P. et al., Proc. Natl. Acad. Sci. USA, 90(14):6444-6448 (1993).
[0116] "Humanized" forms of non-human (e.g., rodent) antibodies are chimeric antibodies that contain minimal sequence derived from non-human antibodies. In most cases, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region (donor antibody) of a non-human species (e.g., mouse, rat, rabbit, or non-human primate) having the desired antigen specificity, affinity, and capacity. In some embodiments, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.
[0117] In addition, humanized antibodies may include residues not found in the recipient antibody or the donor antibody. These modifications are made to further improve antibody performance. Generally, humanized antibodies will include substantially all of at least one and typically two variable domains, wherein all or substantially all of the hypervariable loops correspond to those of non-human immunoglobulins, and all or substantially all of the FRs are those of human immunoglobulin sequences. Humanized antibodies will also optionally include at least a portion of an immunoglobulin constant region, typically at least a portion of a human immunoglobulin. For additional details, see Jones PT. et al., Nature [Nature], 321 (6069): 522-525 (1986); Riechmann L. et al., Nature [Nature], 332 (6162): 323-329 (1988); and Presta LG, Curr. Opin. Biotechnol. [Biotechnol. Review], 3 (4): 394-398 (1992).
[0118] The "percentage (%) of amino acid sequence identity with respect to the polypeptide and antibody sequences identified herein" or "homology" is defined as the percentage of amino acid residues in the candidate sequence that are identical to the amino acid residues in the compared polypeptide after aligning the sequences (taking into account any conservative substitutions as part of the sequence identity). For the purpose of determining the percentage of amino acid sequence identity, alignment can be achieved in a variety of ways in the art, such as using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. One skilled in the art can determine appropriate parameters for measuring alignment, including any algorithm that requires maximum alignment over the full length of the compared sequences. However, for the purposes of this article, amino acid sequence identity % values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was written by Genentech, Inc., and the source code has been submitted with user documentation in the US Copyright Office (Washington DC, 20559), which is registered under US Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc. in South San Francisco, California. The ALIGN-2 program should be compiled for use on a UNIX operating system (preferably digital UNIX V4.0D). All sequence comparison parameters are set by the ALIGN-2 program and do not change.
[0119] The term "Fc receptor" or "FcR" is used to describe a receptor that binds to the Fc region of an antibody. In one embodiment, the FcR of the present invention is an FcR (gamma receptor) that binds to an IgG antibody, and includes receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these receptors. FcγRII receptors include FcγRIIA ("activating receptor") and FcγRIIB ("inhibiting receptor"), and FcγRIIA and FcγRIIB have similar amino acid sequences (these sequences differ primarily in their cytoplasmic domains). The activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. The inhibitory receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain (see M, Annu. Rev. Immunol., 15:203-234 (1997). The term includes allotypes, such as the FcγRIIIA allotypes: FcγRIIIA-Phe158, FcγRIIIA-Val158, FcγRIIA-R131 and / or FcγRIIA-H131. FcRs are reviewed in Ravetch JV. et al., Annu. Rev. Immunol., 9:457-492 (1991); Capel PJ. et al., Immunomethods, 4(1):25-34 (1994); and de Haas M. et al., J. Lab. Clin. Med., 126(4):330-341 (1995). The term "FcR" herein encompasses other FcRs, including those identified in the future. The term also includes the neonatal receptor FcRn, which is responsible for the transfer of maternal IgG to the fetus (Guyer RL. et al., J. Immunol. [Journal of Immunology], 117(2):587-593 (1976) and Kim JK. et al., Eur. J. Immunol. [European Journal of Immunology], 24(10):2429-2434 (1994)).
[0120] The term "FcRn" refers to neonatal Fc receptor (FcRn). FcRn is structurally similar to the major histocompatibility complex (MHC) and consists of an α chain that is non-covalently bound to β2-microglobulin. The various functions of neonatal Fc receptor FcRn are reviewed in Ghetie V. et al., Annu. Rev. Immunol. [Annual Review of Immunology], 18: 739-766 (2000). FcRn plays a role in the passive delivery of immunoglobulin IgG from mother to offspring and in regulating serum IgG levels. FcRn can act as a salvage receptor to bind and transport (both intracellularly or transcellularly) cytosolic IgG in a complete form and rescue them from the default degradation pathway.
[0121] The "CH1 domain" of a human IgG Fc region (also referred to as "C1" of "H1") "domain" typically stretches from about amino acid 118 to about amino acid 215 (EU numbering system).
[0122] The "hinge region" is generally defined as extending from Glu216 to Pro230 of human IgG1 (Burton DR., Mol. Immunol., 22(3):161-206 (1985)). Hinge regions of other IgG isotypes can be aligned with the IgG1 sequence by placing the first and last cysteine residues that form the inter-heavy chain SS bond in the same position.
[0123] The "lower hinge region" of an Fc region is generally defined as the region of residues immediately adjacent to the C-terminus of the hinge region, i.e., residues 233 to 239 of the Fc region. In previous reports, FcR binding was generally attributed to amino acid residues in the lower hinge region of the IgG Fc region.
[0124] The "CH2 domain" (also called "C2" of "H2") of the human IgG Fc region generally extends from about amino acid 231 to about amino acid 340. The CH2 domain is unique in that it is not tightly paired with another domain. Instead, two N-linked branched carbohydrate chains are inserted between the two CH2 domains of the intact native IgG molecule. It is speculated that carbohydrates can provide an alternative to domain-domain pairing and help stabilize the CH2 domain (Burton DR., Mol. Immunol. [Molecular Immunology], 22 (3): 161-206 (1985)).
[0125] The "CH3 domain" (also called a "C2" or "H3" domain) comprises the region of residues in the Fc region that are C-terminal to the CH2 domain (i.e., from about amino acid residue 341 to the C-terminus of the antibody sequence (typically at amino acid residue 446 or 447 for IgG)).
[0126] A "functional Fc region" has an "effector function" of a native sequence Fc region. Exemplary "effector functions" include C1q binding; complement dependent cytotoxicity; Fc receptor binding; antibody dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptor; BCR), etc. Such effector functions generally require an Fc region in combination with a binding domain (e.g., an antibody variable domain), and can be assessed using, for example, the various assays disclosed herein.
[0127] "Clq" is a polypeptide that contains the binding site for the Fc region of an immunoglobulin. Clq, together with two serine proteases, Clr and Cls, forms complex Cl, the first component of the complement dependent cytotoxicity (CDC) pathway. Human Clq can be purchased commercially, for example, from Quidel, San Diego, CA.
[0128] The term "binding domain" refers to a region of a polypeptide that binds to another molecule. In the case of an FcR, the binding domain may comprise the portion of its polypeptide chain responsible for binding to the Fc region (e.g., its α chain). One useful binding domain is the extracellular domain of the FcR α chain.
[0129] An antibody with a variant IgG Fc that has an "altered" FcR binding affinity or ADCC activity is an antibody that has enhanced or diminished FcR binding activity (e.g., FcγR or FcRn) and / or ADCC activity compared to a parent polypeptide or a polypeptide comprising a native sequence Fc region. A variant Fc that "exhibits increased binding" to an FcR binds to at least one FcR with a higher affinity (e.g., a lower apparent Kd or IC50 value) than a parent polypeptide or native sequence IgG Fc. According to some embodiments, the improvement in binding is about 3-fold, preferably about 5-fold, 10-fold, 25-fold, 50-fold, 60-fold, 100-fold, 150-fold, 200-fold, up to 500-fold, or about 25% to 1000% improvement in binding compared to a parent polypeptide. A polypeptide variant that "exhibits reduced binding" to an FcR binds at least one FcR with a lower affinity (e.g., a higher apparent Kd or a higher IC50 value) than the parent polypeptide. The reduction in binding compared to the parent polypeptide may be a reduction in binding of about 40% or more.
[0130] "Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of cytotoxicity in which secreted Ig binds to Fc receptors (FcRs) present on certain cytotoxic cells (e.g., natural killer (NK) cells, neutrophils, and macrophages) so that these cytotoxic effector cells specifically bind to target cells carrying antigens and subsequently kill the target cells with cytotoxins. Antibodies "arm" cytotoxic cells and are absolutely necessary for this killing. Primary cells used to mediate ADCC, NK cells, express only FcγRIII, while monocytes express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch JV. et al., Annu. Rev. Immunol. [Annual Review of Immunology] 9: 457-492 (1991). In order to evaluate the ADCC activity of the target molecule, an in vitro ADCC assay (such as described in U.S. Pat. No. 5,500,362 or 5,821,337 or the Examples below) can be performed. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively or additionally, the ADCC activity of the target molecule can be evaluated in vivo, for example in an animal model, such as disclosed in Clynes R. et al., Proc. Natl. Acad. Sci. USA, [Proceedings of the National Academy of Sciences of the United States] 95 (2): 652-656 (1998).
[0131] A polypeptide comprising a variant Fc region ("exhibiting increased ADCC" or mediating antibody-dependent cell-mediated cytotoxicity (ADCC) more effectively than a polypeptide or parent polypeptide having a wild-type IgG Fc in the presence of human effector cells) is a polypeptide that mediates ADCC substantially more effectively in vitro or in vivo when the amount of the polypeptide having the variant Fc region and the polypeptide having the wild-type Fc region (or parent polypeptide) in the assay is substantially the same. Typically, such variants are identified using any in vitro ADCC assay known in the art, such as an assay or method for determining ADCC activity (e.g., in an animal model, etc.). In one embodiment, a preferred variant is one that mediates ADCC more effectively from about 5 times to about 100 times (e.g., from about 25 to about 50 times) than a wild-type Fc (or parent polypeptide).
[0132] "Complement dependent cytotoxicity" or "CDC" refers to the lysis of target cells in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (Clq) to an antibody (of the appropriate subclass) that binds to its cognate antigen. To assess complement activation, a CDC assay may be performed (e.g., as described in Gazzano-Santoro H. et al., J. Immunol. Methods, 202(2):163-171 (1997)). Polypeptide variants with altered Fc region amino acid sequences, and increased or decreased Clq binding ability are described in U.S. Pat. No. 6,194,551B1 and WO 99 / 51642. The contents of these patent publications are expressly incorporated herein by reference (see also Idusogie EE. et al., J. Immunol., 164(8):4178-4184 (2000)).
[0133] An "effective amount" of an anti-CD73 antibody (or fragment thereof) or composition as disclosed herein is an amount sufficient to achieve a particular stated purpose. An "effective amount" can be determined empirically and by known methods relevant to the stated purpose. The term "therapeutically effective amount" refers to an amount of an anti-CD73 antibody (or variant or antigen-binding fragment thereof) or composition as disclosed herein that is effective to "treat" a disease or disorder in a mammal (also known as a patient). In the case of cancer, a therapeutically effective amount of an anti-CD73 antibody (or variant or antigen-binding fragment thereof) or composition as disclosed herein can reduce the number of cancer cells; reduce tumor size or weight; inhibit (i.e., slow down to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow down to some extent and preferably stop) tumor metastasis; inhibit tumor growth to some extent; and / or alleviate one or more symptoms associated with cancer to some extent. To the extent that an anti-CD73 antibody (or variant or antigen-binding fragment thereof) or composition as disclosed herein can prevent the growth of existing cancer cells and / or kill existing cancer cells, the antibody (or variant or antigen-binding fragment thereof) or composition can be cytostatic and / or cytotoxic. In one embodiment, the therapeutically effective amount is a growth inhibitory amount. In another embodiment, the therapeutically effective amount is an amount that prolongs patient survival. In another embodiment, the therapeutically effective amount is an amount that improves patient progression-free survival.
[0134] A "growth inhibitory amount" of an anti-CD73 antibody (or variant or antigen-binding fragment thereof) of the invention or a composition as disclosed herein is an amount capable of inhibiting the growth of a cell (particularly a tumor, such as a cancer cell) in vitro or in vivo. A "growth inhibitory amount" of a polypeptide, antibody, antagonist or composition of the disclosure for the purpose of inhibiting neoplastic cell growth can be determined empirically and by known methods or by the examples provided herein.
[0135] A "cytotoxic amount" of an anti-CD73 antibody (or variant or antigen-binding fragment thereof) or composition of the present invention is an amount capable of destroying cells (particularly tumors, such as cancer cells) in vitro or in vivo. A "cytotoxic amount" of an anti-CD73 antibody (or variant or antigen-binding fragment thereof) or composition of the present invention for the purpose of inhibiting neoplastic cell growth can be determined empirically and by methods known in the art.
[0136] A "growth inhibitory amount" of an anti-CD73 antibody (or variant or antigen-binding fragment thereof) or composition of the present invention is an amount capable of inhibiting the growth of cells (particularly tumors, such as cancer cells) in vitro or in vivo. A "growth inhibitory amount" of an anti-CD73 antibody (or variant or antigen-binding fragment thereof) or composition of the present disclosure for the purpose of inhibiting neoplastic cell growth can be determined empirically and by known methods or by the examples provided herein.
[0137] As used herein, "pharmaceutically acceptable" or "pharmacologically compatible" refers to materials that are not biologically or otherwise undesirable, e.g., materials that can be incorporated into a pharmaceutical composition administered to a patient without causing any significant undesirable biological effect or interaction in a deleterious manner with any other component of the composition containing the material. Pharmaceutically acceptable carriers or excipients preferably meet the required standards of toxicology and manufacturing testing and / or are included in the inactive ingredient guide compiled by the US Food and Drug Administration.
[0138] The term "detecting" is intended to include determining the presence or absence of a substance, or quantifying the amount of a substance (such as CD73). Thus, the term refers to the use of the materials, compositions and methods of the invention for both qualitative and quantitative determinations. In general, the particular technique used for detection is not important to the practice of the invention.
[0139] For example, "detection" according to the present invention may include: observing the presence or absence of CD73 gene products, mRNA molecules, or CD73 polypeptides; changes in CD73 polypeptide levels or the amount of binding to a target; changes in the biological function / activity of a CD73 polypeptide. In some embodiments, "detection" may include detecting wild-type CD73 levels (e.g., mRNA or polypeptide levels). Detection may include quantifying a change (increase or decrease) in any value between 10% and 90%, or in any value between 30% and 60%, or more than 100%, compared to a control. Detection may include quantifying a change in any value between 2-fold and 10-fold (including end values) or more (e.g., 100-fold).
[0140] As used herein, the term "label" refers to a detectable compound or composition that can be conjugated directly or indirectly to an antibody. The label can itself be detectable (e.g., a radioisotope label or a fluorescent label) or, in the case of an enzyme label, can catalyze chemical alteration of a substrate compound or composition that is detectable. Anti-CD73 Antibodies and Affinity Variants / Mutants
[0141] The present invention relates to antibodies that bind to the CD73 receptor as disclosed herein. The disclosed anti-CD73 antibodies, and their affinity variants and / or mutants, or antigen-binding fragments thereof can be used in various therapeutic and diagnostic methods. Anti-CD73 antibodies are antibodies that bind to CD73 with sufficient affinity and specificity. In some embodiments, the disclosed anti-CD73 antibodies (or their variants or mutants or antigen-binding fragments) can be used as therapeutic agents in targeting and interfering with diseases or conditions associated with the expression of CD73. In various aspects, the disclosed anti-CD73 antibodies (or variants / mutants or antigen-binding fragments thereof) show minimal binding to other proteins. In some embodiments, it is preferred that the disclosed anti-CD73 antibodies (or variants / mutants or antigen-binding fragments thereof) are human or recombinant humanized anti-CD73 monoclonal antibodies.
[0142] Without wishing to be bound by a particular theory, it is believed that the disclosed anti-CD73 antibodies, and affinity variants and / or mutants thereof, or antigen-binding fragments thereof, can increase the internalization of CD73 in cells expressing CD73, thereby resulting in a reduction in the amount of CD73 protein on the plasma membrane on cells to which the disclosed anti-CD73 antibodies, and affinity variants and / or mutants thereof, or antigen-binding fragments thereof bind. Thus, the reduction in the amount of CD73 protein on the plasma membrane is associated with a reduction in the 5'-nucleotidase activity associated with CD73. In some aspects, again without wishing to be bound by a particular theory, it is believed that the reduction in 5'-nucleotidase activity associated with CD73 (via increased internalization) can reduce tumor cell proliferation via enhanced immune cell function at the tumor site due to the reduction in 5'-nucleotidase activity.
[0143] As disclosed herein, the disclosed anti-CD73 antibodies, and affinity variants and / or mutants or antigen-binding fragments thereof, are believed to have beneficial effects in other clinical conditions associated with CD73 expression, such as fibrosis, including idiopathic pulmonary fibrosis. Without wishing to be bound by a particular theory, it is believed that in other such clinical conditions, the disclosed anti-CD73 antibodies, and affinity variants and / or mutants or antigen-binding fragments thereof, may have a positive clinical benefit to patients, such as fibrosis (including idiopathic pulmonary fibrosis), due to a reduction in CD73 protein (and correspondingly, reduced 5'-nucleotidase activity) of appropriate cells expressing CD73.
[0144] According to certain embodiments, the anti-CD73 antibody comprises the CDRs, variable heavy chain regions, and / or variable light chain regions of any one of the antibodies disclosed herein.
[0145] The present invention provides anti-CD73 antibodies, their affinity variants / mutants, and / or antigen-binding fragments thereof. In certain embodiments, a specific anti-CD73 antibody of the present invention, its one or more affinity variants / mutants, and / or its one or more antigen-binding fragments comprise a light chain (LC) variable domain sequence (comprising the specific CDR-L1, CDR-L2, and CDR-L3 sequences listed in Table 1 above) and a heavy chain (HC) variable domain sequence (comprising the specific CDR-H1, CDR-H2, and CDR-H3 sequences listed in Table 2 above). The nucleic acid and amino acid sequences of each light chain and heavy chain of each specific anti-CD73 antibody of the present invention, its one or more affinity variants / mutants, and / or its one or more antigen-binding fragments are also provided in the sequence table below. The present invention provides heavy and light chain variable domains, and the CDRs mentioned herein are combined in all possible pairs to generate a large number of anti-CD73 antibodies, and their one or more affinity variants / mutants, and / or their one or more antigen-binding fragments.
[0146] In certain embodiments, the one or more amino acid substitutions are one or more conservative amino acid substitutions. In certain embodiments, the amino acid substitutions do not substantially reduce the ability of the antibody to bind to the antigen. For example, conservative changes (e.g., conservative substitutions as provided herein) that do not substantially reduce the binding affinity of the disclosed antibodies to the target CD73 can be made. The binding affinity of the anti-CD73 antibody variants can be assessed using the methods described in the Examples below.
[0147] Conservative substitutions are shown in Table 5 under the heading "Conservative Substitutions". More substantial changes are provided in Table 4 under the heading "Exemplary Substitutions", and are further described below with reference to amino acid side chain classes. Amino acid substitutions can be introduced into an antibody of interest, and the products screened for a desired activity (e.g., retained / improved CD73 binding, reduced immunogenicity, or improved ADCC or CDC).
[0148] Table 5: Conservative substitutions
[0149]
[0150]
[0151] Non-conservative substitutions will require exchanging a member of one of these categories for another category.Exemplary substitution variants are affinity-matured antibodies that can be easily generated, such as using affinity maturation techniques based on phage display (such as those disclosed herein).In short, one or more CDR residues are mutated, and the variant antibody is displayed on phage and screened for specific biological activity (such as binding affinity).Changes (e.g., substitutions) can be made in HVR, such as to improve antibody affinity.Such changes can be made in HVR "hot spots" (i.e., residues encoded by codons that undergo mutations at high frequency during the somatic maturation process) (see, e.g., Chowdhury, Methods Mol. Biol. [Molecular Biology Methods] 207: 179-196 (2008)) and / or in SDR (a-CDR), the binding affinity of the resulting variant VH or VL is tested. Affinity maturation by construction of secondary libraries and reselection from secondary libraries has been described, for example, in Hoogenboom HR, Methods in Mol. Biol. 178: 1-37 (2002); Antibody Phage Display, Philippa O'Brien, RA, Humana Press, Totowa, NJ, 2001.
[0152] In some embodiments of affinity maturation, diversity is introduced into the variable genes selected for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then generated. The library is then screened to identify any antibody variants with the desired affinity. Another method for introducing diversity involves an HVR-directed approach in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding can be specifically identified, for example, using alanine scanning mutagenesis or modeling.
[0153] In certain embodiments, an anti-CD73 antibody, variant or mutant, or antigen-binding fragment thereof, may lack an N-glycosylation motif in the heavy or light chain variable region, which may result in differences within a batch of antibodies, resulting in altered function, immunogenicity or stability. Methods for analyzing antibody glycosylation include, but are not limited to, for example, chromatography (e.g., cation exchange chromatography (CEX) or liquid chromatography), mass spectrometry (e.g., electrospray ionization mass spectrometry), and capillary electrophoresis-sodium dodecyl sulfate. Such methods are described, for example, in Jung ST. et al., Curr. Opin. Biotechnol., 22(6):858-67 (2011); Cummings RD, Etzler ME. Antibodies and Lectins in Glycan Analysis. In: Varki A, Cummings RD, Esko JD et al., eds. Essentials of Glycobiology. 2nd ed. Cold Spring Harbor (New York): Cold Spring Harbor Laboratory Press; 2009. Chapter 45; Mulloy B, Hart GW, Stanley P. Structural Analysis of Glycans. In: Varki A, Cummings RD, Esko JD et al., eds. Essentials of Glycobiology. 2nd ed. Cold Spring Harbor (New York): Cold Spring Harbor Laboratory Press; 2009. Chapter 45. Harbor (New York): Cold Spring Harbor Laboratory Press; 2009. Chapter 47; Leymarie N. et al., Anal. Chem., 84(7):3040-3048 (2012); Fernandez DD., European Biopharmaceutical Review, 106-110 (2005); and Raju TS, Methods Mol. Biol., 988:169-180 (2013).
[0154] In certain embodiments, a mutant of a particular anti-CD73 antibody mutant comprises one or more mutations at an N-glycosylation site in one or more CDR regions, such as the sequence NXS / T. An anti-CD73 antibody mutant having one or more mutations at an N-glycosylation site eliminates the N-glycosylation site but retains equivalent function.
[0155] In certain embodiments, the anti-CD73 antibody, variant and / or mutant, or antigen-binding fragment thereof has a higher binding affinity for CD73 than for a CD73 homolog. Typically, an anti-CD73 antibody, and / or variant, or antigen-binding fragment thereof "specifically binds" CD73 (i.e., has no more than about 1 x 10 -7 M, preferably no more than about 1 x 10 -8 and most preferably no more than about 1 x 10 -9 M), but has a binding affinity for non-CD73 that is at least about 50 times, or at least about 500 times, or at least about 1000 times weaker than its binding affinity for CD73. The anti-CD73 antibody that specifically binds to CD73 can be any of the various types of antibodies as defined above, but is preferably a humanized or human antibody.
[0156] In some embodiments, the extent of binding of the anti-CD73 antibody to the non-target protein is less than about 10% of the binding of the antibody to CD73 as determined by methods known in the art, such as ELISA, fluorescence activated cell sorting (FACS) analysis, or radioimmunoprecipitation (RIA). Specific binding can be measured, for example, by determining the binding of a molecule compared to the binding of a control molecule (typically a molecule of similar structure that does not have binding activity). For example, specific binding can be determined by competition with a control molecule similar to the target (e.g., an excess of unlabeled target). In this case, if the binding of the labeled target to the probe is competitively inhibited by an excess of unlabeled target, specific binding is indicated. As used herein, the term "specifically binds" a particular polypeptide or an epitope on a particular polypeptide target or "specifically binds to" or has "specificity" for a particular polypeptide or an epitope on a particular polypeptide target can be expressed as follows: for example, having at least about 10 -4 M, alternatively at least about 10 -5 M, alternatively at least about 10 -6 M, alternatively at least about 10 -7 M, alternatively at least about 10 -8 M, alternatively at least about 10 -9 M, alternatively at least about 10 -10 M, alternatively at least about 10 -11 M, alternatively at least about 10 -12In one embodiment, the term "specific binding" refers to binding in which a molecule binds to a specific polypeptide or an epitope on a specific polypeptide without substantially binding to any other polypeptide or polypeptide epitope.
[0157] Antibody-dependent cell-mediated cytotoxicity (ADCC) is the mechanism of action of therapeutic antibodies against tumor cells. ADCC is a cell-mediated immune defense whereby effector cells of the immune system actively lyse target cells (e.g., cancer cells) whose membrane surface antigens are bound by specific antibodies (e.g., anti-CD73 antibodies and / or affinity variants as described herein). In some embodiments, the anti-CD73 antibodies and / or affinity variants exhibit antibody-dependent cell-mediated cytotoxicity (ADCC) effector functions similar to those of the reference anti-CD73 monoclonal antibody, as demonstrated, for example, by the assays described in the Examples.
[0158] For example, in certain embodiments, the ADCC effector function activity of the anti-CD73 antibodies and / or affinity variants or mutants thereof described herein is at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 100%, or more of the ADCC effector function activity of a reference anti-CD73 antibody. %, or more than 100% (e.g., about 105%, about 106%, about 107%, about 108%, about 109%, about 110%, about 111%, about 112%, about 113%, about 114%, about 115%, about 116%, about 117%, about 118%, about 119%, about 120%, about 121%, about 122%, about 123%, about 124%, about 125%, or about 130%), including any ranges between these values.
[0159] In certain embodiments, the anti-CD73 antibodies, and / or affinity variants thereof, or mutants thereof, exhibit binding affinity to CD73 similar to that of a reference anti-CD73 antibody. In certain embodiments, binding to CD73 is demonstrated by ELISA, as described in the Examples. For example, the binding affinity of anti-CD73 and / or affinity variants thereof, or mutants thereof, to CD73 is about 1%, about 5%, about 10%, about 15%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or more than the binding affinity of the reference anti-CD73 antibody to CD73. About 100% (e.g., about 105%, about 106%, about 107%, about 108%, about 109%, about 110%, about 111%, about 112%, about 113%, about 114%, about 115%, about 116%, about 117%, about 118%, about 119%, about 120%, about 121%, about 122%, about 123%, about 124%, about 125%, or more than about 125%).
[0160] In certain embodiments, the anti-CD73 antibodies, and / or affinity variants or mutants thereof, bind to human CD73 with a Kd between about 0.1 pM and 200 pM (0.2 nM), for example, about 0.1 pM, about 0.25 pM, about 0.5 pM, about 0.75 pM, about 1 pM, about 5 pM, about 10 pM, about 20 pM, about 30 pM, about 40 pM, about 50 pM, about 60 pM, about 70 pM, about 80 pM, about 90 pM, about 100 pM, about 110 pM, about 120 pM, about 130 pM, about 140 pM, about 150 pM, about 160 pM, about 170 pM, about 180 pM, about 190 pM, or more than about 190 pM, including any ranges between these values. In certain embodiments, the anti-CD73 antibody, and / or affinity variant or mutant thereof, binds to CD73 with an affinity that is about 1%, about 5%, about 10%, about 15%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, or more than about 100% (e.g., about 105%, about 110%, about 120%, or about 130%) greater than the binding affinity of a reference anti-CD73 antibody to CD73. In certain embodiments, the binding affinity of anti-CD73, and / or variants or mutants thereof to CD73 is about 1.1 times, about 1.2 times, about 1.3 times, about 1.4 times, about 1.5 times, about 1.6 times, about 1.7 times, about 1.8 times, about 1.9 times, about 2 times, about 2.25 times, about 2.5 times, about 2.75 times, about 3 times, about 3.25 times, about 3.5 times, about 3.75 times, about 4 times, about 4.25 times, about 4.5 times, about 4.75 times, or more than about 4.75 times greater than the binding affinity of a reference anti-CD73 antibody to CD73, including any ranges in between these values.
[0161] In certain embodiments, the anti-CD73 antibodies, and / or variants thereof, or mutants thereof provided herein have an extended in vivo half-life compared to a reference anti-CD73 antibody. In certain embodiments, the in vivo half-life of the anti-CD73 antibodies, and / or variants thereof, or mutants thereof described herein is not shorter than the in vivo half-life of the reference anti-CD73 antibody.
[0162] In certain embodiments, the anti-CD73 antibodies provided herein, and / or variants thereof, or mutants thereof exhibit pharmacokinetic properties similar to those of a reference anti-CD73 antibody. In certain embodiments, the anti-CD73 antibodies provided herein, and / or variants thereof, or mutations thereof exhibit an AUC (area under the curve) of about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or more than 95% (such as about 96%, about 97%, about 98%, about 99%, or more than about 99%) of the serum concentration-time curve of a reference anti-CD73 antibody, including any ranges between these values.
[0163] In certain embodiments, the anti-CD73 antibodies of the present invention, and / or variants thereof, or mutants thereof, comprise the Fc sequence of human IgG (e.g., human IgG1 or human IgG4). In certain embodiments, the Fc sequence has been altered or otherwise modified such that it lacks antibody-dependent cellular cytotoxicity (ADCC) effector function, which is typically associated with its binding to an Fc receptor (FcR). There are many examples of changes or mutations in the Fc sequence that can alter effector function. For example, WO00 / 42072, and Shields et al. J Biol. Chem. [Journal of Biological Chemistry] 9(2):6591-6604 (2001) describe antibody variants with improved or reduced binding to FcR. The contents of these publications are expressly incorporated herein by reference. The anti-CD73 antibodies of the present disclosure, and / or variants thereof, or mutants thereof may be in the following forms: Fab, Fab', F(ab')2, single-chain Fv (scFv), Fv fragments; diabodies and linear antibodies. In addition, the anti-CD73 antibodies, and / or variants thereof, or mutants thereof disclosed herein may be multispecific antibodies, and / or variants or mutants thereof that bind to CD73 but also bind to one or more other mutants thereof and inhibit one or more functions thereof. The anti-CD73 antibodies, and / or variants thereof, or mutants thereof disclosed herein may be conjugated with therapeutic agents (e.g., cytotoxic agents, radioisotopes, and chemotherapeutic agents) or markers (e.g., radioisotopes, fluorescent dyes, and enzymes) for detecting CD73 in patient samples or in vivo by imaging. Other modifications are also provided herein, including conjugation of toxins to anti-CD73 antibodies, and / or variants or mutants thereof.
[0164] Also contemplated herein are nucleic acid molecules encoding anti-CD73 antibodies, and / or variants thereof, and / or mutants thereof, and expression vectors comprising nucleic acid molecules encoding CDRs and / or heavy chain variable domains and / or light chain variable domains, and cells comprising these nucleic acid molecules are also contemplated. The anti-CD73 antibodies of the invention, and / or variants thereof, or mutants thereof can be used in the therapies described herein and can be used to detect CD73 protein in patient samples (e.g., via FACS, immunohistochemistry (IHC), ELISA assays) or in patients.
[0165] Monoclonal antibodies
[0166] Monoclonal antibodies can be prepared, for example, using the hybridoma method (as described in Kohler G. et al., Nature, 174(5):2453-2455 (2005)) or can be made by recombinant DNA methods (U.S. Pat. No. 4,816,567) or can be produced by the methods described herein in the Examples below. In the hybridoma method, a hamster, mouse or other appropriate host animal is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that specifically bind to the immunizing agent. Alternatively, lymphocytes can be immunized in vitro.
[0167] Immunizing agent will typically include a fusion protein of a polypeptide or target protein or a composition comprising a protein. Generally, if human cells are desired, peripheral blood lymphocytes ("PBL") are used, or if non-human mammalian sources are desired, spleen cells or lymph node cells are used. Lymphocytes are then fused to an immortalized cell line using a suitable fusion agent (e.g., polyethylene glycol) to form hybridoma cells (Monoclonal Antibodies: principles and practice, James W. Goding, New York: Academic Press, 1986, pp. 59-103). Immortalized cell lines are typically transformed mammalian cells, particularly myeloma cells of rodent, cattle and human origin. Generally, rat or mouse myeloma cell lines are used. Hybridoma cells can be cultured in a suitable culture medium, which preferably contains one or more substances that inhibit the growth or survival of unfused immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyltransferase (HGPRT or HPRT), the culture medium for the hybridomas typically contains hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.
[0168] Preferred immortalized cell lines are those that fuse efficiently, support stable high-level expression of the antibody by the selected antibody-producing cells, and are sensitive to a culture medium such as HAT medium. More preferred immortalized cell lines are murine myeloma cell lines, which are available, for example, from the Salk Institute Cell Distribution Center, San Diego, California, and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines have also been described for the production of human monoclonal antibodies (Kozbor D. et al., J. Immunol., 133(6):3001-3005 (1984); Monoclonal Antibody Production Techniques and Applications, Brodeur et al., Marcel Dekker, Inc.: New York, 1987, pp. 51-63).
[0169] The presence of monoclonal antibodies against the polypeptide in the culture medium of the hybridoma cells can then be determined. The binding specificity of the monoclonal antibodies produced by the hybridoma cells can be determined by immunoprecipitation or by in vitro binding assays, such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibodies can be determined, for example, by Scatchard analysis of Munson PJ. et al., Anal. Biochem. [Analytical biochemistry], 107 (1): 220-239 (1980).
[0170] After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Monoclonal Antibodies: principles and practice, James W. Goding, New York: Academic Press, 1986, pp. 59-103). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, hybridoma cells can be grown in mammals as ascites.
[0171] The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures (eg, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography).
[0172] Monoclonal antibodies can also be prepared by recombinant DNA methods known in the art and / or developed later. Using conventional procedures (e.g., by using oligonucleotide probes that can specifically bind to the heavy and light chains of the coding murine antibodies), the DNA encoding the monoclonal antibodies provided herein can be easily separated and sequenced. Hybridoma cells provided herein are used as the preferred source of such DNA. Once separated, DNA is placed in expression vectors, and these vectors are then transfected into host cells (such as ape COS cells, Chinese hamster ovary (CHO) cells or myeloma cells) that do not otherwise produce immunoglobulins, so as to obtain the synthesis of monoclonal antibodies in recombinant host cells. It is also possible, for example, to replace the coding sequences of human heavy and light chain constant domains with homologous murine sequences (e.g., Morrison et al., supra), or to modify DNA by covalently binding all or part of the coding sequences of non-immunoglobulin polypeptides to immunoglobulin coding sequences. Such non-immunoglobulin polypeptides can replace the constant domains of the antibodies provided herein, or can replace the variable domains of an antigen binding site of the antibodies provided herein to produce chimeric bivalent antibodies.
[0173] In certain embodiments, the anti-CD73 antibodies and / or variants thereof or mutants thereof provided herein are expressed by a stable mammalian cell line. In certain embodiments, the anti-CD73 antibodies and / or variants thereof or mutants thereof provided herein are expressed from a stable mammalian cell line at a titer of about 2.0 g / L, about 2.5 g / L, about 3.0 g / L, about 3.5 g / L, about 4.0 g / L, about 4.5 g / L, about 5.0 g / L, about 5.5 g / L, about 6.0 g / L, about 6.5 g / L, about 7.0 g / L, or more than about 7.0 g / L (including any range between these values). In certain embodiments, the stable mammalian cell line expressing the anti-CD73 antibodies and / or variants thereof or mutants thereof provided herein is a CHO cell line.
[0174] In certain embodiments, the antibody is a monovalent antibody. Methods for preparing monovalent antibodies are known in the art. For example, one method involves recombinant expression of immunoglobulin light chains and modified heavy chains. The heavy chain is usually truncated at any point in the Fc region to prevent heavy chain crosslinking. Alternatively, the relevant cysteine residue is replaced by another amino acid residue or deleted to prevent crosslinking.
[0175] In vitro methods are also suitable for preparing monovalent antibodies.Digestion of antibodies to produce fragments thereof (particularly Fab fragments) can be accomplished using, but not limited to, techniques known in the art.
[0176] Human antibodies and humanized antibodies
[0177] The anti-CD73 antibodies of the present invention, and / or their variants or mutants thereof are human antibodies. They may also be humanized antibodies. The humanized form of a non-human (e.g., murine) antibody is a chimeric immunoglobulin, an immunoglobulin chain, or a fragment thereof that typically contains a minimal sequence derived from a non-human immunoglobulin (e.g., Fv, Fab, Fab', F(ab')2, or other antigen-binding subsequences of an antibody). Humanized antibodies include human immunoglobulins (receptor antibodies), in which residues from the receptor CDR are replaced by residues from a CDR of a non-human species (donor antibody) (e.g., a mouse, rat, or rabbit with the desired specificity, affinity, and ability). In some embodiments, the Fv framework residues of a human immunoglobulin may be replaced by corresponding non-human residues. Humanized antibodies may also include residues that are not found in the receptor antibody nor in the imported CDR or framework sequence. Generally, a humanized antibody may include substantially all of at least one, typically two variable domains, wherein all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin, and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. A humanized antibody also preferably includes at least a portion of an immunoglobulin constant region (Fc), typically at least a portion of a human immunoglobulin constant region (e.g., Jones PT. et al., Nature [Nature], 321 (6069): 522-525 (1986); Riechmann L. et al., Nature [Nature], 332 (6162): 323-327 (1988); Presta LG, Curr. Opin. Biotechnol. [Biotechnol. Review], 3 (4): 394-398 (1992)).
[0178] Generally, humanized antibodies have one or more amino acid residues introduced from non-human sources. These non-human amino acid residues are generally referred to as "import" residues, which are typically taken from a "import" variable domain. According to one embodiment, substantially according to the method of Winter and colleagues, humanization is carried out by replacing the corresponding sequence of human antibodies with rodent CDR or CDR sequence (Jones PT. et al., Nature [Nature], 321 (6069): 522-525 (1986); Riechmann L. et al., Nature [Nature], 332 (6162): 323-327 (1988); Verhoeyen M. et al., Science [Science], 239 (4847): 1534-1536 (1988)). Therefore, "humanized" antibodies described herein refer to antibodies in which the region substantially less than a complete human variable domain is replaced by the corresponding sequence from non-human species. In practice, humanized antibodies are typically those in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
[0179] As an alternative to humanization, human antibodies can be generated. For example, it is now possible to produce transgenic animals (e.g., mice) that are capable of producing a complete human antibody repertoire in the absence of endogenous immunoglobulin production after immunization. For example, homozygous deletions of antibody heavy chain joining region (JH) genes in chimeric and germline mutant mice have been described that result in complete inhibition of endogenous antibody production. Transferring the human germline immunoglobulin gene array into such germline mutant mice will result in the production of human antibodies upon antigen challenge, see, e.g., Jakobovits A. et al., Proc. Natl. Acad. Sci. USA, 90(6):2551-2555 (1993); Jakobovits A. et al., Nature, 362(6417):255-258 (1993); Bruggemann M. et al., Year Immunol., 7:33-40 (1993); U.S. Pat. Nos. 5,545,806, 5,569,825, 5,591,669; 5,545,807; and WO97 / 17852.
[0180] Alternatively, human antibodies can be prepared by introducing human immunoglobulin loci into transgenic animals, such as mice in which endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, production of human antibodies is observed that closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This method is known in the art, see, for example, Marks JD. et al., Biotechnology, 10(7):779-783 (1992); Lonberg N. et al., Nature, 368(6474):856-859 (1994); Morrison SL., Nature, 368(6474):812-813 (1994); Fishwild DM. et al., Nat. Biotechnol., 14(7):845-851 (1996); Neuberger M., Nat. Biotechnol., 14(7):826 (1996); Lonberg N. et al., Int. Rev. Immunol., 13(1):65-93 (1995).
[0181] Alternatively, phage display technology (McCafferty J. et al., Nature [Nature], 348 (6301): 552-554 (1990)) can be used to produce human antibodies and antibody fragments in vitro from immunoglobulin variable (V) domain gene repertoires from unimmunized donors. According to one embodiment of the technology, the antibody V domain sequence is cloned in frame into a major or minor coat protein gene of a filamentous bacteriophage (e.g., M13 or fd) and displayed as a functional antibody fragment on the surface of the phage particle. Phage display can be performed in a variety of formats, for example, as described in the Examples section below or as reviewed in, for example, Johnson KS. et al., Curr. Opin. Struct. Biol. [Structural Biology Perspectives], 3 (4): 564-571 (1993). V gene segments from several sources can be used for phage display. Clackson T. et al., Nature, 352(6336):624-628 (1991) isolated a variety of anti-oxazolone antibodies from a small random combinatorial library of V genes derived from the spleen of immunized mice. Libraries of V genes from unimmunized human donors can be constructed, and antibodies to a variety of antigens (including self-antigens) can be isolated essentially following the techniques described in Marks JD. et al., J. Mol. Biol., 222(3):581-597 (1991), or Griffith AD. et al., EMBO J. 12(2):725-734 (1993). See also, U.S. Pat. Nos. 5,565,332 and 5,573,905.
[0182] As discussed above, human antibodies can also be generated by in vitro activated B cells using methods known in the art.
[0183] Human antibodies can also be produced using various techniques known in the art, including phage display libraries. Hoogenboom HR. et al., J. Mol. Biol., 227(2):381-388 (1991); Marks JD. et al., J. Mol. Biol., 222(3):581-597 (1991). The techniques of Cole et al. and Boerner et al. can also be used to prepare human monoclonal antibodies (Monoclonal Antibodies and Cancer Therapy, Cole et al., Alan Liss, Inc., 1985, p. 77, and Boerner P. et al., J. Immunol., 147(1):86-95 (1991)).
[0184] Multispecific Antibodies
[0185] Multispecific antibodies are monoclonal antibodies, preferably human antibodies or humanized antibodies (e.g., bispecific antibodies having binding specificity for at least two antigens) that have binding specificity for two or more different antigens. For example, one of the binding specificities may be for a5-1 protein, and the other may be for any other antigen. According to a preferred embodiment, the other antigens are cell surface proteins or receptors or receptor subunits. For example, the cell surface protein may be a natural killer (NK) cell receptor. Therefore, according to one embodiment, the bispecific antibodies of the present invention may bind to both CD73 and, for example, a second cell surface receptor.
[0186] Suitable methods for preparing bispecific antibodies are known in the art. For example, the recombinant production of bispecific antibodies is based on the coexpression of two immunoglobulin heavy chain / light chain pairs, wherein the two heavy chains have different specificities (Milstein C et al., Nature [Nature], 305 (5934): 537-540 (1983)). Due to the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, only one of which has the correct bispecific structure. Purification of the correct molecule is usually completed by an affinity chromatography step. Similar methods are disclosed in the art, for example in WO93 / 08829 and in Traunecker A. et al., EMBO J. [European Molecular Biology Association Journal], 10 (12): 3655-3659 (1991).
[0187] The antibody variable domains (antibody-antigen binding sites) with the desired binding specificity can be fused to the immunoglobulin constant domain sequence. The fusion is preferably with the immunoglobulin heavy chain constant domain comprising at least part of the hinge, CH2 and CH3 regions. Preferably, the first heavy chain constant region (CH1) containing the required site for light chain binding is present in at least one of these fusions. DNA encoding the immunoglobulin heavy chain fusion and (if necessary) the immunoglobulin light chain is inserted into a separate expression vector and co-transfected into a suitable host organism. For further details on the generation of bispecific antibodies, see, for example, Suresh MR. et al., Methods Enzymol. [Enzymology Methods], 121: 210-228 (1986).
[0188] Various techniques for preparing and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies are produced using leucine zippers (Kostelny SA. et al., J. Immunol. [Journal of Immunology], 148 (5): 1547-1553 (1992)). Leucine zipper peptides from Fos and Jun proteins are linked to the Fab' portions of two different antibodies by gene fusion. Antibody homodimers are reduced in the hinge region to form monomers and then oxidized to form antibody heterodimers. This method can also be used to produce antibody homodimers. The "double antibody" technology described in Hollinger P. et al., Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States], 90 (14): 6444-6448 (1993) provides an alternative mechanism for preparing bispecific antibody fragments. The fragment comprises a VH connected to a VL by a linker that is too short to allow pairing between two domains on the same chain. Thus, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen binding sites. Another strategy for preparing bispecific antibody fragments by using single-chain Fv (sFv) dimers has also been reported. See Gruber M. et al., J. Immunol. [Journal of Immunology], 152(11): 5368-5374 (1994).
[0189] Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared (Tutt A. et al., J. Immunol., 147(1) 60-69 (1991)).
[0190] Heteroconjugate Antibodies
[0191] Heterologous conjugate antibodies are composed of two covalently linked antibodies. For example, it has been proposed that such antibodies target immune system cells to unwanted cells and are used to treat HIV infection. It is contemplated that these antibodies can be prepared in vitro using known methods in synthetic protein chemistry (including those involving cross-linking agents). For example, immunotoxins can be constructed using disulfide exchange reactions or by forming thioether bonds. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those known in the art.
[0192] Effector function engineering
[0193] It may be desirable to modify the antibodies provided herein in terms of effector function to enhance, for example, the effectiveness of the antibodies in treating cancer. For example, one or more cysteine residues may be introduced into the Fc region, thereby allowing the formation of interchain disulfide bonds in this region. The homodimeric antibodies thus generated may have improved internalization capacity and / or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron PC. et al., J. Exp. Med. [Journal of Experimental Medicine], 176 (4): 1191-1195 (1992) and Shopes B., J. Immunol. [Journal of Immunology], 148 (9): 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterologous bifunctional cross-linkers known in the art. Alternatively, antibodies may be engineered to have dual Fc regions, thereby having enhanced complement lysis and ADCC capabilities. See, for example, Stevenson GT. et al., Anticancer Drug Des., 3(4): 219-230 (1989).
[0194] Mutations or changes in the Fc region sequence can be made to improve FcR binding (e.g., FcγR, FcRn). According to one embodiment, the antibodies of the invention have at least one altered effector function selected from the group consisting of ADCC, CDC, and improved FcRn binding compared to native IgG or a parent antibody. Several examples of useful specific mutations are described in, e.g., Shields RL. et al., J. Biol. Chem., 276(6):6591-6604 (2001); Presta, LG. et al., Biochem. Soc. Trans. 30(4):487-490 (2002); and WO00 / 42072.
[0195] According to one embodiment, the Fc receptor mutation is a substitution at at least one position selected from the group consisting of 238, 239, 246, 248, 249, 252, 254, 255, 256, 258, 265, 267, 268, 269, 270, 272, 276, 278, 280, 283, 285, 286, 289, 290, 292, 293, 294, 295, 296, 298, 301, 303, 305,307,309,312,315,320,322,324,326,327,329,330,331,332,333,334,335,337,338,340,360,373,376,378,382,388,389,398,414,416,419,430,434,435,437,438 or 439, wherein the numbering of the residues in the Fc region is according to the EU numbering system. In some embodiments, the Fc receptor mutation is a D265A substitution. In some embodiments, the Fc receptor mutation is a N297 A substitution. Other suitable mutations are known in the art, for example, as listed in U.S. Patent No. 7,332,581.
[0196] Immunoconjugates
[0197] The present invention also relates to immunoconjugates comprising an antibody, or variants or mutants thereof, conjugated to a cytotoxic agent (such as a chemotherapeutic agent), a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant or animal origin or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).
[0198] Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, Dianthus caryophyllus proteins, Phytolaca americana proteins (PAPI, PAPII and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes. A variety of radionuclides can be used to produce radioconjugated antibodies. Examples include 212 Bi, 131 I. 131In, 90 Y and 186 Re. Exemplary chemotherapeutic agents useful for generating such immunoconjugates include those described elsewhere herein.
[0199] In certain embodiments, the anti-CD73 antibodies of the present invention, and / or variants thereof, or mutants thereof are conjugated to maytansine, maytansinoid, or calicheamicin. In certain embodiments, the anti-CD73 antibodies of the present invention, and / or variants thereof, or mutants thereof are conjugated to maytansine alkaloid DM1.
[0200] Conjugates of antibodies and cytotoxic agents are prepared using a variety of bifunctional protein coupling agents (e.g., N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (e.g., dimethyl adipimidate HCl), active esters (e.g., disuccinimidyl suberate), aldehydes (e.g., glutaraldehyde), bisazido compounds (e.g., bis(p-azidobenzoyl)hexanediamine), bisdiazonium derivatives (e.g., bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (e.g., tolylene 2,6-diisocyanate), and bis-active fluorine compounds (e.g., 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described by Vitetta ES. et al., Science, 238(4830):1098-1104 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriamine-pentaacetic acid (MX-DTPA) is an exemplary chelator for conjugating radionucleotides to antibodies. See, WO 94 / 11026.
[0201] In certain embodiments, the anti-CD73 antibodies of the present invention, and / or variants or mutants thereof, can be conjugated to a "receptor" (such as streptavidin) for tumor pretargeting, wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent, and then administration of a "ligand" (e.g., avidin) conjugated to a cytotoxic agent (e.g., radionucleotide).
[0202] Covalent modification
[0203] Covalent modification of anti-CD73 antibodies, variants, mutants, and fragments thereof are included within the scope of the present disclosure. One type of covalent modification includes reacting a target amino acid residue of a polypeptide with an organic derivatizing agent that is capable of reacting with a selected side chain or N-terminal or C-terminal residue of the polypeptide. Derivatization with a bifunctional agent is useful, for example, for crosslinking a polypeptide to a water-insoluble support matrix or surface for use in a method of purifying an antibody, and vice versa. Commonly used crosslinking agents include, for example, 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters (e.g., esters with 4-azidosalicylic acid), homobifunctional imidoesters (including disuccinimidyl esters such as 3,3'-dithiobis(succinimidyl-propionate)), bifunctional maleimides (such as bis-N-maleimido-1,8-octane) and agents (such as methyl-3-[(p-azidophenyl)-dithio]propionimidoester).
[0204] Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of the hydroxy groups of seryl or threonyl residues, methylation of the α-amino groups of lysine, arginine, and histidine side chains (Proteins: Structure and Molecular Properties, Thomas E. Creighton, WH Freeman & Co., San Francisco, 1983, pp. 79-86), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.
[0205] Another type of covalent modification of the polypeptide involves linking the polypeptide to one of a variety of nonprotein polymers, such as polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in a manner known in the art (e.g., as set forth in U.S. Pat. Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; or 4,179,337).
[0206] chimeric molecules
[0207] The anti-CD73 antibodies of the present invention, and / or variants or mutants thereof, may also be modified if it is advantageous to form a chimeric molecule comprising a polypeptide (e.g., an immunoadhesion protein or peptibody) fused to another heterologous polypeptide or amino acid sequence.
[0208] In one embodiment, such a chimeric molecule comprises a fusion of a polypeptide with a protein transduction domain that targets the polypeptide for delivery to various tissues, and more specifically across the brain-blood barrier, using, for example, the protein transduction domain of the human immunodeficiency virus TAT protein (Schwarze SR. et al., Science 285(5433):1569-1572 (1999)).
[0209] In certain embodiments, such chimeric molecules comprise a fusion of a polypeptide with a tag polypeptide that provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is typically located at the amino or carboxyl terminus of the polypeptide. The presence of such a polypeptide with an epitope tag can be detected using an antibody against the tag polypeptide. In addition, the provision of an epitope tag makes it easy for the polypeptide to be purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. A variety of tag polypeptides and their respective antibodies are known in the art. Examples include polyhistidine (poly-His) or polyhistidine-glycine (poly-His-gly) tags; influenza HA tag polypeptide and its antibody 12CA5 (Field J. et al., Mol. Cell. Biol., 8(5):2159-2165 (1988)); c-myc tag and its 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies (Evan GI. et al., Mol. Cell. Biol., 5(12):3610-3616 (1985)); and herpes simplex virus glycoprotein D (gD) tag and its antibody (Paborsky LR. et al., Protein Eng., 3(6):547-553 (1990)). Other tag polypeptides include Flag peptide (Hopp TP. et al., Bio / Technology, 6:1204-1210 (1988)); KT3 epitope peptide (Martin GA. et al., Science, 255(5041):192-194 (1992)); α-tubulin epitope peptide (Skinner MP. et al., J. Biol. Chem., 266(9):15163-15166 (1991)); and T7 gene 10 protein peptide tag (Lutz-Freyermuth C. et al., Proc. Natl. Acad. Sci. USA, 87(16):6393-6397 (1990)).
[0210] In alternative embodiments, the chimeric molecule may comprise a fusion of a polypeptide with an immunoglobulin or an immunoglobulin specific region. For a bivalent chimeric molecule (e.g., "immunoadhesion protein"), such a fusion may be a fusion with an IgG molecule Fc region. The Ig fusions of the present invention include approximately or only comprise residues 94-243, residues 33-53, or residues 33-52 of a person to replace a polypeptide of at least one variable region in an Ig molecule. In a particularly preferred embodiment, the immunoglobulin fusion comprises hinge, CH2, and CH3 of an IgG1 molecule, or hinge, CH1, CH2, and CH3 regions. The production of immunoglobulin fusions is known in the art, see, e.g., U.S. Patent No. 5,428,130.
[0211] Immunoliposome
[0212] The anti-CD73 antibodies of the present invention, and / or variants thereof, or mutants thereof can also be formulated as immunoliposomes. Liposomes containing antibodies are prepared by methods known in the art, such as described by Epstein DA et al., Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States], 82 (11): 3688-3692 (1985); and Hwang KJ et al., Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States], 77 (7): 4030-4034 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. U.S. Pat. No. 5,013,556 discloses liposomes with enhanced circulation time.
[0213] Particularly useful liposomes can be generated by reverse phase evaporation with a lipid composition comprising phosphatidylcholine, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE). The liposomes are extruded through a filter having a defined pore size to produce liposomes having a desired diameter. The Fab' fragments of the antibodies disclosed herein can be conjugated to the liposomes via a disulfide exchange reaction as described in Martin FJ. et al., J. Biol. Chem. [Journal of Biological Chemistry], 257(1): 286-288 (1982). The liposomes may also optionally contain an antitumor agent, a growth inhibitor or a chemotherapeutic agent (such as doxorubicin). See, Gabizon A. et al., J. Natl. Cancer Inst. [Journal of the National Cancer Institute], 81(19): 1484-1488 (1989).
[0214] Treatment with anti-CD73 antibodies, variants or mutants thereof
[0215] The disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions provided herein can be administered to a subject (e.g., a mammal such as a human) to treat a disease, disorder, or clinical condition associated with CD73 expression, CD73 overexpression, or abnormal CD73 function. For example, cancers associated with the expression of CD73 may be, but are not limited to, lymphoma, renal cancer, lung cancer, colon cancer, liver cancer, gastric cancer, primary effusion lymphoma, osteosarcoma, and non-Hodgkin's lymphoma. Another embodiment of a disease, disorder, or clinical condition associated with CD73 expression may be fibrosis, including idiopathic pulmonary fibrosis. In certain embodiments, the present invention provides anti-CD73 antibodies and / or variants / mutants (or fragments thereof) described herein for the manufacture of a medicament for treating cancer or fibrosis in a subject. In certain embodiments, the subject to be treated is a mammal (e.g., a human, non-human primate, rat, mouse, cattle, horse, pig, sheep, goat, dog, cat, etc.). In certain embodiments, the subject is a human. In certain embodiments, the subject is a clinical patient, a clinical trial volunteer, an experimental animal, etc. In certain embodiments, the subject is suspected of having or being at risk for cancer or fibrosis.
[0216] In some embodiments, the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions provided herein can be administered to a subject (e.g., a mammal such as a human) to treat cancer recurrence or recurrence of a cancer associated with CD73 expression.
[0217] In some embodiments, the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or the pharmaceutical compositions provided herein can be administered to a subject (e.g., a mammal such as a human) to treat a refractory or resistant cancer associated with CD73 expression.
[0218] In some embodiments, the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or the pharmaceutical compositions provided herein can be administered to a subject (e.g., a mammal such as a human) to provide adjuvant therapy for a cancer associated with CD73 expression.
[0219] In some embodiments, the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or the pharmaceutical compositions provided herein can be administered to a subject (e.g., a mammal such as a human) to provide maintenance therapy for a cancer associated with CD73 expression.
[0220] In some embodiments, the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or the pharmaceutical compositions provided herein can be administered to a subject (e.g., a mammal such as a human) to treat an aggressive cancer associated with CD73 expression.
[0221] In some embodiments, the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or the pharmaceutical compositions provided herein can be administered to a subject (e.g., a mammal such as a human) to treat a non-aggressive cancer associated with CD73 expression.
[0222] In some embodiments, the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions provided herein can be administered to a subject (e.g., a mammal such as a human) to increase progression-free survival of a subject diagnosed with a cancer associated with CD73 expression.
[0223] In some embodiments, cancers associated with CD73 expression that can be treated using the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof can be multidrug resistant (MDR) or drug sensitive. Examples of cancers include, but are not limited to, carcinomas, lymphomas, blastomas, sarcomas, hematological cancers, and leukemias. In some embodiments, cancers associated with CD73 expression that can be treated using the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof include, but are not limited to: colorectal cancer, ovarian cancer, gastric cancer, gallbladder cancer, leukemia, chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), prostate cancer, melanoma, breast cancer, triple-negative breast cancer (TNBC), bladder cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, glioma, head and neck cancer, thyroid cancer, B-cell acute lymphocytic leukemia, medulloblastoma, atypical teratoid / rhabdoid tumor, and oral squamous cell carcinoma. In additional embodiments, cancers associated with CD73 expression that can be treated using the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof include, but are not limited to, blood (or hematopoietic tissue) cancer, bladder cancer, brain cancer, breast cancer (e.g., triple-negative breast cancer, TNBC), central and peripheral nervous system cancer, cervical cancer, colon cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer (including small cell lung cancer), esophageal cancer, gallbladder cancer, gastrointestinal cancer, cancer of the genitourinary tract, lymphoid lineage hematopoietic tumors, myeloid lineage hematopoietic tumors, ovarian cancer, pancreatic cancer, rectal cancer, gastric cancer, prostate cancer, skin cancer (including squamous cell carcinoma) and thyroid cancer.
[0224] In some embodiments, the cancer associated with CD73 expression that can be treated using the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof can be a hematological cancer. In still other aspects, the hematological cancer is selected from leukemia, myeloma, or lymphoma, including but not limited to: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), hairy cell leukemia, chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), Hodgkin lymphoma, classical Hodgkin lymphoma (cHL), non-Hodgkin lymphoma primary mediastinal B-cell lymphoma (NHL PMBCL), non-Hodgkin lymphoma, multiple myeloma, single myeloma, limited myeloma, extramedullary myeloma, small lymphocytic lymphoma, B-cell non-Hodgkin lymphoma, and large B-cell lymphoma. Exemplary hematopoietic tumors of the lymphoid lineage include, but are not limited to, leukemias, acute lymphocytic leukemias, acute lymphoblastic leukemias, B-cell lymphomas, T-cell lymphomas, Hodgkin's lymphomas, non-Hodgkin's lymphomas, hairy cell lymphomas, and Burkitt's lymphomas. Hematopoietic tumors of the myeloid lineage include, but are not limited to, acute and chronic myeloid leukemias, myelodysplastic syndromes, and promyelocytic leukemias; tumors of mesenchymal origin, including fibrosarcomas and rhabdomyosarcomas.
[0225] In other embodiments, the cancer associated with CD73 expression that can be treated using the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof can be a cancer of the brain or central nervous system. Central and peripheral nervous system tumors include, but are not limited to, astrocytomas, neuroblastomas, gliomas, and schwannomas. Other exemplary brain cancers or central nervous system cancers include: glioma, medulloblastoma, primitive neuroectodermal tumor (PNET), acoustic neuroma, glioma, meningioma, pituitary adenoma, schwannoma, CNS lymphoma, primitive neuroectodermal tumor, craniopharyngioma, chordoma, medulloblastoma, central neuroblastoma, central neurocytoma, pinealoma, pineoblastoma, atypical teratoid rhabdoid tumor, chondrosarcoma, chondroma, choroid plexus carcinoma, choroid plexus papilloma, craniopharyngioma, dysembryoplastic neuroepithelioma, gangliocytoma, germ cell tumor, hemangioblastoma, hemangiopericytoma and metastatic brain tumor. In yet another aspect, glioma is selected from ependymoma, astrocytoma, oligodendroglioma and oligoastrocytoma. In an even further aspect, the glioma is selected from the group consisting of juvenile pilocytic astrocytoma, subependymal giant cell astrocytoma, ganglioglioma, subependymoma, pleomorphic xanthoastrocytoma, anaplastic astrocytoma, glioblastoma multiforme, brain stem glioma, oligodendroglioma, ependymoma, oligoastrocytoma, cerebellar astrocytoma, desmoplastic pediatric astrocytoma, subependymal giant cell astrocytoma, diffuse astrocytoma, mixed glioma, optic nerve glioma, gliomatosis cerebri, multifocal gliomatous tumor, multicentric glioblastomamultiforme tumor, gangliocytoma, and ganglioneuroma.
[0226] Other exemplary tumors associated with CD73 expression that can be treated using the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof include, but are not limited to, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocarcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumors, lung cancer, small cell lung cancer, bladder cancer, epithelial carcinoma, osteosarcoma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, melanoma, teratoma, xenoderoma pigmentosum, keratoctanthoma, follicular thyroid carcinoma, and Kaposi's sarcoma.
[0227] Many diagnostic methods are known in the art for cancer (e.g., melanoma, non-small cell lung cancer (NSCLC), head and neck cancer, urothelial carcinoma, breast cancer (e.g., triple negative breast cancer, TNBC), gastric cancer, classical Hodgkin lymphoma (cHL), non-Hodgkin lymphoma primary mediastinal B-cell lymphoma (NHL PMBCL), mesothelioma, ovarian cancer, lung cancer (e.g., small-cell lung cancer), esophageal cancer, nasopharyngeal carcinoma (NPC), biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer) or any other disease that exhibits abnormal CD73 function and the clinical description of these diseases. Such methods include, but are not limited to, for example, immunohistochemistry, PCR, fluorescence in situ hybridization (FISH). Additional details on diagnostic methods for abnormal CD73 activity or expression are described in the art.
[0228] The disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein can be administered by any suitable route, including, for example, intravenously, intramuscularly, or subcutaneously. In some embodiments, the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein can be administered by parenteral administration. "Parenteral" refers to intravenous, subcutaneous, and intramuscular administration.
[0229] In some embodiments, the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein can be administered in combination with at least one agent (such as a second, third, or fourth agent). The at least one agent can be any suitable agent known to treat cancer or fibrosis (including idiopathic pulmonary fibrosis).
[0230] In various embodiments, the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein can be administered in combination with at least one agent for cancer treatment. In specific embodiments, the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein can be administered in combination with at least one agent for cancer treatment, such as oxaliplatin, leucovorin, fluorouracil (5-FU), gemcitabine, paclitaxel (including protein-bound paclitaxel (e.g., but not limited to nanoparticle albumin-bound paclitaxel, which is sometimes referred to as "nab-paclitaxel"), or a combination thereof.
[0231] Additional examples of at least one agent for cancer treatment include, but are not limited to, chemotherapeutic agents, immunotherapeutic agents, cancer vaccines, anti-angiogenic agents, cytokines, hormone therapy, gene therapy, biological therapy, and radiation therapy. For example, at least one agent known to treat cancer can be a known cytostatic or cytotoxic or anticancer agent (such as an anti-tumor agent), a growth inhibitor, a cytotoxic agent, or a chemotherapeutic agent (such as docetaxel, gefitinib, FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin), irinotecan, cisplatin, carboplatin, paclitaxel, bevacizumab (anti-VEGF antibody), FOLFOX-4, infused fluorouracil, leucovorin ), and oxaliplatin, afatinib, gemcitabine, capecitabine, pemetrexed, tivantinib, everolimus, CpG-ODN, rapamycin, lenalidomide, vemurafenib, endostatin, lapatinib, PX-866, Imprime PGG, and irlotinibm.
[0232] In some embodiments, the anti-CD73 antibody and / or variant / mutant (or fragment thereof) is conjugated to an additional agent. For example, the at least one agent comprises uracil mustard, nitrogen mustard, cyclophosphamide, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozotocin, dacarbazine, temozolomide, thiotepa, altretamine, methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, phosphate), pentostatin, bortezomib, vinblastine, vincristine, vinorelbine, vindesine, bleomycin, actinomycin D, daunorubicin, doxorubicin, epirubicin, dexamethasone, clofarabine, cladribine, pemextresed, idarubicin, paclitaxel, docetaxel, ixabepilone lone), mithramycin, topotecan, irinotecan, deoxycoformycin, mitomycin-C, L-asparaginase, interferon, etoposide, teniposide 17α-ethinylestradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, dromostanolone propionatepropionate, testolactone, megestrol acetate, tamoxifen, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, hydroxyprogesterone, aminoglutethimide, estramustine, medroxyprogesterone acetate, leuprolide, flutamide, toremifene, goserelin, cisplatin, carboplatin, hydroxyurea ( hydroxyurea), amsacrine, procarbazine, mitotane, mitoxantrone, levamisole, navelbene, anastrazole, letrazole, capecitabine, reloxafine, droloxafine, hexamethylmelamine, oxaliplatin Iressa (gefitinib, Zd1839), (capecitabine), (erlotinib, azacitidine (5-azacytidine; 5-AzaC), temozolomide Gemcitabine (eg, (gemcitabine HCl)) and vasostatin.
[0233] In various embodiments, the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein can be administered in combination with at least one agent, such as an alkylating agent, such as thiotepa and CYTOXAN(R) cyclophosphamide; alkyl sulfonates, such as busulfan, improsulfan, and piposulfan; aziridines, such as benzodopa, carboquone, meturedopa, and uredopa; ethyleneimine and Methylamelamines, including hexamethylmelamine, tromethamine, trietylenephosphoramide, triethiylenethiophosphoramide, and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); delta-9-tetrahydrocannabinol (dronabinol, MARINOL(R)); beta- camptothecin (including its synthetic analogs topotecan (HYCAMTIN(R)), CPT-11 (irinotecan, CAMPTOSAR(R)), acetylcamptothecin, scopolectin and 9-aminocamptothecin); bryostatin; callystatin; CC-1065 (including its synthetic analogs adozelesin, carzelesin and bizelesin) ; podophyllotoxin; podophyllinic acid; teniposide; cryptophycins (specifically cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including synthetic analogs, KW-2189 and CBl-TML); eleutherobin; pancratistatin; sarcodictyin; spongistatin;Nitrogen mustards, such as chlorambucil, naphthyl mustard, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uramustine; nitrosureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics, such as enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gamma ll and calicheamicin omega ll (see, e.g., Nicolaou et al., KC. et al., Angew. Chem. Int. Ed. Engl., 33:183-186 (1994); dynemicin, including dynemicin A; esperamicin;and neocarzinostatin chromophores and related chromoprotein enediyne antibiotic chromophores), aclacinomycins, actinomycins, authramycins, azaserine, bleomycins, actinomycin C, carabicin, carminomicin, carzinophilin, chromomycinis, actinomycin D, daunomycin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including ADRIAMYCIN(R), morpholino-doxorubicin, cyano morpholino-doxorubicin, 2-pyrrolino-doxorubicin, doxorubicin HCl liposome injection (DOXIL(R) and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptoni grin), streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; antimetabolites, such as methotrexate, gemcitabine (GEMZAR(R)), tegafur (UFTORAL(R)), capecitabine (XELODA(R)), epothilones, and 5-fluorouracil (5-FU); folate analogs, such as leucovorin, methotrexate, pteropterin, trimetrexate; purine analogs, such as fludalafil; 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs, such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens, such as calusterone, drostanolone propionate, cyclothiodine, melastosane, testolactone; antiadrenal drugs, such as aminoglutethimide, mitotane, trilostane; folic acid supplements, such as folinic acid; aceglatone;aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptinium acetate acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansine alkaloids, such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; 2-ethylhydrazide; procarbazine; PSK(R) polysaccharide complex (JHS Natural Products, Eugene, OR); razoxane; rhizoxin; sizolan; spirogermanium; tenuazonic acid acid; triiminoquinone; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A, and anguidine); urethane; vindesine (ELDISEME(R), FILDESIN(R)); dacarbazine; mannomustine; dibromomannitol; dibromodulanol; pipobroman; gasitoxin (gacytoxin) tosine); arabinoside ("Ara-C"); thiotepa; taxanes, such as paclitaxel (TAXOL(R)), albumin-engineered nanoparticle formulations of paclitaxel (ABRAXANE(TM)), and docetaxel (TAXOTERE(R)); chloranbucil; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs, such as cisplatin and carboplatin; vinblastine (VELBAN(R)); platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine (ONCOVIN(R)); oxaliplatin; leucovorin;Navelbine(R); novantrone; edatrexate; daunomycin; aminopterin; ibandronate; topoisomerase inhibitor RFS2000; difluoromethylornithine (DMFO); retinoids, such as retinoic acid; any pharmaceutically acceptable salt, acid or derivative thereof; and combinations of two or more thereof, such as CHOP (abbreviation for cyclophosphamide, doxorubicin, vincristine and prednisolone combination therapy), and FOLFOX (abbreviation for oxaliplatin (ELOXATIN(TM)) combined with 5-FU and leucovorin). ;
[0234] In various embodiments, the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein can be administered in combination with at least one agent that is an angiogenesis inhibitor, such as, but not limited to: angiostatin (a fragment of plasminogen); anti-angiogenic antithrombin III; Angiozyme; ABT-627; Bay12-9566; fluazifop (Benefin); bevacizumab; BMS-275291; cartilage-derived inhibitor (CDI); CAI; CD 59 complement fragments; CEP-7055; Col3; combretastatin A-4; endostatin (collagen XVIII fragment); fibronectin fragment; gro-β; halofuginone; heparinases; heparin polyhexose fragments; HMV833; human chorionic gonadotropin (hCG); IM-862; interferon α / β / γ; interferon-induced protein (IP-10); interleukin-12; Kringle 5 (fragment of plasminogen); Marimastat; inhibitor of metalloproteinases (TIMP); 2-methoxyestradiol; MMI 270 (CGS27023A); MoAb IMC-1C11; Neovastat; NM-3; panzem; PI-88; placental ribonuclease inhibitor; plasminogen activator inhibitor; platelet factor-4 (PF4); prinomastat; prolactin 16kD fragment; proliferator-associated protein (PRP); PTK 787 / ZK 222594; retinoids; solimastat; squalamine; SS 3304; SU 5416; SU6668; SU11248; tetrahydrocortisone-S; tetrathiomolybdate; thalidomide; thrombospondin-1 (TSP-1); TNP-470; transforming growth factor-β (TGF-b); vasculostatin; vasculostatin (calreticulin fragment); ZD6126; ZD 6474; farnesyl transferase inhibitors (FTIs); and bisphosphonates.
[0235] In various embodiments, the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein can be administered in combination with at least one agent selected from a DNA-interacting agent, such as cisplatin or doxorubicin; a topoisomerase II inhibitor, such as etoposide; a topoisomerase I inhibitor, such as CPT-11 or topotecan; a microtubule-interacting agent, such as naturally occurring or synthetic paclitaxel, docetaxel, or an epothilone (e.g., ixabepilone); a hormonal agent, such as tamoxifen; a thymidylate synthase inhibitor (thymidilate synthase inhibitor); Inhibitors) such as 5-fluorouracil; and antimetabolites such as methotrexate, other tyrosine kinase inhibitors such as Iressa and OSI-774; angiogenesis inhibitors; BTK inhibitors, SYK inhibitors, ITK inhibitors, PI3-kinase inhibitors, FLT3 inhibitors, EGF inhibitors; PAK inhibitors, VEGF inhibitors; CDK inhibitors; SRC inhibitors; c-Kit inhibitors; Her1 / 2 inhibitors and monoclonal antibodies against growth factor receptors such as erbitux (EGF) and herceptin (Her2) and other protein kinase modulators. These agents can be used in combination with differentiation agents such as ATRA, EZH2 inhibitors, DNMT inhibitors, corticosteroids, IDH1 inhibitors, IDH2 inhibitors and vitamin C.
[0236] In various embodiments, the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein can be administered in combination with small molecules that enhance DNA damage killing in cancer cells, including PARP inhibitors, MDM2 inhibitors, NAMPT inhibitors, and HSP90 inhibitors.
[0237] In various embodiments, the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein may be administered in combination with one or more immunotherapeutic agents (including antagonists, antibodies, and immunomodulators, including but not limited to: HERCEPTINS, RITUXANS, OVAREX TM , PANOREX@, BEC2, IMC-C225, VITAMIN, CAMPATH@I / H, Smart MI95, LYMPHOCIDE TM , Smart ID10 and ONCOLYM TM, rituximab, gemtuzumab or trastuzumab) in combination. In other embodiments, the immunotherapeutic agent can be an antibody targeting PD-1, PD-L1, PD-L2, CTLA4, LAG3, TIGIT, TIM3, CEACAM-1, galectin-1, galectin-9, BLTA, CD69, CD113, GPR56, 2B4, CD48, PD1H, LAIR1, TIM-1, TIM-4, VISTA, GARP, CD73, CD39, A2AR, B7-1, B7-2, 4-1BBL, CD137, CD28, CD28H, GITR, GITRL, ICOS, ICOS-L, OX40, OX40L, CD70, CD27, CD40, DR3, or a combination of antibodies for such targets. In some embodiments, the immunotherapeutic agent can be an antagonist targeting PD-1, PD-L1, PD-L2, CTLA4, LAG3, TIGIT, TIM3, CEACAM-1, galectin-1, galectin-9, BLTA, CD69, CD113, GPR56, 2B4, CD48, PD1H, LAIR1, TIM-1, TIM-4, VISTA, GARP, CD73, CD39, A2AR, or a combination thereof; an agonist targeting B7-1, B7-2, 4-1BBL, CD137, CD28, CD28H, GITR, GITRL, ICOS, ICOS-L, OX40, OX40L, CD70, CD27, CD40, DR3, or a combination thereof; or a combination of the foregoing antagonists and agonists.
[0238] In various embodiments, the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein may be administered in combination with antibodies or combinations of such antibodies that target cell surface molecules on immune cells or cancer cells (including but not limited to: EGFR, HER2, CD38, mesothelin, CD33, CD37, CD19, CD20, CD3, CD123, CD70, BAFFR, CD4, CD8, CD56, CD38). In some embodiments, the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein may be administered in combination with antibodies or combinations of such antibodies that target cell surface molecules on immune cells or cancer cells (including but not limited to: EGFR, HER2).
[0239] In various embodiments, the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein can be administered in combination with at least one chemotherapeutic agent (e.g., alkylating agents, antimetabolites, platinate agents, paclitaxel, anti-hormonal agents, topoisomerase inhibitors, tubulin agents, signal transduction inhibitors (e.g., kinase inhibitors), and other chemotherapeutic agents). A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include: alkylating agents, such as thiotepa and cyclophosphamide Alkyl sulfonates, such as busulfan, improsulfan, and piposulfan; aziridines, such as benzodopa, carboquone, meturedopa, and uredopa; ethyleneimines and methylamelamines, including hexamethylmelamine, trothamide, trietylenephosphoramide, triethiylenethiophosphoramide, and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); delta-9-tetrahydrocannabinol (dronabinol, ); β-lapachone; lapachol; colchicine; betulinic acid; camptothecin (including the synthetic analogue topotecan CPT-11 (irinotecan, ), acetylcamptothecin, scopolectin, and 9-aminocamptothecin); bryostatin; callystatin; CC-1065 (including its synthetic analogs adozelesin, carzelesin, and bizelesin); podophyllotoxin; podophyllinic acid; acid; teniposide; cryptophycins (specifically cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including synthetic analogs, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; sarcodictyin; spongistatin; nitrogen mustards, such as chlorambucil, naphthyl mustard, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, amide), uramustine; nitrosoureas, such as carmustine, chlorozotocin, fotemustine, cyclohexyl lomustine, nimustine, and ranimnustine; antibiotics, such as enediyne antibiotics (e.g., calicheamicins, especially calicheamicin gamma 1I and calicheamicin omega 1I (see, e.g., Nicolaou KC. et al., Angew. Chem. Int. Ed. Engl.[Angewandte Chemie International Edition], 33:183-186 (1994); dynemicins, including dynemicin A; esperamicin; and neocarzinostatin chromophores and related chromoprotein enediyne antibiotic chromophores), aclacinomycins, actinomycins, authramycins, azaserine, bleomycins, actinomycin C, carabicin, carminomicin, carzinophilin, chromomycinis, actinomycin D, daunomycin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including. Morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, liposome doxorubicin HCl injection Doxorubicin Liposomal TLC D-99 PEGylated liposomal doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; antimetabolites such as methotrexate, gemcitabine tegafur Capecitabine epothilones and 5-fluorouracil (5-FU); folic acid analogs such as folinic acid, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; antiadrenal agents such as aminoglutethimide, mitotane, trilostane; folic acid supplements such as folinic acid; aceglatone; aldophosphamide glycosides; glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptinium acetate acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansine alkaloids, such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; 2-ethylhydrazide; procarbazine; polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; siroxan; spirogermanium; tenuazonic acid; triazinequinone; 2,2′,2″-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A, and anguidine); urethan; dacarbazine; mannomustine; dibromomannitol; dibromodulanol; pipobroman; gacytosine; arabinoside (“Ara-C”); thiotepa; taxanes, such as paclitaxel Paclitaxel (ABRAXANE TM ) of albumin engineered nanoparticle formulations, and docetaxel Chloranbucil; 6-thioguanine; mercaptopurine; methotrexate; platinum agents, such as cisplatin, oxaliplatin, and carboplatin; vincas, which prevent tubulin from polymerizing to form microtubules, including vinblastine Vincristine Vindesine Vinorelbine Etoposide (VP-16); ifosfamide; mitoxantrone; leucovorin; novantrone; edatrexate; daunomycin; aminopterin; ibandronate; topoisomerase inhibitor RFS2000; difluoromethylornithine (DMFO); retinoids, such as retinoic acid, including bexarotene Bisphosphonates, such as clodronate (e.g. or ), etidronate NE-58095, Zoledronic Acid / Zoledronate Alendronate Pamidronate Tiludronate Risedronate Troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); antisense oligonucleotides, particularly those that inhibit the expression of genes in signaling pathways associated with abnormal cell proliferation, such as PKC-α, Raf, H-Ras, and epidermal growth factor receptor (EGF-R); vaccines, such as Vaccines and gene therapy vaccines, e.g. vaccine, Vaccines and vaccines; topoisomerase 1 inhibitors (eg, ); rmRH (e.g., ); BAY439006 (sorafenib; Bayer); SU-11248 (Pfizer); perifosine, COX-2 inhibitors (e.g., celecoxib or etoricoxib), proteasome inhibitors (e.g., PS341); bortezomib CCI-779; ipifarnib (R11577); orafenib, ABT510; Bcl-2 inhibitors, such as blimersen sodium pixantrone; EGFR inhibitors (see below for definition); tyrosine kinase inhibitors (see below for definition); and any pharmaceutically acceptable salts, acids or derivatives thereof; and combinations of two or more thereof, such as CHOP (an abbreviation for cyclophosphamide, doxorubicin, vincristine and prednisolone combination therapy), and FOLFOX (oxaliplatin (ELOXATIN TM ) is an abbreviation for the treatment regimen combining 5-FU and leucovorin).
[0240] As used herein, chemotherapeutic agents include "antihormonal agents" or "endocrine therapeutic agents" that are used to modulate, reduce, block or inhibit the effects of hormones that promote cancer growth. They may themselves be hormones, including but not limited to: antiestrogens with mixed agonist / antagonist profiles, including tamoxifen 4-Hydroxytamoxifen, Toremifene Idoxifene, droloxifene, raloxifene Trioxifene, raloxifene, and selective estrogen receptor modulators (SERMs) such as SERM3; pure antiestrogens without agonist properties, such as fulvestrant and EM800 (such agents can block estrogen receptor (ER) dimerization, inhibit DNA binding, increase ER turnover and / or inhibit ER levels); aromatase inhibitors, including steroidal aromatase inhibitors such as formestane and exemestane and nonsteroidal aromatase inhibitors such as anastrozole Letrozole and aminoglutethimide, and other aromatase inhibitors including vorozole Megestrol acetate fadrozole and 4(5)-imidazole; luteinizing hormone-releasing hormone agonists, including leuprolide ( and ), goserelin, buserelin and tripterelin; sex steroids, including progestins such as megestrol acetate and medroxyprogesterone acetate, estrogens such as diethylstilbestrol and conjugated estrogens (premarin), and androgens / retinoids such as fluoxymesterone, all-trans retinoic acid (and fenretinide; onapristone; antiprogestins; estrogen receptor downregulators (ERDs); antiandrogens such as flutamide, nilutamide and bicalutamide; and any pharmaceutically acceptable salts, acids or derivatives of the foregoing; and combinations of two or more of the foregoing.
[0241] As used herein, "taxane" is a chemotherapeutic agent that inhibits microtubule depolymerization. Examples include paclitaxel Paclitaxel (ABRAXANE TM ) of albumin engineered nanoparticle formulations, and docetaxel A preferred taxane is paclitaxel.
[0242] As used herein, the term "EGFR inhibitor" refers to a compound that binds to EGFR or otherwise directly interacts with EGFR and prevents or reduces its signaling activity, and may alternatively be referred to as an "EGFR antagonist". Examples of such agents include antibodies and small molecules that bind to EGFR. Examples of antibodies that bind to EGFR include MAb 579 (ATCC CRL HB 8506), MAb 455 (ATCC CRL HB8507), MAb 225 (ATCC CRL 8508), MAb 528 (ATCC CRL8509) (see, U.S. Pat. No. 4,943,533, Mendelsohn et al.) and variants thereof, such as chimeric 225 (C225 or Cetuximab; ) and reshaped human 225 (H225) (see, WO 96 / 40210, Imclone Systems Inc.); IMC-11F8 (fully human EGFR targeting antibody (Imclone)) antibodies that bind to type II mutant EGFR (U.S. Pat. No. 5,212,290); humanized and chimeric antibodies that bind to EGFR as described in U.S. Pat. No. 5,891,996; and human antibodies that bind to EGFR, such as ABX-EGF or panitumumab (see WO 98 / 50433, (Abgenix / Amgen)); EMD 55900 (Stragliotto G. et al., Eur. J. Cancer 32A(4):636-640 (1996); EMD7200 (matuzumab), a humanized EGFR antibody directed against EGFR and competing with both EGF and TGF-α for EGFR binding (EMD / Merck); a human EGFR antibody, HuMax-EGFR (GenMab); fully human antibodies designated E1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3, and E7.6.3 and described in U.S. Pat. No. 6,235,883; MDX-447 (Medarex Inc); and mAb 806 or humanized mAb 806 (Johns TG. et al., J. Biol. Chem. 279(29):30375-30384 (2004). Anti-EGFR antibodies can be conjugated to cytotoxic agents to generate immunoconjugates (see, e.g., EP659,439A2, Merck Patent GmbH). EGFR antagonists include small molecules, such as the compounds described in: U.S. Pat. Nos. 5,616,582, 5,457,105, 5,475,001, 5,654,307, 5,679,683, 6,084,095, 6,265,410, 6,455,534, 6,521,620, 6,596,726, and 5,747,498, and the following PCT publications: WO 98 / 14451, WO 98 / 50038, WO 99 / 09016, and WO 99 / 24037.Specific small molecule EGFR antagonists include OSI-774 (CP-358774, erlotinib,. Genentech / OSI Pharmaceuticals); PD 183805 (CI 1033, 2-acrylamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholino)propoxy]-6-quinazolinyl]-, dihydrochloride, Pfizer Inc.); ZD1839, gefitinib (IRESSA J) 4-(3′-chloro-4′-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline, AstraZeneca); ZM 105180 ((6-amino-4-(3-methylphenyl-amino)-quinazoline, Zeneca); BIBX-1382 (N8-(3-chloro-4-fluoro-phenyl)-N2-(1-methyl-piperidin-4-yl)-pyrimido[5,4-d]pyrimidine-2,8-diamine, Boehringer Ingelheim Ingelheim); PKI-166 ((R)-4-[4-[(1-phenylethyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenol); (R)-6-(4-hydroxyphenyl)-4-[(1-phenylethyl)amino]-7H-pyrrolo[2,3-d]pyrimidine); CL-387785 (N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide); EKB-569 (N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butyramide) (Wyeth); AG1478 (Sugen); AG1571 (SU 5271; Sugen); dual EGFR / HER2 tyrosine kinase inhibitors such as lapatinib (GW 572016 or N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]6[5[[[2-methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-aminoquinazoline; Glaxo-SmithKline).
[0243] "Tyrosine kinase inhibitors" are molecules that inhibit the tyrosine kinase activity of tyrosine kinases such as HER receptors. Examples of such inhibitors include the EGFR-targeted drugs mentioned in the preceding paragraphs; small molecule HER2 tyrosine kinase inhibitors, such as TAK165 (available from Takeda); CP-724,714 (oral selective inhibitor of ErbB2 receptor tyrosine kinase (Pfizer and OSI); dual HER inhibitors, such as EKB-569 (available from Wyeth), which preferentially binds to EGFR but inhibits cells that overexpress both HER2 and EGFR; Lapatinib ( GW572016; available from Glaxo-SmithKline), an oral HER2 and EGFR tyrosine kinase inhibitor; PKI-166 (available from Novartis); pan-HER inhibitors such as canertinib (CI-1033; Pharmacia); Raf-1 inhibitors such as ISIS-5132, an antisense agent that inhibits Raf-1 signaling (available from ISIS Pharmaceuticals); Pharmaceuticals); non-HER targeted TK inhibitors, such as imatinib mesylate (GLEEVAC J), available from Glaxo; MAPK extracellular regulated kinase I inhibitor CI-1040 (available from Pharmacia); quinazolines, such as PD153035, 4-(3-chloroanilino)quinazoline; pyridopyrimidines; pyrimidopyrimidines; pyrrolopyrimidines, such as CGP59326, CGP 60261 and CGP 62706; pyrazolopyrimidines, 4-(phenylamino)-7H-pyrrolo[2,3-d]pyrimidine; curcumin (diferuloylmethane, 4,5-bis(4-fluoroanilino)phthalimide); tyrphostines containing a nitrothiophene moiety; PD-0183805 (Warner-Lamber); antisense molecules (e.g., those that bind to HER-encoding nucleic acids); quinoxalines (U.S. Pat. No. 5,804,396); tryphostins (U.S. Pat. No. 5,804,396); ZD6474 (AstraZeneca); PTK-787 (Novartis / Schering AG)); pan-HER inhibitors, such as CI-1033 (Pfizer); Affinitac (ISIS 3521;Isis / Lilly); imatinib mesylate (Gleevac; Novartis); PKI 166 (Novartis); GW2016 (Glaxo SmithKline); CI-1033 (Pfizer); EKB-569 (Wyeth); Semaxinib (Sugen); ZD6474 (AstraZeneca); PTK-787 (Novartis / Schering AG); INC-1C11 (Imclone); or as described in any of the following patent publications: U.S. Pat. No. 5,804,396; WO 99 / 09016 (American Cyanamid); WO 98 / 43960 (American Cyanamid); WO 97 / 38983 (Warner Lambert); WO 99 / 06378 (Warner Lambert); WO 99 / 06396 (Warner Lambert); WO 96 / 30347 (Pfizer Inc.); WO 96 / 33978 (Zeneca); WO 96 / 3397 (Zeneca); and WO 96 / 33980 (Zeneca). ;
[0244] In various embodiments, the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein can be administered in combination with actinomycin D, capecitabine, carboplatin, cisplatin, colchicine, daunomycin, docetaxel, doxorubicin, epirubicin, etoposide, 5-fluorouracil, gemcitabine, melphalan, methotrexate, mitomycin C, mitoxantrone, paclitaxel, thalidomide, topotecan, vinblastine, and vincristine.
[0245] In various embodiments, the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein can be administered in combination with one or more additional therapies or clinical interventions (such as radiation therapy, surgery, chemotherapy, and / or targeted therapy). In certain embodiments, the disclosed anti-CD73 antibodies and / or variants (or fragments thereof) and / or pharmaceutical compositions provided herein are administered in combination with radiation therapy for the disclosed cancers.
[0246] In some embodiments, the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein may be administered in conjunction with surgery (e.g., the surgery may be performed before administration of the disclosed anti-CD73 antibodies, the surgery may be performed after administration of the disclosed anti-CD73 antibodies, and / or the surgery may be performed simultaneously or nearly simultaneously with administration of the disclosed anti-CD73 antibodies).
[0247] Depending on the indication to be treated and factors related to administration familiar to those skilled in the art, the anti-CD73 antibodies, variants, mutants or fragments thereof provided herein will be administered at an effective dose, such as a dose that effectively treats the indication while minimizing toxicity and side effects. It is generally preferred to use the maximum dose of the pharmacological agent of the present disclosure (alone or in combination with other therapeutic agents), that is, the highest safe dose based on reasonable medical judgment. However, one of ordinary skill in the art will understand that patients may insist on lower doses or tolerable doses for medical reasons, psychological reasons, or almost any other reason. In some embodiments, the effective dose may be such that the desired response is to inhibit the progression of a disease or condition, such as the progression of cancer. This may involve only temporarily slowing the progression of the disease, but more preferably, this involves permanently stopping the progression of the disease. This can be monitored by conventional diagnostic methods known to those of ordinary skill in the art for any particular disease. The desired response to the treatment of a disease or condition may also be to delay the onset or even prevent the onset of a disease or condition.
[0248] Toxicity and therapeutic efficacy of the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, determining the LD 50 (the dose that is lethal to 50% of the population) and ED 50 (the dose that is therapeutically effective in 50% of the patient population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio LD 50 / ED 50 Compounds that exhibit large therapeutic indices may be desirable. Although the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein that exhibit toxic side effects may be used, care should be taken to design delivery systems that target such compounds to the site of affected tissue, thereby minimizing potential damage to uninfected cells and thereby reducing side effects.
[0249] The data obtained from cell culture assays and animal studies can be used to formulate a range of dosages for use in humans. The dosage of the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein is preferably within the range of ED 50The dosage may vary within this range depending on the dosage form employed and the route of administration utilized. For any disclosed anti-CD73 antibody and / or variant or mutant (or fragment thereof) and / or pharmaceutical composition provided herein, the therapeutically effective amount can be initially estimated from cell culture assays. The dosage can be formulated in animal models to achieve an IC including as determined in cell culture experiments. 50 The circulating plasma concentration range of the drug can be determined. This information can be used to more accurately determine useful doses in humans. The levels in plasma can be measured, for example, by high performance liquid chromatography.
[0250] The anti-cancer activity of the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein can be determined by using various experimental animal models known in the art or described in Yamanaka K. et al., Microbiol. Immunol. 45(7):507-514 (2001) (e.g., SCID mouse model or nude mice with human tumor transplants).
[0251] The disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein can be tested in vitro, and then in vivo, for the desired therapeutic or prophylactic activity prior to use in humans. For example, in vitro assays that can be used to determine whether administration of a particular treatment regimen is indicated include in vitro cell culture assays, in which a patient tissue sample is grown in culture, exposed to a regimen or otherwise administered a regimen, and the effect of such a regimen on the tissue sample is observed.
[0252] A lower level of proliferation or survival of the contacted cells may indicate that the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein may be effective in treating the selected disorder in the subject. Alternatively, tumor cell lines or malignant cell lines (rather than cultured cells from patients) may be used to screen the regimen. Such survival and / or growth may be assessed using a number of assays known in the art; for example, cell proliferation may be measured by measuring 3H-thymidine incorporation, by direct cell counting, by detecting changes in the transcriptional activity of known genes such as proto-oncogenes or cell cycle markers; cell viability may be assessed by trypan blue staining, while differentiation may be visually assessed based on changes in morphology, etc.
[0253] Prior to testing in humans, the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein for therapy can be tested in suitable animal model systems (including but not limited to rats, mice, chickens, cows, monkeys, rabbits, etc.). The main animal models of cancer known and widely used in the art include mice, as described in Hann B. et al., Curr. Opin. Cell Biol. [New Perspectives in Cell Biology] 13(6): 778-784 (2001), the entire contents of which are incorporated herein by reference.
[0254] In addition, any assay known to those of skill in the art can be used to assess the prophylactic and / or therapeutic utility of the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) and / or pharmaceutical compositions provided herein for treating, preventing, managing, or ameliorating one or more symptoms associated with a disease or disorder as described above.
[0255] Those skilled in the art can readily determine a suitable daily dose for treating or preventing the disorders described herein. For the treatment of the disclosed cancers, a typical dose may be, for example, in the range of 0.001 μg to 1000 μg; however, doses below or above this exemplary range are within the scope of the present disclosure. The daily dose may be from about 0.1 μg / kg of total body weight to about 100 mg / kg of total body weight (e.g., about 5 μg / kg, about 10 μg / kg, about 100 μg / kg, about 500 μg / kg, about 1 mg / kg, about 50 mg / kg, or a range defined by any two of the foregoing values), preferably from about 0.3 μg / kg of total body weight to about 10 mg / kg of total body weight (e.g., about 0.5 μg / kg, about 1 μg / kg, about 50 μg / kg, about 150 μg / kg, about 300 μg / kg, about 750 μg / kg, about 1.5 mg / kg, about 5 mg / kg, Or a range defined by any two of the foregoing values), more preferably from about 1 μg / kg total body weight to 1 mg / kg total body weight (e.g., about 3 μg / kg, about 15 μg / kg, about 75 μg / kg, about 300 μg / kg, about 900 μg / kg, or a range defined by any two of the foregoing values), and even more preferably from about 0.5 mg / kg total body weight / day to 10 mg / kg total body weight / day (e.g., about 2 mg / kg, about 4 mg / kg, about 7 mg / kg, about 9 mg / kg, or a range defined by any two of the foregoing values, including any range between the foregoing values). As mentioned above, the therapeutic or preventive efficacy can be monitored by regularly evaluating the treated patient. For repeated administration over several days or longer, depending on the condition, the treatment is repeated until the desired disease symptom suppression occurs. However, other dosage regimens may be useful and within the scope of the present disclosure. The desired dose can be delivered by administering the composition as a single bolus, by administering the composition as multiple boluses, or by administering the composition as a continuous infusion.
[0256] The pharmaceutical composition comprising an anti-CD73 antibody, variant, mutant or fragment thereof can be administered once, twice, three times or four times a day. The composition can also be administered at a frequency lower than daily administration, for example, six times a week, five times a week, four times a week, three times a week, twice a week, once a week, once every two weeks, once every three weeks, once a month, once every two months, once every three months or once every six months. The composition can also be administered, for example, in an implant with a sustained release formulation that gradually releases the composition for use over a period of time and allows the composition to be administered at a lower frequency, for example, once a month, once every 2-6 months, once a year or even a single administration. Sustained release devices (e.g., pellets, nanoparticles, microparticles, nanospheres, microspheres, etc.) can be administered by injection.
[0257] Antibodies and / or variants or mutants (or their fragments) can be given in a single daily dose, or the total daily dose can be given in divided doses twice, three times or four times a day. Compositions can also be given at a frequency lower than that given daily, for example, six times a week, five times a week, four times a week, three times a week, twice a week, once a week, once every two weeks, once every three weeks, once a month, once every two months, once every three months or once every six months. Antibodies (or their fragments) can also be given, for example, in implants with sustained-release formulations, which gradually release the composition for use over a period of time, and allow the composition to be given with less frequency, for example, once a month, once every 2-6 months, once a year or even single administration. Sustained-release devices (e.g. pellets, nanoparticles, microparticles, nanospheres, microspheres, etc.) can be given by injection or surgical implantation in various positions.
[0258] Cancer treatment can be evaluated by, for example, but not limited to, tumor regression, reduction in tumor weight or size, time to progression, duration of survival, progression-free survival, overall response rate, duration of response, quality of life, protein expression and / or activity. Methods for determining efficacy of therapy can be employed, including, for example, measuring response by radiographic imaging.
[0259] In some embodiments, therapeutic efficacy is measured as percent tumor growth inhibition (%TGI), calculated using the equation 100-(T / C x 100), where T is the mean relative tumor volume of treated tumors and C is the mean relative tumor volume of untreated tumors. In certain embodiments, the %TGI is about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, or more than 95%. In certain embodiments, the %TGI of anti-CD73 and / or variants or mutants thereof is the same as or higher than the %TGI of a reference anti-CD73 antibody, for example, by about 1.1 times, about 1.2 times, about 1.3 times, about 1.4 times, about 1.5 times, about 1.6 times, about 1.7 times, about 1.8 times, about 1.9 times, about 2 times, about 2.1 times, about 2.2 times, about 2.3 times, about 2.4 times, about 2.5 times, about 2.6 times, about 2.7 times (including any ranges between these values), or is about 2.7 times higher than the %TGI of a reference anti-CD73 antibody.
[0260] Pharmaceutical composition
[0261] The disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) of the present invention can be prepared into pharmaceutical compositions comprising suitable carriers or excipients so that they are suitable for administration. Suitable pharmaceutical compositions of antibodies are obtained in the form of lyophilized formulations or aqueous solutions by mixing antibodies (or fragments thereof) having the desired purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. ed. (1980)). Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers (such as phosphates, citrates and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethylammonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens, such as methyl or propyl parabens; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 1 0 residues); proteins such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides and other carbohydrates, including glucose, mannose, or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., zinc-protein complexes); and / or nonionic surfactants such as TWEEN®. TM 、PLURONICS TM Or polyethylene glycol (PEG). Exemplary antibody formulations are described in WO 98 / 56418, which is expressly incorporated herein by reference. Freeze-dried pharmaceutical compositions suitable for subcutaneous administration are described in WO 97 / 04801. Such freeze-dried pharmaceutical compositions can be reconstituted with a suitable diluent to a high protein concentration, and the reconstituted formulation can be administered subcutaneously to a mammal to be treated herein.
[0262] In some embodiments, the disclosed pharmaceutical composition is suitable for parenteral or intravenous administration. In some embodiments, the disclosed pharmaceutical composition suitable for parenteral administration can be aqueous and non-aqueous preparations that are isotonic with the blood of the intended subject; aqueous and non-aqueous sterile suspensions may include suspension systems designed to target the blood components of one or more organs of the compound. Preparations may be present in unit dose or multi-dose sealed containers (e.g., ampoules or vials). Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets of the previously described types. Parenteral and intravenous preparations may include minerals and other materials to make them compatible with the selected injection or delivery system type.
[0263] Common pharmaceutically acceptable carriers for parenteral administration include water, suitable oils, saline, aqueous dextrose (glucose) or related sugar solutions, and diols such as propylene glycol or polyethylene glycol. Solutions for parenteral administration preferably contain water-soluble salts of the active ingredient, suitable stabilizers, and (if necessary) buffering substances. Antioxidants (such as sodium bisulfite, sodium sulfite, or ascorbic acid), alone or in combination, are suitable stabilizers. Citrates and sodium EDTA can also be used as carriers. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methylparaben or propylparaben, or chlorobutanol. Suitable pharmaceutical carriers are described in Remington cited above.
[0264] Injectable formulations can be prepared in conventional forms, either as liquid solutions or suspensions; as solid forms suitable for dissolving or suspending in a liquid prior to injection; or as emulsions. Preferably, sterile injectable suspensions are formulated using suitable pharmaceutically acceptable carriers and other optional ingredients as described above, according to techniques known in the art.
[0265] Parenteral administration can be carried out in many ways, but preferably a syringe, catheter, or similar device is used to effect parenteral administration of the formulations described herein. The formulation can be injected systemically so that the active agent is distributed substantially throughout the bloodstream.
[0266] In addition, the formulation can also be injected locally into the target site. For example, it is desirable to inject into a specific part of the body to treat cancer or fibrosis. The advantage of local administration via injection is that it limits or avoids exposure of the whole body to one or more active agents (e.g., inhibitors and / or other therapeutic agents). It should be noted that in the context of the present invention, the term local administration includes regional administration, for example, by delivering a formulation for a part of the body by delivering it to the blood vessels serving that body region. Local delivery can be direct, for example, intratumoral delivery. Local delivery can also be nearly direct, i.e., intralesional or intraperitoneal, that is, delivered to an area sufficiently close to the tumor or infection site such that the inhibitor exhibits the desired pharmacological activity. Thus, when local delivery is desired, the pharmaceutical formulation is preferably delivered intralesionally, intratumorally, or intraperitoneally.
[0267] In certain embodiments, the pharmaceutical composition is in unit dosage form. In this form, the composition is divided into unit doses containing an appropriate amount of the active ingredient. The unit dosage form can be a packaged preparation that contains discrete amounts of the preparation, such as a lyophilized powder in a vial or an ampoule.
[0268] The pharmaceutical composition herein may also contain more than one active compound necessary for the specific indication treated, preferably those active compounds with complementary activities that do not adversely affect each other. For example, it may be desirable to further provide an antitumor agent, a growth inhibitor, a cytotoxic agent or a chemotherapeutic agent. Such molecules are suitably present in an amount combination effective for the intended purpose. The effective amount of such other agents depends on the amount of antibodies present in the formulation, the type of disease or disorder or treatment, and other factors discussed above. These are generally used with the same dosage and administration route as described herein, or with from about 1% to 99% of the dosage used so far. The active ingredient may also be embedded in a microcapsule prepared, for example, by coagulation technology or by interfacial polymerization, such as hydroxymethylcellulose or gelatin-microcapsules and poly(methyl methacrylate) microcapsules in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in coarse emulsions. Such technology is disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. Editor (1980).
[0269] Sustained release formulations can be prepared. Suitable examples of sustained release formulations include semipermeable matrices of solid hydrophobic polymers containing the antagonist, which are in the form of shaped articles, such as films or microcapsules. Examples of sustained release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate), or poly(vinyl alcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and ethyl-L-glutamic acid, non-degradable ethylene-vinyl, degradable lactic acid-glycolic acid copolymers (such as LUPRON DEPOT TM (Injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate)) and poly-D-(-)-3-hydroxybutyric acid. Although polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid are able to release molecules for more than 100 days, certain hydrogels release proteins in shorter time periods. When encapsulated antibodies are retained in the body for a long time, they can denature or aggregate due to exposure to moisture at 37°C, resulting in loss of biological activity and possible changes in immunogenicity. Rational strategies can be designed to achieve stabilization based on the mechanisms involved. For example, if the aggregation mechanism is found to be the formation of intermolecular SS bonds through sulfo-disulfide exchange, stabilization can be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
[0270] Lipofectin or liposomes can be used to deliver the polypeptides and antibodies (or fragments thereof) or compositions of the present invention into cells. Where an antibody fragment is used, the smallest inhibitory fragment that specifically binds to the target protein binding domain is preferred. For example, based on the variable region sequence of the antibody, a peptide molecule can be designed to retain the ability to bind to the target protein sequence. Such peptides can be chemically synthesized and / or produced by recombinant DNA technology. See, e.g., Marasco WA. et al., Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States of America] 90(16):7889-7893 (1993).
[0271] The active ingredient can also be embedded in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, such as hydroxymethylcellulose or gelatin-microcapsules and poly-(methyl methacrylate) microcapsules in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in macroemulsions, respectively. Such techniques are disclosed in Remington's PHARMACEUTICAL SCIENCES, supra.
[0272] Sustained-release preparations can be prepared. Suitable embodiments of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing antibodies (or fragments thereof), which are in the form of molded articles, such as films or microcapsules. Embodiments of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol)), polylactides (U.S. Patent No. 3,773,919), copolymers of L-glutamic acid and ethyl-L-glutamic acid, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers (such as LUPRON DEPOT TM (injectable microspheres composed of lactic acid-glycolic acid copolymers and leuprolide acetate)) and poly-D-(-)-3-hydroxybutyric acid. Although polymers (e.g., ethylene-vinyl acetate and lactic acid-glycolic acid) can release molecules for more than 100 days, some hydrogels release proteins in shorter time periods. When encapsulated antibodies remain in the body for a long time, they can denature or aggregate due to exposure to moisture at 37°C, resulting in loss of biological activity and possible changes in immunogenicity. Rational strategies can be designed to achieve stabilization based on the mechanisms involved. For example, if the aggregation mechanism is found to be the formation of intermolecular SS bonds through sulfo-disulfide exchange, stabilization can be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
[0273] In certain embodiments, the formulation comprises greater than about 0.5 mg / mL, greater than about 1 mg / mL, greater than about 2 mg / mL, greater than about 3 mg / mL, greater than about 4 mg / mL, greater than about 5 mg / mL, greater than about 6 mg / mL, greater than about 7 mg / mL, greater than about 8 mg / mL, greater than about 9 mg / mL, greater than about 10 mg / mL, greater than about 11 mg / mL, greater than about 12 mg / mL, greater than about 13 mg / mL, greater than about 14 mg / mL, greater than about 15 mg / mL, greater than about 16 mg / mL, greater than about 17 mg / mL, greater than about 18 mg / mL, greater than about 19 mg / mL, greater than about 20 mg / mL, greater than about 21 mg / mL, greater than about 22 mg / mL, greater than about 23 mg / mL, greater than about 24 mg / mL, greater than about 25 mg / mL, greater than about 26 mg / mL, greater than about 27 mg / mL, greater than about 28 mg / mL, greater than about 29 mg / mL, greater than about 30 mg / mL, greater than about 31 mg / mL, greater than about 32 mg / mL, greater than about 33 mg / mL, greater than about 34 mg / mL, greater than about 35 mg / mL, greater than about 36 mg / mL, greater than about 37 mg / mL, greater than about 38 mg / mL, greater than about 39 mg / mL, greater than about 40 mg / mL, greater than about 41 mg / mL, greater than about An anti-CD73 antibody and / or variant or mutant thereof described herein at a concentration of about 17 mg / mL, above about 18 mg / mL, above about 19 mg / mL, above about 20 mg / mL, above about 21 mg / mL, above about 22 mg / mL, above about 23 mg / mL, above about 24 mg / mL, above about 25 mg / mL, above about 26 mg / mL, above about 27 mg / mL, above about 28 mg / mL, above about 29 mg / mL, or above about 30 mg / mL, including any ranges between these values.
[0274] The formulation containing the disclosed antibody should have a pH (in the final formulation) that is not similar to the isoelectric point value of the antibody or fragment, for example, if the pH of the formulation is 7, then a pI of from 8 to 9 or higher may be appropriate. Although not wishing to be bound by theory, it is believed that this may ultimately provide a final formulation with improved stability, such as the antibody or fragment remaining in solution. For example, in certain embodiments, the disclosed pharmaceutical formulation with a pH in the range of 4.0 to 7.0 may include: 1 mg / mL to 200 mg / mL of an antibody according to the present disclosure and 1 to 100 mM of a buffer, and optionally one or more of the following: (a) 0.001% to 1% of a surfactant, (b) 10 mM to 500 mM of a stabilizer, (c) 10 mM to 500 mM of a stabilizer and 5 mM to 500 mM of a tonicity agent, and / or (d) 5 mM to 500 mM of a tonicity agent. Suitable buffers include, but are not limited to, citrate, glycine, phosphate, acetate, succinate, and bicarbonate. For example, a formulation of about pH 6 may include 1 to 50 mg / mL of antibody, 20 mM L-histidine HCl, 240 mM trehalose, and 0.02% polysorbate 20. Alternatively, a formulation of about pH 5.5 may include 1 to 50 mg / mL of antibody, 20 mM citrate buffer, 240 mM sucrose, 20 mM arginine, and 0.02% polysorbate 20.
[0275] In certain embodiments, an anti-CD73 antibody and / or variant or mutant thereof (e.g., at a concentration of greater than about 0.5 mg / mL, greater than about 1 mg / mL, greater than about 5 mg / mL, greater than about 10 mg / mL, greater than about 15 mg / mL, greater than about 20 mg / mL, or greater than about 25 mg / mL, including any ranges between these values) is formulated in a buffer comprising citrate, NaCl, acetate, succinate, glycine, polysorbate 80 (Tween 80), or any combination of the foregoing. In certain embodiments, an anti-CD73 antibody and / or variant thereof (e.g., at a concentration of greater than about 0.5 mg / mL, greater than about 1 mg / mL, greater than about 5 mg / mL, greater than about 10 mg / mL, greater than about 15 mg / mL, greater than about 20 mg / mL, or greater than about 25 mg / mL, including any ranges between these values) is formulated in a buffer comprising about 100 mM to about 150 mM glycine. In certain embodiments, the anti-CD73 antibodies and / or variants thereof are formulated in a buffer comprising about 50 mM to about 100 mM NaCl. In certain embodiments, the anti-CD73 antibodies and / or variants or mutants thereof are formulated (e.g., at a concentration of greater than about 0.5 mg / mL, greater than about 1 mg / mL, greater than about 5 mg / mL, greater than about 10 mg / mL, greater than about 15 mg / mL, greater than about 20 mg / mL, or greater than about 25 mg / mL (including any ranges between these values)) in a buffer comprising about 10 mM to about 50 mM acetate. In certain embodiments, the anti-CD73 antibodies and / or variants thereof are formulated in a buffer comprising about 10 mM to about 50 mM succinate. In certain embodiments, the anti-CD73 antibody and / or variant or mutant thereof is formulated in a buffer comprising about 0.005% to about 0.02% polysorbate 80 (e.g., at a concentration of greater than about 0.5 mg / mL, greater than about 1 mg / mL, greater than about 5 mg / mL, greater than about 10 mg / mL, greater than about 15 mg / mL, greater than about 20 mg / mL, or greater than about 25 mg / mL, including any ranges between these values). In certain embodiments, the anti-CD73 antibody and / or variant or mutant thereof is formulated in a suitable buffer to provide a buffered pH between about 5.1 and 5.6. For example, the anti-CD73 antibody and / or variant or mutant thereof can be formulated in a buffer comprising 10 mM citrate, 100 mM NaCl, 100 mM glycine, and 0.01% polysorbate 80, wherein the formulation is at pH = 5.5.
[0276] In certain embodiments, a formulation (such as a formulation comprising a buffer comprising 10 mM citrate, 100 mM NaCl, 100 mM glycine, and 0.01% polysorbate 80, wherein the formulation is at pH = 5.5) comprising an anti-CD73 antibody and / or variant or mutant thereof described herein (e.g., at a concentration greater than about 0.5 mg / mL, greater than about 1 mg / mL, greater than about 5 mg / mL, greater than about 10 mg / mL, greater than about 15 mg / mL, greater than about 20 mg / mL, or greater than about 25 mg / mL, including any ranges between these values) is stable at room temperature (such as at about 20°C-25°C) for about 0.5 week, 1.0 week, 1.5 week, 2.0 week, 2.5 week, 3.5 week, 4.0 week, 4.5 week, or 5.0 week, including any ranges between these values. In certain embodiments, a formulation (such as a formulation comprising a buffer comprising 10 mM citrate, 100 mM NaCl, 100 mM glycine, and 0.01% polysorbate 80, wherein the formulation is at pH = 5.5) comprising an anti-CD73 antibody and / or variant or mutant thereof described herein (e.g., at a concentration greater than about 0.5 mg / mL, greater than about 1 mg / mL, greater than about 5 mg / mL, greater than about 10 mg / mL, greater than about 15 mg / mL, greater than about 20 mg / mL, or greater than about 25 mg / mL, including any ranges between these values) is stable under accelerated conditions (such as storage at about 37°C) for about 0.5 weeks, 1.0 weeks, 1.5 weeks, 2.0 weeks, 2.5 weeks, 3.5 weeks, 4.0 weeks, 4.5 weeks, or 5.0 weeks, including any ranges between these values).
[0277] Size exclusion chromatography (SEC) is a well-known and widely used method for protein stability studies to detect potential fragmentation and aggregation corresponding to physical and chemical instabilities. In certain embodiments, a formulation comprising 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody described herein and / or variants or mutants thereof shows an increase of less than about 1.6%, 1.4%, 1.2%, 1.0%, 0.8%, 0.6%, 0.4%, 0.2%, or 0.1%, including any ranges between these values, of high molecular weight species (HMWS) after 1 week at 37°C, relative to the % of initial high molecular weight species, as measured using SEC. In certain embodiments, formulations comprising 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody described herein exhibit an increase of less than about 2.0%, 1.8%, 1.6%, 1.4%, 1.2%, 1.0%, 0.8%, 0.6%, 0.4%, 0.2%, or 0.1%, including any ranges between these values, in high molecular weight species after 2 weeks at 37°C, relative to the % of initial high molecular weight species as measured using SEC. In certain embodiments, a formulation comprising 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody and / or variant or mutant thereof described herein exhibits an increase of less than about 3.3%, 3.2%, 3.1%, 3.0%, 2.9%, 2.8%, 2.7%, 2.6%, 2.5%, 2.4%, 2.2%, 2.0%, 1.8%, 1.6%, 1.4%, 1.2%, 1.0%, 0.8%, 0.6%, 0.4%, 0.2%, or 0.1%, including any ranges between these values, in high molecular weight species after 4 weeks at 37°C relative to the % of initial high molecular weight species as measured using SEC.
[0278] In certain embodiments, a formulation comprising 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody and / or variant or mutant thereof described herein exhibits an increase of less than about 1.6%, 1.4%, 1.2%, 1.0%, 0.8%, 0.6%, 0.4%, 0.2%, or 0.1%, including any ranges between these values, in low molecular weight species (LMWS) after 1 week at 37°C, relative to the % of initial low molecular weight species as measured using SEC. In certain embodiments, a formulation comprising 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody and / or variant or mutant thereof described herein exhibits an increase of less than about 2.0%, 1.8%, 1.6%, 1.4%, 1.2%, 1.0%, 0.8%, 0.6%, 0.4%, 0.2%, or 0.1%, including any ranges between these values, in low molecular weight species after 2 weeks at 37°C, relative to the % of initial low molecular weight species as measured using SEC. In certain embodiments, a formulation comprising 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody and / or variant or mutant thereof described herein exhibits an increase of less than about 2.4%, 2.2%, 2.0%, 1.8%, 1.6%, 1.4%, 1.2%, 1.0%, 0.8%, 0.6%, 0.4%, 0.2%, or 0.1%, including any ranges between these values, in low molecular weight species after 4 weeks at 37°C, relative to the % of initial low molecular weight species as measured using SEC.
[0279] In certain embodiments, a formulation comprising 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody and / or variants thereof or mutants thereof described herein exhibits a decrease of no more than about 0.2%, 0.4%, 0.6%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, or 3.5%, including any ranges in between these values, of monomer relative to the % of initial monomer after 1 week at 37°C as measured using SEC. In certain embodiments, a formulation comprising 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody and / or variants thereof or mutants thereof described herein exhibits a decrease of no more than about 0.2%, 0.4%, 0.6%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, or 3.5%, including any ranges in between these values, of monomer relative to the % of initial monomer after 2 weeks at 37°C as measured using SEC. In certain embodiments, a formulation comprising 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody and / or variants thereof or mutants thereof described herein exhibits a decrease of no more than about 0.2%, 0.4%, 0.6%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, or 3.5%, including any ranges in between these values, of monomer relative to the % of initial monomer after 2 weeks at 37°C as measured using SEC.
[0280] Cation exchange chromatography (CEX) is a well-known and widely used tool to detect protein degradation events, such as deamidation or oxidation (Moorhouse KG. et al., J. Pharm. Biomed. Anal. [Journal of Pharmaceutical and Biomedical Analysis] 16 (4): 593-603 (1997)). Degradation products are typically referred to as acidic or basic species. Acidic species are variants that elute earlier than the main peak of CEX, while basic species are variants that elute later than the main peak of CEX. In certain embodiments, as measured using CEX, after 1 week at 37° C., the acidic peak portion of a formulation containing 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody and / or variant thereof or mutant thereof described herein does not exceed about 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15% of the total protein (including any ranges between these values). In certain embodiments, the acidic peak portion of a formulation comprising 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody and / or variant or mutant thereof described herein does not exceed about 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, or 18% (including any ranges between these values) of total protein after 2 weeks at 37°C as measured using CEX. In certain embodiments, the acidic peak portion of a formulation comprising 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody and / or variant or mutant (or fragment) thereof described herein does not exceed about 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, or 27% (including any ranges in between these values) of total protein after 2 weeks at 37°C as measured using CEX.
[0281] In certain embodiments, the basic peak fraction of a formulation comprising 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody and / or variant or mutant thereof (or fragment) described herein does not exceed about 39%, 40%, 41%, 42%, 43%, 44%, 45%, or 46% (including any ranges between these values) of the total protein after 1 week at 37°C as measured using CEX. In certain embodiments, the basic peak fraction of a formulation comprising 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody and / or variant or mutant thereof (or fragment) described herein does not exceed about 39%, 40%, 41%, 42%, 43%, 44%, 45%, or 46% (including any ranges between these values) of the total protein after 2 weeks at 37°C as measured using CEX. In certain embodiments, the basic peak fraction of a formulation comprising 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody and / or variant or mutant (or fragment) described herein does not exceed about 39%, 40%, 41%, 42%, 43%, 44%, 45%, or 46% (including any ranges between these values) of the total protein after 4 weeks at 37°C as measured using CEX.
[0282] In certain embodiments, the main peak portion of a formulation comprising 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody and / or variant or mutant (or fragment) thereof described herein is no less than about 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, or 46% (including any ranges between these values) of the total protein after 1 week at 37°C as measured using CEX. In certain embodiments, the basic peak portion of a formulation comprising 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody and / or variant or mutant (or fragment) thereof described herein is no less than about 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, or 46% (including any ranges between these values) of the total protein after 2 weeks at 37°C as measured using CEX. In certain embodiments, the basic peak portion of a formulation comprising 5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, or 25 mg / mL of an anti-CD73 antibody and / or variant or mutant (or fragment) thereof described herein is no less than about 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, or 46% (including any ranges between these values) of the total protein after 4 weeks at 37°C as measured using CEX.
[0283] Formulations for in vivo administration must be sterile. This can be readily achieved, for example, by filtration through sterile filtration membranes.
[0284] Diagnostic and imaging methods using anti-CD73 antibodies and variants / mutants thereof
[0285] Labeled anti-CD73 antibodies, variants, mutants, fragments thereof, and derivatives and analogs thereof that specifically bind to CD73 can be used for diagnostic purposes to detect, diagnose or monitor diseases and / or disorders associated with expression, abnormal expression and / or activity of CD73. For example, the disclosed anti-CD73 antibodies and / or variants or mutants (or fragments thereof) provided herein can be used in in situ, in vivo, ex vivo and in vitro diagnostic assays or imaging assays. A method for detecting CD73 expression comprises (a) determining expression of a polypeptide in a cell (e.g., tissue) or body fluid of an individual using one or more antibodies disclosed herein, and (b) comparing the gene expression level to a standard gene expression level, wherein an increase or decrease in the determined gene expression level compared to the standard expression level indicates abnormal expression.
[0286] Additional embodiments provided herein include methods for diagnosing a disease or disorder associated with expression or abnormal expression of CD73 in an animal (e.g., a mammal such as a human). These methods comprise detecting a CD73 molecule in a mammal. In certain embodiments, the diagnosis comprises: (a) administering an effective amount of a labeled anti-CD73 antibody and / or a variant or mutant (or fragment) thereof to a mammal; (b) waiting for a period of time after administration to allow the labeled anti-CD73 antibody and / or a variant or mutant (or fragment) thereof to preferentially concentrate at sites expressing CD73 in the subject (and clearing unbound labeled molecules to background levels); (c) determining background levels; and (d) detecting labeled molecules in the subject, such that detection of labeled molecules above background levels indicates that the subject suffers from a specific disease or disorder associated with expression or abnormal expression of CD73. Background levels can be determined by different methods, including comparing the amount of the detected labeled molecule to a standard value previously determined for a specific system.
[0287] The anti-CD73 antibodies and / or variants or mutants (or fragments thereof) provided herein can be used to determine protein levels in biological samples using classical immunohistological methods known to those skilled in the art (e.g., see Jalkanen et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen et al., J. Cell. Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as enzyme-linked immunosorbent assays (ELISAs) and radioimmunoassays (RIAs). Suitable antibody assay labels are known in the art and include enzyme labels (e.g., glucose oxidase); radioactive isotopes, such as iodine ( 131 I. 125 I. 123 I. 121 I), carbon ( 14 C) Sulfur ( 35 S), tritium ( 3 H), Indium ( 115m In, 113m In, 112 In, 111 In), Technetium ( 99 Tc, 99m Tc), thallium ( 201 Ti、Ga( 68 Ga, 67 Ga), Palladium ( 103 Pd), molybdenum ( 99 Mo), xenon ( 133 Xe、Fluorine( 18 F) Samarium153 Sm), Lutetium ( 177 Lu), Gadolinium ( 159 Gd), promethium ( 149 Pm), Lanthanum ( 140 La), Ytterbium ( 175 Yb), holmium ( 166 Ho), Yttrium ( 90 Y), Scandium ( 47 Sc), rhenium ( 186 Re, 188 Re、Pr( 142 Pr), rhodium ( 105 Rh), ruthenium ( 97 Ru); luminol; and fluorescent labels (such as fluorescein, rhodamine, and biotin).
[0288] Techniques known in the art can be applied to labeled antibodies (or fragments thereof) provided herein. Such techniques include, but are not limited to, the use of bifunctional conjugates (see, e.g., U.S. Pat. Nos. 5,756,065; 5,714,631; 5,696,239; 5,652,361; 5,505,931; 5,489,425; 5,435,990; 5,428,139; 5,342,604; 5,274,119; 4,994,560; and 5,808,003).
[0289] Alternatively, or in addition, the level of nucleic acid or mRNA encoding CD73 in cells can be measured, for example, via fluorescence in situ hybridization using a nucleic acid-based probe corresponding to a nucleic acid encoding CD73 or its complementary sequence; (FISH; see WO 98 / 45479 published in October 1998), Southern blotting, Northern blotting, or polymerase chain reaction (PCR) techniques, such as real-time quantitative PCR (RT-PCR). CD73 overexpression can also be studied by measuring shed antigen in biological fluids such as serum, for example, using an antibody-based assay (see also, e.g., U.S. Pat. No. 4,933,294, issued June 12, 1990; WO 91 / 05264, issued April 18, 1991; U.S. Pat. No. 5,401,638, issued March 28, 1995; and Sias et al., J. Immunol. Methods 132:73-80 (1990)). In addition to the above assays, various in vivo and ex vivo assays are available to those skilled in the art. For example, cells in a mammal can be exposed to an antibody, which is optionally labeled with a detectable marker (e.g., a radioisotope), and the binding of the antibody to the cells can be assessed, for example, by external scanning for radioactivity or by analyzing a sample (e.g., a biopsy or other biological sample) taken from a mammal previously exposed to the antibody.
[0290] Products and kits
[0291] In various embodiments, the present invention relates to a kit comprising the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions provided herein, and one or more of: (a) at least one agent known to treat cancer; or (b) instructions for treating cancer.
[0292] In additional embodiments, the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions provided herein, and at least one agent known to treat cancer are co-formulated.
[0293] In still further embodiments, the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions provided herein, and at least one agent known to treat cancer are co-packaged.
[0294] In further embodiments, an agent known to treat cancer is a hormonal therapeutic agent. In still further embodiments, the hormonal therapeutic agent is selected from one or more of the group consisting of leuprolide, tamoxifen, raloxifene, megestrol acetate, fulvestrant, triptorelin, medroxyprogesterone acetate, letrozole, anastrozole, exemestane, bicalutamide, goserelin, histrelin, fluoxymesterone, estramustine, flutamide, toremifene, degarelix, nilutamide, abarelix, and testolactone, or a pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof.
[0295] In further embodiments, at least one agent known to treat cancer is a chemotherapeutic agent. In still further embodiments, the chemotherapeutic agent is selected from one or more of the group consisting of an alkylating agent, an antimetabolite agent, an antitumor antibiotic agent, a mitotic inhibitor, an mTOR inhibitor, or other chemotherapeutic agent.
[0296] In further embodiments, the anti-tumor antibiotic agent is selected from one or more of the following group, which consists of doxorubicin, mitoxantrone, bleomycin, daunomycin, actinomycin D, epirubicin, idarubicin, plicamycin, mitomycin, pentostatin and valrubicin, or a pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof.
[0297] In further embodiments, the antimetabolite agent is selected from one or more of the group consisting of gemcitabine, 5-fluorouracil, capecitabine, hydroxyurea, mercaptopurine, pemetrexed, fludarabine, nelarabine, cladribine, clofarabine, cytarabine, decitabine, pralatrexate, floxuridine, methotrexate and thioguanine, or a pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof.
[0298] In further embodiments, the alkylating agent is selected from one or more of the following group, the group consisting of: carboplatin, cisplatin, cyclophosphamide, chlorambucil, melphalan, carmustine, busulfan, cyclohexyl lomustine, dacarbazine, oxaliplatin, ifosfamide, nitrogen mustard, temozolomide, thiotepa, bendamustine and streptozotocin, or a pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof.
[0299] In further embodiments, the mitotic inhibitor is selected from one or more of the group consisting of irinotecan, topotecan, rubitecan, cabazitaxel, docetaxel, paclitaxel, etoposide, vincristine, ixabepilone, vinorelbine, vinblastine and teniposide, or a pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof.
[0300] In further embodiments, the mTOR inhibitor is selected from one or more of the group consisting of everolimus, siroliumus and temsirolimus, or a pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof.
[0301] In additional embodiments, the kit further comprises instructions for providing the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions provided herein in combination with surgery. In still further embodiments, the kit further comprises instructions for providing the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions provided herein in combination with surgery, wherein these instructions provide for performing surgery prior to administering at least one compound. In yet further embodiments, the kit further comprises instructions for providing the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions provided herein in combination with surgery, wherein these instructions provide for performing surgery after administering the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions provided herein. In even further embodiments, the kit further comprises instructions for providing the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or the pharmaceutical compositions provided herein in combination with surgery, wherein the instructions provide for performing the surgery after administering the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or the pharmaceutical compositions provided herein, and wherein the instructions provide for administering the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or the pharmaceutical compositions provided herein is for achieving preoperative debulking of a tumor. In still further embodiments, the kit further comprises instructions for providing the compound in combination with surgery, wherein the instructions provide for performing the surgery after administering the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or the pharmaceutical compositions provided herein, and wherein the instructions provide for performing the surgery at approximately the same time as administering the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or the pharmaceutical compositions provided herein.
[0302] In additional embodiments, the kit further comprises instructions for providing the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions in combination with radiation therapy. In still further embodiments, the kit further comprises instructions for providing the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions in combination with radiation therapy, wherein the instructions provide for performing radiation therapy prior to administering the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions. In yet further embodiments, the kit further comprises instructions for providing the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions in combination with radiation therapy, wherein the instructions provide for performing radiation therapy after the step of administering the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions. In even further embodiments, the kit further comprises instructions for providing the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions in combination with radiation therapy, wherein the instructions provide for performing the radiation therapy substantially simultaneously with the step of administering the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions.
[0303] In further embodiments, the kit further comprises a plurality of dosage forms, the plurality comprising one or more doses; wherein each dose comprises a therapeutically effective amount of the disclosed anti-CD73 antibody, variant, mutant and / or fragment thereof, and / or pharmaceutical composition and at least one pharmaceutical agent. In still further embodiments, the kit further comprises a plurality of dosage forms, the plurality comprising one or more doses; wherein each dose comprises a therapeutically effective amount of the disclosed anti-CD73 antibody, variant, mutant and / or fragment thereof, and / or pharmaceutical composition and at least one pharmaceutical agent, and wherein each dose of the disclosed anti-CD73 antibody, variant, mutant and / or fragment thereof, and / or pharmaceutical composition is co-formulated with at least one pharmaceutical agent known to treat cancer. In yet further embodiments, the kit further comprises a plurality of dosage forms, the plurality comprising one or more doses; wherein each dose comprises a therapeutically effective amount of the disclosed anti-CD73 antibody, variant, mutant and / or fragment thereof, and / or pharmaceutical composition and at least one pharmaceutical agent, and wherein each dose of the disclosed anti-CD73 antibody, variant, mutant and / or fragment thereof, and / or pharmaceutical composition is co-packaged with at least one pharmaceutical agent known to treat cancer.
[0304] In additional embodiments, the kit further comprises a plurality of dosage forms, the plurality comprising one or more doses; wherein each dose comprises a therapeutically effective amount of the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions (formulated for intravenous administration), and at least one pharmaceutical agent (formulated for oral administration and / or intravenous administration). In still further embodiments, the kit further comprises a plurality of dosage forms, the plurality comprising one or more doses; wherein each dose comprises a therapeutically effective amount of the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions (formulated for intravenous administration), and at least one pharmaceutical agent (formulated for oral administration). In yet further embodiments, the kit further comprises a plurality of dosage forms, the plurality comprising one or more doses; wherein each dose comprises a therapeutically effective amount of the disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions (formulated for intravenous administration), and at least one pharmaceutical agent (formulated for intravenous administration).
[0305] The disclosed anti-CD73 antibodies, variants, mutants and / or fragments thereof, and / or pharmaceutical compositions can be conveniently provided as a kit, wherein two or more components (which may be active or inactive ingredients, carriers, diluents, etc.) are provided with instructions for preparing the actual dosage form for the patient or the person administering the drug to the patient. Such kits may have all the necessary materials and ingredients contained therein, or these kits may contain instructions for using or making materials or components that must be independently obtained by the patient or the person administering the drug to the patient. In further embodiments, the kit may include optional components that facilitate administration of unit doses to the patient, such as vials for reconstitution of powder forms, syringes for injection, customized IV delivery systems, inhalers, etc. Additionally, the kit may include instructions for preparing and administering the composition. The kit may be manufactured as a single-use unit dose for one subject, for multiple uses for a specific subject (at a constant dose or where the efficacy of a single compound may vary as therapy progresses); or the kit may contain multiple doses suitable for administration to multiple patients ("bulk packaging"). The kit components may be packaged in cartons, blister packs, bottles, tubes, and the like.
[0306] In further embodiments, the disclosed kits can be packaged in a daily dosing regimen (e.g., packaged on cards, packaged with dosing cards, blister packs, or blow-molded plastic packages, etc.). Such packaging promotes the product and increases patient compliance with the medication regimen. Such packaging can also reduce patient confusion. The present disclosure features a kit that further includes instructions for use.
[0307] In other embodiments, the present invention also provides pharmaceutical packaging or test kit, which comprises one or more containers filled with one or more components of pharmaceutical composition of the present invention. Related to this container or such containers can be a mark in a form that is regulated by a government agency that manages drug or biological product manufacturing, use or sales, which reflects that manufacturing, use or sales agency approval is used for people to give.
[0308] In various embodiments, the disclosed kits may also include compounds and / or products that are co-packaged, co-formulated, and / or co-delivered with other components. For example, a drug manufacturer, drug distributor, physician, compounding shop, or pharmacist may provide a kit comprising the disclosed compounds and / or products and another component for delivery to a patient.
[0309] It is contemplated that the disclosed kits can be used with the disclosed methods of preparation, the disclosed methods of use or treatment, and / or the disclosed compositions.
[0310] Also provided are kits useful for various purposes, such as kits for isolating or detecting CD73 in a patient, optionally in combination with an article of manufacture. For the isolation and purification of CD73, the kit may contain a molecule that is combined with beads (e.g., SEPHAROSE TM The invention relates to an anti-CD73 antibody and / or variant or mutant (or fragment) thereof provided herein coupled to a bead (or a cell-free bead). A kit containing the antibody (or fragment thereof) can be provided for in vitro detection and quantification of CD73, for example, in ELISA or Western blotting. As with the article of manufacture, the kit comprises a container and a label or packaging insert on or associated with the container. For example, the container holds a composition comprising at least one anti-CD73 antibody and / or variant or mutant (or fragment) thereof provided herein. Additional containers that may be included contain, for example, diluents and buffers, control antibodies. The label or packaging insert may provide a description of the composition and instructions for intended in vitro or diagnostic use.
[0311] Another embodiment provided herein is an article containing materials for treating the disclosed cancer. The article may include a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, etc. The container can be made of a variety of materials, such as glass or plastic. Typically, the container holds a composition that effectively treats the condition and may have a sterile access port (for example, the container may be an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic needle). At least one active agent in the composition is an anti-CD73 antibody and / or variant or mutant (or fragment) thereof provided herein. The label or package insert indicates that the composition is used to treat a specific condition. The label or package insert will further include instructions for administering the antibody composition to the patient. Articles and kits containing the combination therapy described herein are also contemplated.
[0312] Package inserts refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications and / or warnings concerning the use of such therapeutic products. In one embodiment, the package insert indicates that the composition is used to treat cancer (e.g., head and neck cancer, lung cancer, or colorectal cancer).
[0313] Additionally, the article of manufacture may further comprise a second container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials desirable from a commercial and user perspective, including other buffers, diluents, filters, needles, and syringes.
[0314] Having now generally described aspects of the present invention, the following examples describe some additional aspects of the present invention. Although aspects of the present invention are described in conjunction with the following examples and corresponding text and drawings, it is not intended that aspects of the present invention be limited to this description. On the contrary, it is intended to encompass all alternatives, modifications, and equivalents included within the spirit and scope of the present invention.
[0315] Example
[0316] The following examples are presented to provide a person of ordinary skill in the art with a complete disclosure and description of how to prepare and evaluate the compounds, compositions, articles, devices and / or methods claimed herein, and are intended to be purely exemplary of the present invention and are not intended to limit the scope of the invention as the inventors believe. Although every effort has been made to ensure the accuracy of numbers (e.g., amounts, temperatures, etc.), some errors and deviations should still be considered. Unless otherwise indicated, parts are parts by weight, temperatures are ° C or ambient temperature, and pressures are atmospheric or near atmospheric.
[0317]
[0318] Example 1. Preparation of anti-CD73 antibodies and variants.
[0319] Human Fab initial phage display library was selected using human CD73-ECD / His. After four rounds of panning with biotinylated huCD73-ECD / His coupled to M-280 (Thermo Fisher Scientific #11205D), fifty-two possible clones with CD73 binding activity and immobilized CD73 enzyme blocking activity were selected and four sequences (N1 to N4) were determined. The selected variable sequences were then cloned into the L234F, L235E, P331S mutants of the human IgG1 Fc backbone to become full-length antibodies for in vitro functional analysis (CD73 binding, CD73 enzyme activity blocking, antibody-mediated CD73 internalization). N1, N2 and N4 were also lead cloned into human wild-type or C219S mutant IgG2 Fc backbones. Based on in vitro efficacy and in vivo efficacy testing (MDA-MB-231 xenograft model), N1 and N4 were selected for the following affinity maturation and determination of the wtIgG2 backbone.
[0320] Antibody lead clone N1 and lead clone N4 were used for affinity maturation experiments based on in vitro phage display to generate additional clones with improved CD73 binding activity performance and CD73 enzyme blocking activity performance. A CDR-L1 / CDR-L3 / CDR-H3 (focused on 3 CDRs) nucleic acid library of the N1 lead clone was generated via PCR, cloned into a phage display vector and transformed into E. coli TG1 cells to generate a phage library. After three rounds of panning with biotinylated huCD73-ECD / His, fifteen Fab clones with different sequences were screened out via binding assays and enzyme blocking assays, and two Fabs (N1#2 and N1#9) were found to have better efficacy. For affinity maturation of the N4 lead clone, a CDR-L3 / CDR-H1 / CDR-H3 nucleic acid library was first generated to generate a phage library. After three rounds of panning, six Fab clones (N4#1 to N4#6) with different sequences were screened out via binding assays and enzyme blocking assays. Then, a CDR-L1 / CDR-L2 / CDR-H2 nucleic acid library of N4#1, N4#4, N4#5, and N4#6 clones was generated to produce a phage library. After three rounds of panning, N4#4-3, N4#6-2, N4#6-3, N4#6-4, and N4#6-5 clones with better binding activity and enzyme blocking activity were selected.
[0321] After affinity maturation, N1#2, N1#9, N4#5, N4#6, N4#4-3, N4#6-2, N4#6-3, N4#6-4, N4#6-5 were cloned into the IgG2 Fc backbone to become full-length antibodies and subjected to in vitro efficacy testing (including CD73 protein binding ELISA, CD73-expressing tumor cell binding, immobilization and cell CD73 enzyme blocking, antibody-mediated CD73 internalization) and in vivo efficacy testing (NCI-H292 xenograft model), and N1#2, N1#9, N4#6-3, N4#6-4 clones were selected. Based on sequence alignment and CMC stability, these four clones were modified to produce N1#2-P, N1#9-PH, N4#6-3-P, N4#6-4-P. N1#9-PH has better soluble CD73 enzyme blocking efficacy, and N4#6-3-P and N4#6-4-P can induce surface CD73 internalization. N1#9-PH, N4#6-3-P, and N4#6-4-P can alleviate AMP-mediated T cell inhibition and have anti-tumor activity against MDA-MB-231 xenografts in vivo. In addition, N4#6-4-P can induce CD73 downregulation and block CD73 enzyme activity in xenograft tumors, and has better anti-tumor activity than other anti-CD73 antibodies in the NCI-H292 xenograft model.
[0322] The amino acid sequence alignments of the light and heavy chain variable regions of the anti-CD73 lead clones N1, N2, and N4 selected from the initial phage panning are shown in Figure 1A and Figure 1B The amino acid sequence alignment of the light chain variable regions derived from the affinity matured N1 and N4 variants is shown in Fig. 9 , in which the Kabat-defined CDRs (complementarity determining regions) are underlined and marked in bold, and the amino acid sequence alignment of the heavy chain variable regions derived from the affinity-matured N1 and N4 variants is shown in Fig.10 In the example above, the CDRs (complementarity determining regions) defined by Kabat are underlined and marked in bold. These selected variable sequences are then cloned into the human IgG2 Fc backbone to become full-length antibodies. The amino acids of the light chain constant region and heavy chain constant region of human antibodies can be selected as follows (not limiting the amino acid sequences of the light and heavy chain variable regions herein):
[0323] wtIgG2 isotype heavy chain constant region (SEQ ID NO: 112)
[0324] mtIgG2 isotype heavy chain constant region (SEQ ID NO: 113)
[0325] tmtIgG1 isotype heavy chain constant region (SEQ ID NO: 114)
[0326] Light chain constant region (SEQ ID NO: 115)
[0327] N1#2-P heavy chain (SEQ ID NO: 116)
[0328] N1#9-PH heavy chain (SEQ ID NO: 117)
[0329] N4#6-3-P_Heavy Chain (SEQ ID NO: 118)
[0330] N4#6-4-P heavy chain (SEQ ID NO: 119)
[0331] Fig.14 An amino acid sequence alignment of the light chains of the N1 and N4 front variants is shown, with the Kabat-defined CDRs (complementarity determining regions) underlined and in bold, and Fig.15 The amino acid sequence alignment of the heavy chain variable regions of the N1 and N4 front variants is shown, with the Kabat-defined CDRs (complementarity determining regions) underlined and marked in bold. These sequences were then cloned into the human IgG2 Fc backbone to become full-length antibodies.
[0332] Example 2. CD73 binding ability of selected antibodies.
[0333] ELISA assays were performed to evaluate the binding of selected antibodies to recombinant human CD73-ECD / His proteins. Goat anti-human IgG Fd (or Fc) antibodies were coated overnight at 4°C on 96-well EIA microplates at thirty nanograms per well. After blocking with 5% skim milk (in PBS), serially diluted antibodies were added and incubated at room temperature for 1 hour. Unbound antibodies were removed and the wells were washed three times with 1×PBST containing 0.05% Tween20. Biotin-labeled CD73-ECD / His proteins were added to the wells at thirty nanograms per well and incubated for another hour at room temperature. Unbound biotin-labeled CD73-ECD / His was washed three times with 1×PBST containing 0.05% Tween20. Avidin-HRP was then added to the wells and incubated at room temperature for 30 minutes. Excess secondary antibodies were removed by washing three times with 1×PBST containing 0.05% Tween20. After washing, the plate was developed using TMB. The absorbance at a wavelength of 450 nm was read by a microplate reader.
[0334] The selected anti-CD73 antibodies were tested for binding to recombinant human CD73 protein by ELISA, and the binding data are shown in Figure 2A middle.
[0335] The whole cell binding ability of anti-CD73 antibodies was tested by incubating MDA-MB-231 or NCI-H292 cells with serially diluted antibodies in FACS buffer (PBS containing 2% FBS) at 4°C for 30 minutes. The cells were washed with FACS buffer and the binding was detected for another 30 minutes at 4°C with FITC-labeled goat anti-human IgG (H+L) antibody (or PE-labeled goat anti-human IgG Fcγ). The binding of antibodies to the cell surface was measured by the mean fluorescence intensity (MFI) of the staining. Flow cytometry analysis was performed using a Cytomics FC500 or CytoFLEX flow cytometer (Beckman Coulter Inc.). Figure 2B and 2C Selected anti-CD73 antibodies are shown to bind to CD73-expressing human tumor cells MDA-MB-231 (human breast cancer) cells ( Figure 2B ) and NCI-H292 (human mucoepidermoid lung cancer) cells ( Figure 2C ).
[0336] In these studies, anti-CD73 ref-1 antibody and HLX01 (anti-CD20) were used as positive and negative controls, respectively. These data indicate that all selected anti-CD73 antibodies can bind to human CD73 recombinant protein and human tumor cells expressing CD73.
[0337] Figures 11A-11B CD73 binding of N1 and N4 variants is also shown. Selected variants were tested by flow cytometry for binding to CD73-expressing MDA-MB-231 ( Fig.11A ) and NCI-H292( Fig. 11B ) cells. HLX01 (anti-CD20) was used as a negative control. These data indicate that after affinity maturation, all N1 and N4 variants can bind to human tumor cells expressing CD73. In both cell lines, the N4 variant has better CD73 binding ability than the N1 variant. The ranking of whole cell binding ability is: N4#5, N4#6-4, N4#6-5>N4#6-2>N4#4-3, N4#6, N4#6-3, N1#9>N1#2.
[0338] Figures 16A-16C The CD73 binding ability of N1 and N4 front variants is shown. The binding of anti-CD73 antibodies to recombinant human CD73 protein was tested by ELISA ( Fig.16A ), anti-CD73 antibodies were tested by flow cytometry for interaction with CD73-expressing human tumor cells MDA-MB-231 ( Fig. 16B ) and NCI-H292( Fig. 16C). Anti-CD73 ref-1 antibody and anti-CD73 ref-2 antibody were used as positive controls, while HLX01 (anti-CD20) was used as a negative control. These data indicate that N4#6-3-P, N4#6-4-P, and N1#9-PH bind to recombinant CD73 and surface CD73 on MDA-MB-231 cells with comparable affinity. N1#9-PH binds slightly better to NCI-H292 cells expressing CD73 than N4#6-3-P and N4#6-4-P do.
[0339] Example 3. Effect of anti-CD73 lead clone on soluble CD73 enzyme activity and cellular CD73 enzyme activity.
[0340] The ability of anti-CD73 antibodies to inhibit the enzymatic activity of human recombinant CD73 protein and cell surface CD73 was tested. CD73 catalyzes the hydrolysis of AMP into adenosine and inorganic phosphate by measuring the ATP-dependent oxidation of fluorescein inhibited by AMP (CellTiter-Glo assay; Promega). Fifteen nanograms of recombinant human CD73-ECD / His protein were incubated at 37°C with serially diluted anti-CD73 antibodies, ATP (final concentration 100 μM) and AMP (final concentration 300 μM) in assay buffer (25 mM Tris, 5 mM MgCl2, pH 7.46). The same volume of CellTiter-Glo reagent was added to the reaction and mixed for 2 min in a white 96-well microplate. After incubation for 10 min, the cold light was measured.
[0341] Cells expressing CD73 (5E3-1E4 cells / well) were resuspended in culture medium and placed in a 96-well microplate (or pre-seeded for 24 hours). Three-fold (or five-fold) serial dilutions of the antibody were added to each culture. After incubation at 37°C for 15 minutes, AMP (final concentration 225 μM) was added and incubated for 4-20 hours. After centrifugation, the culture supernatant was collected, placed in a 96-well microplate, and ATP was added to a final concentration of 100 μM for incubation for 2 minutes. The same volume of CellTiter-Glo reagent was added to each well and mixed for 2 minutes. After incubation for 10 minutes, the cold light was measured.
[0342] Data showing the effects of the anti-CD73 lead clone on soluble CD73 enzymatic activity and cellular CD73 enzymatic activity are shown in Figure 3A and 3BThese data indicate that all selected antibodies can inhibit the enzymatic activity of both human soluble CD73 and surface CD73. In the soluble CD73 enzymatic activity assay, a loss of inhibition was observed when IgG was in stoichiometric excess relative to sCD73. This so-called "hook effect" can arise from monovalent antibody binding driven by the Fab arms on the same IgG molecule competing for limited binding sites on the target antigen.
[0343] The ability of anti-CD73 lead clones N1, N2, N4 with different IgG isotypes to inhibit cellular CD73 enzymatic activity was tested. MDA-MB-231 cells were incubated with anti-CD73 antibodies. ATP, AMP, and CellTiter-Glo reagent were added and luminescence was recorded. APCP was used as a positive control in the enzyme activity assay. The effects of these anti-CD73 lead clones with different IgG Fc regions on cellular CD73 enzymatic activity are shown in Fig. 6A (lead clone N1), 6B (lead clone N2) and 6C (lead clone N4).
[0344] These data indicate that the wtIgG2 isotype cloned by N1 has better blocking activity than tmtIgG1 and mtIgG2 isotypes. The tmtIgG1 isotype cloned by N2 has better blocking activity than wtIgG2 and mtIgG2 isotypes. N4 with the wtIgG2 isotype showed the best blocking activity than tmtIgG1 and mtIgG2 isotypes. The tmtIgG1 isotype has the following Fc site specific changes: L234F, L235E and P331S.
[0345] Figures 17A-17C It was also shown that the N1 and N4 front variants had an effect on the soluble CD73 enzymatic activity ( Fig.17A ) and cell surface CD73 enzyme activity ( Fig. 17B and Fig. 17C ). The ability of anti-CD73 antibodies to inhibit human recombinant CD73 protein and cell surface CD73 enzyme activity was tested. Recombinant CD73 protein ( Fig.17A )、MDA-MB-231( Fig. 17B ) and NCI-H292( Fig. 17C ) cells were incubated with anti-CD73 antibody. ATP, AMP and CellTiter-Glo were added and luminescence was recorded. Anti-CD73 ref-1 antibody, anti-CD73 ref-2 antibody and APCP were used as positive controls. HLX01 (anti-CD20) was used as a negative control.
[0346] Figures 17A-17CThe data presented in show that N1#9-PH is superior to N4#6-3-P and N4#6-4P in inhibiting soluble CD73 enzymatic activity. However, N1#9-PH and N4#6-4-P showed comparable blocking activity on cell surface CD73 enzymatic activity.
[0347] Example 4. Antibody-mediated CD73 internalization of anti-CD73 lead clone.
[0348] Tumor cells (5E4 to 1E5 cells / well) were suspended in culture medium and incubated with anti-CD73 antibodies at different concentrations for 4 hours. After removing the culture medium, the cells were suspended in FACS buffer (PBS containing 2% FBS) and incubated with mouse anti-human CD73 antibody (4G4) at 4°C for 30 minutes. The cells were washed with FACS buffer and incubated with FITC-labeled goat anti-mouse IgG (H+L) antibody or Alexa488-labeled goat anti-mouse IgG Fcγ antibody. Flow cytometric analysis was performed using a CytomicsFC500 or CytoFLEX flow cytometer (Beckman Coulter Inc.). Anti-CD73 ref-1 antibody and HLX01 (anti-CD20) were used as positive and negative controls, respectively.
[0349] Figure 4 The data shown in indicate that only N4-tmtIgG1 can induce CD73 internalization. N1-tmtIgG1 and N2-tmtIgG1 cannot induce CD73 internalization.
[0350] FIG7 also shows antibody-mediated CD73 internalization of anti-CD73 antibodies with different IgG Fc regions. Fig. 7A )、N2( Figure 7B ) and N4( Figure 7C After incubation with different IgG isotypes of N4, the cell surface expression of CD73 was measured by flow cytometry. Anti-CD73 ref-1 antibody and HLX01 (anti-CD20) were used as positive and negative controls, respectively. The data showed that N4 (but not N1 and N2) could induce CD73 internalization. There were no obvious differences between different IgG isotypes.
[0351] Fig.13 Antibody-mediated CD73 internalization of the N1 and N4 variants is also shown. NCI-H292 cells were incubated with the N1 and N4 variants, and cell surface expression of CD73 was measured by flow cytometry. Anti-CD73 ref-1 antibody and anti-CD73 ref-2 antibody were used as positive controls, while HLX01 (anti-CD20) was used as a negative control. The data indicate that after affinity maturation, the N4 variant can induce CD73 internalization, and the N1 variant still cannot induce CD73 internalization.
[0352] Fig.18A and 18B Antibody-mediated CD73 internalization of N1 and N4 front variants was also demonstrated. Fig.18A ) and NCI-H292( Fig.18B ) cells were incubated with anti-CD73 N1 and N4 variants. After incubation, cell surface expression of CD73 was measured by flow cytometry. Anti-CD73 ref-1 and anti-CD73 ref-2 antibodies were used as positive controls, while HLX01 (anti-CD20) was used as a negative control. These data indicate that N4#6-3-P and N4#6-4-P can induce CD73 internalization in both CD73-expressing cancer cells.
[0353] Example 5. CD73 binding of selected antibodies with different IgG Fc regions.
[0354] Binding of anti-CD73 antibodies to cell surface CD73 was tested by incubating MDA-MB-231 cells with serially diluted biotinylated anti-CD73 antibodies in FACS buffer (PBS containing 2% FBS) at 4°C for 30 minutes. Cells were washed with FACS buffer and binding was detected with streptavidin-FITC at 4°C for 30 minutes. Flow cytometric analysis was performed using Cytomics FC500 (Beckman Coulter Inc.).
[0355] The variable sequences of N1, N2, and N4 were cloned into human wild-type or C219S mutant IgG2 Fc backbones. N1 was tested by flow cytometry ( Figure 5A )、N2( Figure 5B )、N4( Figure 5C Binding of different IgG isotypes of ) to human MDA-MB-231 cells expressing CD73. Anti-CD73 ref-1 antibody and HLX01 (anti-CD20) were used as positive and negative controls, respectively.
[0356] Shown in Figures 5A-5C The data in indicate that there is no difference between the different IgG isotypes of N1 in terms of CD73 binding ability. The data also show that the N2 clone (tmtIgG1 isotype) has better CD73 binding activity than the wtIgG2 and mtIgG2 isotypes, and the N4 clone (tmtIgG1 isotype) has better CD73 binding activity than the wtIgG2 and mtIgG2 isotypes.
[0357] Example 6. Anti-CD73 lead clones in the MDA-MB-231 (human triple-negative breast cancer) xenograft mouse model Tumor growth inhibitory activity.
[0358] The in vivo activity of anti-human CD73 antibodies was studied in a xenograft mouse model using immunocompromised NOD / SCID (non-obese diabetic / severe combined immunodeficiency) mice. A total of 1E7 human triple-negative breast cancer MDA-MB-231 cells expressing CD73 in 100 μL of PBS were mixed with 100 μL of Matrigel (Corning, CA, USA) (at a 1:1 ratio) and implanted subcutaneously into the flanks of female NOD / SCID mice (Biolasco, Taipei, Taiwan). When the tumor size reached 150-300 mm 3 At day 14 after tumor inoculation, 5 mg / kg of anti-CD73 antibody or 10 mL / kg of placebo was intraperitoneally administered twice a week or at the indicated time. Tumors were observed and measured until day 45. Tumor volume was defined as TV (tumor volume) = (length x width 2 ) / 2.
[0359] The tumor growth curve is shown in Fig. 8A The individual tumor volumes on day 45 are shown in Figure 8B All data points are mean ± SEM. The data demonstrate that, except for the tmtIgG1 isotype of the N1, N2, and N4 clones, all anti-CD73 antibodies have anti-tumor activity (TGI ≥ 50%) in the MDA-MB-231 xenograft model. N1-wtIgG2, N1-mtIgG2, N2-wtIgG2, and N2-mtIgG2 almost completely inhibited tumor growth.
[0360] Fig. 20 The tumor growth inhibitory activity of N1 and N4 variants in the MDA-MB-231 (human triple-negative breast cancer) xenograft mouse model was also shown. Mice (n=5 mice / group) were subcutaneously transplanted with MDA-MB-231 cells. Seven days after tumor inoculation, when the transplanted tumor size reached approximately 100 mm 3 The first dose of the test article was given at 100 mg / kg and 2 mg / kg of the antibody intraperitoneally twice a week for 5-6 weeks. All data points are mean ± SEM. These data demonstrate that all N1 and N4 front variants have anti-tumor activity against MDA-MB-231 xenografts in vivo. N4#6-3-P, N4#6-4-P and N1#9-PH have better anti-tumor activity than the anti-CD73 reference antibody.
[0361] Example 7. Effects of N1 and N4 variants on immobilized CD73 enzymatic activity.
[0362] The ability of N1 and N4 variants to inhibit the activity of immobilized CD73 enzymes was tested. Goat anti-human IgG Fd antibodies were coated overnight at 4°C on white high-affinity 96-well microplates at three hundred nanograms per well. After blocking with 5% skim milk (in PBS), serially diluted antibodies were added and incubated at room temperature for 1 hour. Unbound antibodies were removed and the wells were washed three times with 1×PBST containing 0.05% Tween20. Twenty-five microliters of 100ng / mL CD73-ECD / His protein in assay buffer (25mM Tris, 5mM MgCl2, pH 7.46) were added to the wells and incubated for another 1 hour at room temperature. Twenty-five microliters of 66μM ATP and 200μM AMP mixture were added and incubated at 37°C for 9 minutes. The same volume of CellTiter-Glo reagent was added to the reaction mixture and the contents were mixed (in a white 96-well microplate) for 2min. After incubation for 10min, the cold light was measured. Anti-CD73 ref-1 antibody, anti-CD73 ref-2 antibody were used as positive controls, and HLX01 (anti-CD20) was used as a negative control.
[0363] The effects of N1 and N4 variants on the enzymatic activity of immobilized CD73 are shown in Fig.12 These data indicate that after affinity maturation, all N1 and N4 variants can inhibit CD73 enzymatic activity. The CD73 enzymatic blocking activity of the N1 variant is superior to that of the N4 variant and the anti-CD73 ref-2 antibody, but is comparable to that of the anti-CD73 ref-1 antibody. Blocking of immobilized CD73 enzymatic activity: N1#2, N1#9>N4#6-4, N4#6-5>N4#4-3, N4#6-2>N4#6-3, N4#5>N4#6.
[0364] Example 8. Reversal of the inhibitory effect of AMP on T cell activity by N1 and N4 anterior variants.
[0365] CD73 catalyzes adenosine monophosphate (AMP) to produce adenosine extracellularly. Adenosine inhibits immune responses (including those of T cells, NK cells, and dendritic cells) by activating A2aR and A2bR receptors. In addition to CD73 enzymatic inhibition and internalization, the functional effects of CD73 inhibition on T cell proliferation by anti-CD73 antibodies were also examined.
[0366] Human T cells were isolated from peripheral blood mononuclear cells (PBMC) using the MagniSort Human T Cell Enrichment Kit (eBioscience, Inc.) and suspended in complete medium (RPMI-1640 containing 10% FBS) containing 50 IU / mL recombinant human IL-2 (eBioscience, Inc.). T cells (5E4 cells / reaction) in a volume of 100 μL were incubated with Dynabeads TM Human T-activating factor CD3 / CD28 (Thermo Fisher Scientific) was mixed at a ratio of 1:0.5 cells to beads. AMP (1 mM) and serially diluted antibodies were added to each reaction in a volume of 100 μL. Reactions without activation beads (unstimulated group), containing only CD3 / CD28 beads (stimulated group), or containing CD3 / CD28 beads and AMP (AMP-mediated inhibition group) were used as assay controls. Anti-CD73ref-1 antibody, anti-CD73 ref-2 antibody, and APCP were used as positive controls. HLX04 (anti-VEGF) was used as a negative control. Cells were cultured at 37°C for 4 days. On day 4, cells were collected, washed, and resuspended in fresh RPMI-1640 medium. T cell proliferation was analyzed by CellTiter-Glo assay. Culture supernatants were collected for cytokine measurement. Human IFN-γ ELISA MAX was used. TM IFN-γ levels were measured using the Bio-Rad Bio-Tech Deluxe kit (BioLegend, Inc.).
[0367] Reversal of the inhibitory effect of AMP on T cell activity by N1 and N4 anterior variants was shown in Fig.19A and 19B In. CD3 + T cell proliferation was followed by CellTiter-Glo assay ( Fig.19A ), and human IFN-γ ELISA MAX TM Deluxe Kit( Fig.19B ) IFN-γ secretion was measured. Anti-CD73 ref-1 antibody, anti-CD73 ref-2 antibody and APCP were used as positive controls. HLX04 (anti-VEGF) was used as a negative control. Fig.19A and 19B The data shown in the Figures indicate that N1 and N4 front variants can enhance T cell proliferation and IFN-γ secretion in a dose-dependent manner. The data further indicate that N4#6-3-P, N4#6-4-P and N1#9-PH can alleviate AMP-mediated T cell inhibition.
[0368] Example 9. Expression of N1 and N4 front variants in the NCI-H292 (human mucoepidermoid lung cancer) xenograft mouse model Tumor growth inhibitory activity.
[0369] The in vivo activity of anti-human CD73 antibodies was studied in a xenograft mouse model using immunocompromised BALB / c nude mice. A total of 5E6 NCI-H292 cells in 100 μL of PBS were mixed with 100 μL of Matrigel (Corning, CA, USA) (at a 1:1 ratio) and implanted subcutaneously into the flanks of male BALB / c nude mice (Biolasco, Taipei, Taiwan). When the tumor size reached 150-300 mm 3 Anti-CD73 antibody or placebo was given intraperitoneally twice a week for 3 weeks. Tumors were observed and measured twice a week. Tumor volume was defined as TV (tumor volume) = (length x width 2 ) / 2.
[0370] Fig.21 The tumor growth inhibitory activity of N1 and N4 front variants in the NCI-H292 (human mucoepidermoid lung cancer) xenograft mouse model was shown. Mice (n = 5 mice / group) were subcutaneously transplanted with NCI-H292 cells. The first dose of the test article was given 3 days after tumor inoculation. Mice were treated intraperitoneally with 50, 10 and 2 mg / kg of the antibody twice a week for 3 weeks. All data points are mean ± SEM. The data demonstrate that N4#6-4-P has better anti-tumor activity than other anti-CD73 antibodies in the NCI-H292 xenograft model.
[0371] Example 10. Effects of N1 and N4 front variants on cellular CD73 enzymatic activity in NCI-H292 xenograft tumors.
[0372] A total of 5E6 NCI-H292 cells in 100 μL of PBS were mixed with 100 μL of Matrigel (Corning, CA, USA) (at a 1:1 ratio) and implanted subcutaneously into the flanks of male BALB / c nude mice (Biolasco, Taipei, Taiwan) 4 days before antibody administration. Mice were treated intraperitoneally with 30 mg / kg antibody, APCP, and placebo on day 0, and tumors were collected on days 1, 3, and 7. Tumor cells (2E4) were resuspended in assay buffer (25 mM Tris, 5 mM MgCl2, pH 7.46) and treated with ATP (final concentration 100 μM) and AMP (final concentration 300 μM) at 37°C for 45 minutes. The same volume of CellTiter-Glo reagent was added to the reaction mixture and the contents were mixed for 2 min (in a white 96-well microplate). After incubation for 10 min, cold light was measured.
[0373] Fig. 22 The effect of N1 and N4 front variants on cellular CD73 enzymatic activity in NCI-H292 xenograft tumors is shown. The ability of N1 and N4 front variants to inhibit CD73 enzymatic activity in the NCI-H292 xenograft model was tested. Mice (n=4 mice / group) were subcutaneously transplanted with NCI-H292 cells 4 days before antibody treatment. Antibodies, APCP, and placebo were injected intraperitoneally on day 0. Tumors were resected on days 1, 3, and 7 after antibody administration. CD73 enzymatic activity in tumors was measured by CellTiter-Glo assay.
[0374] The data demonstrated that the N1 and N4 front variants could inhibit CD73 enzymatic activity in the NCI-H292 xenograft model. N4#6-3-P and N4#6-4-P were superior to N1#9-PH and anti-CD73 reference antibodies in blocking CD73 enzymatic activity in tumors.
[0375] Example 11. Effects of N1 and N4 anterior variants on CD73 expression and cellular CD73 enzymatic activity in MDA-MB-231 xenograft tumors Active role.
[0376] A total of 1E7 MDA-MB-231 cells in 100 μL of PBS were mixed with 100 μL of Matrigel (Corning, CA, USA) (at a 1:1 ratio) and implanted subcutaneously into the flanks of female NOD / SCID mice (Biolasco, Taipei, Taiwan) 7 days before antibody administration. Mice were treated intraperitoneally with 2 mg / kg antibody and 10 mL / kg placebo on day 0. Tumors were collected on days 1, 3, and 7. To measure surface CD73 expression levels, 5E4 tumor cells were resuspended in FACS buffer (PBS containing 2% FBS) and treated with anti-human and anti-mouse FcR blocking reagents at 4°C for 30 minutes. After centrifugation, the cells were then incubated with mouse anti-human CD73 antibody (4G4) at 4°C for 30 minutes. The cells were washed with FACS buffer and incubated with Alexa488-labeled goat anti-mouse IgG Fcγ antibody at 4°C for another 30 minutes. Flow cytometry analysis was performed using a CytoFLEX flow cytometer (Beckman Coulter Inc.). A total of 2E4 tumor cells were resuspended in assay buffer (25mM Tris, 5mM MgCl2, pH 7.46) for CD73 enzyme activity measurement. The cell suspension was treated with ATP (final concentration 100 μM) and AMP (final concentration 300 μM) at 37°C for 45 minutes. The same volume of CellTiter-Glo reagent was added to the reaction mixture and mixed for 2 min (in a white 96-well microplate). After incubation for 10 min, the cold light was measured.
[0377] Fig.23A and 23B The effect of N1 and N4 variants on CD73 expression and cellular CD73 enzymatic activity in MDA-MB-231 xenograft tumors is shown. CD73 expression was measured by mean fluorescence intensity (MFI) of the staining ( Fig.23A ), and CD73 enzyme activity in tumors was measured by CellTiter-Glo assay ( Fig. 23B ). The data demonstrated that N4#6-4-P could downregulate surface CD73 expression and inhibit CD73 enzymatic activity in the MDA-MB-231 xenograft mouse model compared with the placebo group.
[0378] Example 12. Cross-binding of N1 and N4 front variants to CD73-expressing cells of mice and monkeys.
[0379] The binding of anti-CD73 antibodies was evaluated by incubating 4T1 or LLC-MK2 cells (1E5 cells / test) with serially diluted antibodies in FACS buffer (PBS containing 2% FBS) at 4°C for 30 minutes. The cells were washed with FACS buffer and the binding was detected for another 30 minutes at 4°C with FITC-labeled goat anti-human IgG (H+L) antibody. The binding of antibodies to the cell surface was measured by the mean fluorescence intensity (MFI) of the staining. Flow cytometric analysis was performed using a Cytomics FC500 or CytoFLEX flow cytometer (Beckman Coulter Inc.).
[0380] Fig.24A and 24B The N1 and N4 variants were shown to cross-bind with mouse and monkey CD73-expressing cells. Anti-CD73 antibodies were tested by flow cytometry for binding to CD73-expressing mouse breast cancer 4T1 cells ( Fig.24A ) and monkey kidney epithelial LLC-MK2 cells ( Fig. 24B ) binding. HLX01 was used as a negative control. These data indicate that the N1 and N4 front variants are cross-reactive with monkey CD73-expressing cells. The N1 and N4 front variants cannot cross-bind with mouse CD73.
[0381] The foregoing embodiments are provided for illustrative purposes only, and are only possible embodiments of the embodiments proposed for a clear understanding of the principles of the present invention, and are not intended to limit the scope of the present invention in any way. Without substantially departing from the spirit and principles of the present invention, many changes and modifications may be made to one or more of the above-mentioned embodiments. All such modifications and variations are intended to be included within the scope of the present invention and are protected by the appended claims.
Claims
1. Use of an anti-CD73 antibody or an antigen-binding fragment thereof, or a conjugate comprising the anti-CD73 antibody or its antigen-binding fragment and a therapeutic agent, or a composition comprising the anti-CD73 antibody or its antigen-binding fragment or the conjugate and a pharmaceutically acceptable carrier in the manufacture of a medicament for treating cancer associated with CD73 expression, CD73 overexpression and / or abnormal CD73 function in a subject, wherein the cancer associated with CD73 expression, CD73 overexpression and / or abnormal CD73 function is selected from: melanoma, non-small cell lung cancer (NSCLC), head and neck cancer, urothelial carcinoma, gastric cancer, classical Hodgkin lymphoma (cHL), non-Hodgkin lymphoma primary mediastinal B-cell lymphoma (NHLPMBCL), mesothelioma, esophageal cancer, nasopharyngeal carcinoma (NPC), biliary tract cancer, cervical cancer, thyroid cancer, bladder cancer, pancreatic cancer and salivary gland cancer, Wherein the anti-CD73 antibody or antigen-binding fragment thereof comprises: (i) a light chain (LC) variable domain sequence comprising: a) CDR-L1 of the amino acid sequence of SEQ ID NO: 5, b) CDR-L2 of the amino acid sequence of SEQ ID NO: 11, and c) CDR-L3 of the amino acid sequence of SEQ ID NO: 20, and a heavy chain variable domain (VH) sequence comprising: a) CDR-H1 of the amino acid sequence of SEQ ID NO: 25, b) CDR-H2 of the amino acid sequence of SEQ ID NO: 30, and c) CDR-H3 of the amino acid sequence of SEQ ID NO: 43; (ii) a light chain (LC) variable domain sequence comprising: a) CDR-L1 of the amino acid sequence of SEQ ID NO: 8, b) CDR-L2 of the amino acid sequence of SEQ ID NO: 15, and c) CDR-L3 of the amino acid sequence of SEQ ID NO: 24, and a heavy chain variable domain (VH) sequence comprising: a) CDR-H1 of the amino acid sequence of SEQ ID NO: 27, b) CDR-H2 of the amino acid sequence of SEQ ID NO: 32, and c) CDR-H3 of the amino acid sequence of SEQ ID NO: 45; or (iii) a light chain (LC) variable domain sequence comprising: a) CDR-L1 of the amino acid sequence of SEQ ID NO:9, b) CDR-L2 of the amino acid sequence of SEQ ID NO:16, and c) CDR-L3 of the amino acid sequence of SEQ ID NO:24, and a heavy chain variable domain (VH) sequence comprising: a) CDR-H1 of the amino acid sequence of SEQ ID NO:27, b) CDR-H2 of the amino acid sequence of SEQ ID NO:37, and c) CDR-H3 of the amino acid sequence of SEQ ID NO:
45.
2. The use according to claim 1, wherein the therapeutic agent is selected from the group consisting of: cytotoxic agents, radioisotopes, chemotherapeutic agents, anti-tumor agents and growth inhibitory agents.
3. The method according to claim 1 or 2, wherein the subject is further administered with other therapeutic agents selected from the group consisting of anti-tumor agents, chemotherapeutic agents, growth inhibitory agents, cytotoxic agents, and immunotherapeutic agents.
4. The use according to claim 1 or 2, wherein the subject is further administered radiotherapy or surgery.
Citation Information
Patent Citations
Immunoconjugates
EP0659439A2
Synthetic phosphatidyl cholines useful in forming liposomes
US4485045A
Liposomes containing modified cholesterol for organ targeting
US4544545A
Plasminogen activator derivatives
US4640835A
Recombinant immunoglobin preparations
US4816567A
